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Abstract 
Natural α,β-epoxyketone proteasome inhibitors produced primarily by Streptomyces 
species, such as TMC-86A, are potent anticancer compounds. The enzymes 
responsible for biosynthesis of their key α,β-epoxyketone pharmacophore had yet to 
be determined at the onset of this research. Elucidation of the responsible enzymes 
and their putative substrate would allow for stereoselective completion of a 
synthetically challenging epoxidation reaction, responsible for the high cost of 
epoxyketone pharmaceuticals produced by industry. 
 
Abstract	figure:	The	α,β-epoxyketone	proteasome	inhibitor	TMC-86A	from	Streptomyces	
chromofuscus.	The	epoxyketone	pharmacophore	is	highlighted	in	red.	
 
The cytochrome P450 TmcI and the flavin-dependent TmcF enzymes from the TMC-
86A biosynthetic gene cluster in Streptomyces chromofuscus, believed to have a role 
in epoxyketone biosynthesis, were cloned, expressed and overproduced. Potential 
substrates were produced through a peptide coupling synthetic route. In vitro assays 
demonstrated that EpnF, a TmcF homologue, could produce α,β-epoxyketone 
compounds with an α-dimethyl-β-keto carboxylic acid substrate. These substrates 
were prone to decarboxylative degradation, therefore stable methyl ester precursors 
were synthesised as an alternative. Using an esterase, methyl ester precursors were 
hydrolysed to reproduce the previously observed epoxyketone compound in a one pot 
reaction with EpnF. Substrate specificity of EpnF was probed by in vitro assay using 
an alanine derived analogue, which was found to be a viable substrate for the enzyme. 
Lastly, the EpnF catalytic cycle was interrogated with a synthesised authentic standard 
of a proposed intermediate, which was observed to co-elute with the desired 
intermediate from a quenched EpnF assay using UHPLC-MS chromatography.
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1.1 Natural products 
Natural products produced by plants, bacteria and fungi have an extraordinary range 
of bioactivities, and can serve as vital leads in the development of pharmaceutically 
and agriculturally relevant compounds.1,2 Anticancer activity is found in natural 
products such as taxol 1 (figure 1.1A), a terpene produced in the bark of Taxus 
breuifolia.3–5 Many natural products exhibit antibacterial activity, for example the 26S 
rRNA binder erythromycin A 2 (figure 1.1B), a polyketide marcrolide produced by 
bacterium Saccharopolyspora erythraea.6,7 For crop protection, the nonribosomal 
peptide bassianolide 3 (figure 1.1C) from the fungus Beauveria bassiana is an 
exemplar of a potent insecticidal virulence factor.8 While bioactive and beneficial 
natural products are produced from an extensive range of sources, some of the most 
prolific producers of clinically and agriculturally relevant compounds are 
Streptomyces species. 
 
 
Figure	 1.1.	 A:	 Structure	 of	 the	 terpene	 taxol	 from	Taxus	breuifolia.	 B:	 Structure	 of	 the	
macrolide	 erythromycin	 A	 from	 Saccharopolyspora	 erythraea.	 C:	 Structure	 of	 peptide	
bassianolide	from	Beauveria	bassiana.	
 
1.1.1 Streptomyces natural products 
Streptomyces species are filamentous Gram-positive bacteria from the actinobacteria 
phylum, with high GC content DNA.9 Their life-cycle revolves around the dispersal 
of spores from aerial hyphae, which follows their initial growth as a vegetative 
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mycelium through soil-bound branching hyphae.10 Streptomyces are the focus of great 
academic and industrial interest for being the foremost producers of bioactive 
secondary metabolites (figure 1.2), with some models predicting production of over 
100000 antimicrobial compounds from the genus as a whole of which contemporary 
research has uncovered but a fraction.11 
 
 
Figure	 1.2.	 A:	 Structure	 of	 streptomycin.	 B:	 Structure	 of	 streptanoate.	 C:	 Structure	 of	
bleomycin.	
 
One of the earliest discovered Streptomyces natural products was the trisaccharide 
streptomycin 4, isolated from Streptomyces griseus in 1943 (figure 1.2A).9 
Streptomycin is a potent antibiotic still in use today, with discovery of its efficacy 
against Mycobacterium tuberculosis earning Selman Waksman the 1952 Nobel 
prize.12,13 Anticancer compounds have also been routinely discovered in Streptomyces 
species. A recent example of one such compound is streptanoate 5 from Streptomyces 
sp. DE3 (figure 1.2B), putatively the first bioactive butanoate discovered in a 
Streptomycete.14 Streptanoate was demonstrated to have a lower half maximal 
inhibitory concentration (IC50) against some cancer cell lines than established anti-
cancer pharmaceuticals, while having limited toxicity against healthy cell lines. A 
well-established clinically approved antitumoral natural product is the hybrid non-
ribomsomal peptide synthetase (NRPS) polyketide synthase (PKS) derived bleomycin 
from S. verticillus.15 Bleomycin 6 anticancer activity is due to its effectiveness at DNA 
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scission, and is used to treat a variety of cancers, though resistance to bleomycin 
continues to develop.16 NRPS-PKS hybrid epoxyketone proteasome inhibitors, 
derived primarily from actinomycetes including Streptomyces species, are a further 
example of an anticancer class of natural products. 
 
1.2 Epoxyketone compounds 
Epoxyketone compounds are irreversible and highly selective inhibitors of the 26S 
proteasome.17 Their pharmacophore is the terminal α,β-epoxyketone moiety 7, 
comprised of adjacent electrophilic epoxide and ketone functionalities (figure 1.3).  
 
 
Figure	1.3.	The	α,β-epoxyketone	pharmacophore.	
 
The backbone of epoxyketone compounds typically incorporates polyketide, 
nonribosomal peptide and fatty acid elements. To date, a wide range of epoxyketone 
proteasome inhibitors have been reported in the literature (table 1.1). 
 
Table	1.1:	Reported	epoxyketone	proteasome	inhibitors	with	stereochemistry	where	
known,	arranged	chronologically,	with	predicted	or	confirmed	stereochemistry.	
Compound 
species 
Structure 
Year 
discovered 
Eponemycin (8) 
S. hygroscopicus18 
 
 
1990 
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Epoxomicin (9) 
Actinomycetes 
strain No. 
Q996-1719  
1992 
Epopromycin A 
(10)/B (11) 
S. sp. NK0400020 
 
1997 
TMC-86A (12)/B 
(13)  
S. sp. TC 108421 
 
1999 
TMC-96 (14) 
Saccharothrix sp. 
TC 109421 
 
1999 
Carmaphycin A 
(15)/B (16) 
Symploca sp22 
 
2012 
Tryptopeptin A 
(17) 
Streptomyces sp. 
KUSC-G1123 
 
2015 
Landepoxcin A 
(18) 
soil metagenome 
library24  
2015 
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Clarepoxcin A (19) 
soil metagenome 
library24 
 
2015 
Macyranone A (20) 
Cystobacter 
fuscus25 
 
2015 
 
While other epoxyketone compounds exist, they are not known to inhibit the 26S 
proteasome. Natural products such as asukamycin 22 from S. nodosus subsp. 
asukaensis and manumycin 21 from S. parvulus have cyclic epoxyketones located 
centrally in their respective structures which contribute to their antibacterial and 
antifungal activity rather than inhibiting the proteasome.26,27 Trapoxin A 23 from 
Helicoma ambiens does have a terminal epoxyketone, but has been demonstrated to 
act as an irreversible inhibitor of histone deacetylase HDAC8.28,29 While still 
possessing a mechanism of action dependent on nucleophilic attack by the biological 
target, presumably the peptide backbone of the other epoxyketones is important in 
producing specificity for the proteasome which trapoxin A lacks. 
 
Figure	 1.4.	 A:	 Structures	 of	 the	 cyclic	 epoxyketones	 manumycin	 and	 asukamycin.	 B:	
Structure	of	linear	epoxyketone	trapoxin	A,	a	histone	deacetylase	HDAC8	inhibitor.	
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1.2.1 The 26S proteasome 
The 26S proteasome is a threonine protease responsible for degradation of 
polyubiquitinated proteins, and is comprised of a cylindrical 20S core particle with 
19S regulatory particles attached to each end.30 Proteins are ubiquitinated by action of 
E1 (ubiquitin activating enzyme), E2 (ubiquitin carrier protein) and E3 enzymes 
(ubiquitin ligase) respectively, attaching the 76 amino acid peptide to a protein’s 
lysine residue. Ubiquitination of position 48 lysine of ubiquitin that is already attached 
to a protein builds a polyubiquitin chain.31 
 
 
Figure	 1.5:	 Structure	 of	 the	 26S	 proteasome,	 demonstrating	 proteolysis	 of	 a	
polyubiquitinated	protein.	
 
The regulatory particle is composed of 19 subunits, which work together to recognize 
a polyubiquitinated protein substrate, cleave off the polyubiquitin chain, and then by 
action of a hexameric group of 6 ATPase subunits unfold and translocate the protein 
through a pore in the core particle.30 The 20S core particle is made up of four 
heptameric subunits, a core of two β subunits where degradation of substrates takes 
place by action of N-terminal threonine residues, capped by two α subunits which 
maintain an aperture for protein translocation when in complex with the regulatory 
particle (figure 1.5).32 
This degradation pathway, apart from assisting with cell homeostasis and providing a 
protein quality control mechanism, also has a role in transcriptional regulation. For 
Core particle
α αβ β
Regulatory particles
Protein
Polyubiquitin
ATP
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this reason cancers like multiple myeloma depend heavily on action of the proteasome, 
making epoxyketone compounds effective anticancer therapies.17,31 
 
1.2.2 Mechanism of proteasome inhibition by epoxyketone 
compounds 
Epoxyketone binding to the 26S proteasome was first discovered through feeding of 
a biotin labelled eponemycin analogue to murine thymoma cell line EL4. Denaturation 
of proteins in the cell lysate and their isolation using avidin-agarose, trypsin digest 
and subsequent matrix assisted laser desorption ionization-time of flight (MALDI-
TOF) spectroscopy revealed the biotin tagged proteins to be subunits of the 
proteasome.33 
 
 
Figure	 1.6.	 A:	 Proposed	 mechanism	 of	 action	 of	 epoxyketone	 proteasome	 inhibitors,	
demonstrating	 initial	 nucleophilic	 attack	 either	 by	 intermolecular	 or	 intramolecular	
activation,	 followed	 by	 6	 Exo-tet	 (top	 route)	 or	 the	more	 recently	 proposed	 7	 Exo-tet	
(bottom	route)	ring	closure.	B:	Active	site	of	human	20S	core	particle	crystallised	with	
epoxomicin	by	Schrader	and	coworkers.34	
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The specific mechanism of action for inhibition of the 26S proteasome was elucidated 
with the crystal structure of 20S proteasome core particle bound to epoxomicin, 
suggesting covalent morpholine moiety 26 between epoxomicin and the N-terminal 
catalytic threonine of the proteasome. This strongly implicated a mechanism of 
nucleophilic attack on the electrophilic pharmacophore, resulting in 6 Exo-tet ring 
closure favoured by Baldwin’s rules due to this angle of attack being achievable from 
an energetically favourable conformation (figure 1.6A).35,36 More recent higher 
resolution crystallographic data with synthetic epoxyketone oprozomib indicated 7 
Exo-tet ring closure with this threonine residue to produce oxazapan adduct 27 was 
more likely (figures 1.6A and 1.6B).37,34 If accurate this revised mechanism is 
interesting, as aside from epoxyketones which have a second electrophile located at 
both the α and β positions relative to the ketone functionality, it proposes other more 
trivially synthesised β-keto electrophiles may be suitable proteasome inhibitors.  
The proposal of a mechanism of action for proteasome inhibition, in addition to a high 
degree of specificity for the proteasome itself compared to existing boronic acid based 
proteasome inhibitors, lead to an increased interest in industry to develop synthetic 
epoxyketone compounds.  
 
1.2.3 Epoxyketone pharmaceuticals and their synthesis 
In the first attempt to epoxyketone pharmaceuticals, Crews et al investigated synthesis 
of an epoxyketone with improved activity over epoxomicin through a classic 
medicinal chemistry approach.38 Initially the length of the peptide leading into the 
epoxyketone pharmacophore was varied, followed by variation of the amino acid side 
chains when optimal length had been determined. Finally by altering derivatization 
following the terminal amide functionality on the N-terminus, the potent proteasome 
inhibitor YU-101 was produced. 
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Figure	1.7:	Structures	of	synthetic	epoxyketones	YU-101,	carfilzomib	and	oprozomib.	
 
With YU-101 in hand, the San Franciso-based company Proteolix set about trying to 
improve on the compound’s efficacy, producing a library of hundreds of variants.17 
Through the screening process however, it was found that the bioactivity of YU-101 
28 could not be readily improved upon. The remaining issue with YU-101 28 was its 
poor water solubility, and to rectify this a morpholine adduct was attached to the N-
terminus, producing carfilzomib 29 (figure 1.7). Carfilzomib 29 is currently licenced 
to treat the cancer multiple myeloma, and is effective against cancer that is resistant 
to the previous generation of boronic acid inhibitors. A second generation of 
epoxyketone compounds, including orally available oprozomib 30, are currently 
undergoing clinical trials (figure 1.7).39 
While synthesis of the peptide portion of these synthetic epoxyketones proceeds 
through trivial solid phase peptide coupling using a coupling reagent (coupling 
reagents are discussed in sections 3.1.2.2, 3.1.2.3 and 4.1.3), the synthesis of the 
epoxyketone pharmacophore is more challenging. Using a Boc-protected α,β-
unsaturated ketone derived from Weinreb-Nahm ketone synthesis (section 3.1.2.3), 
the routinely used basic epoxidation of the alkene bond using hydrogen peroxide, 
benzonitrile and Hunig’s base is cited as resulting in a 76% yield with a 
stereoselectivity of 1.7:1 (63%:37%) for the desired enantiomer – with epimerisation 
resulting basic deprotonation of the acidic α-proton as well as epimerisation resulting 
from use of a coupling reagent (see section 3.1.2.1 and figure 3.3 for more detail).40 
After Boc-deprotection, subsequent coupling to the solid phase synthesised peptide 
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has been reported to result in an additional 5% to 30% epimerization of the 
stereocenter adjacent to the epoxyketone, with yields varying from 20-70%.38 
 
 
Scheme	1.1:	Key	losses	in	enantioselectivity	during	epoxyketone	synthesis.	
 
This synthetic process is far from enantioselective, resulting in high production costs 
and an estimated $10000 cost for a typical 28-day cycle of carfilzomib 29. Discovery 
of an enzyme which could catalyse efficient epoxyketone formation in aqueous 
conditions and with a high degree of enantioselectivity, without the need for organic 
solvents or strongly oxidizing reagents like hydrogen peroxide, would help to lower 
the cost of industrial synthesis by increasing efficiency. In order to identify the 
enzyme responsible for pharmacophore formation in nature, the biosynthetic gene 
clusters of TMC-86A 12 and eponemycin 8 were investigated (table 1.1, figure 1.8). 
 
1.3 TMC-86A and eponemycin 
Before the onset of this project, production of TMC-86A 12 was discovered in S. 
chromofuscus ATCC49982 by the Challis group, and a biosynthetic gene cluster most 
likely to be responsible identified within the sequenced genome. Production of 
structurally related eponemycin 8 and its gene cluster from S. hygroscopicus 
ATCC53709 had already been reported by Moore et al.41 As both compounds are 
relatively short for epoxyketones (figure 1.8), with just two additional amino acid 
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stereocenters in addition to the epoxyketone stereocenter, they were ideal candidates 
for the purposes of synthesising substrate analogues. 
 
 
Figure	1.8:	Structures	TMC-86A	and	eponemycin.	
 
1.3.1 Biosynthetic gene cluster 
Biosynthesis of TMC-86A 12 was linked to the tmc gene cluster through preparation 
of a tmcH knockout mutant in S. chromofuscus by Dr. D. Zabala, which abrogated 
production of TMC-86A 12.42 Similarly, whole pathway expression of the epn cluster 
in S. albus by Moore et al revealed eponemycin to be the major metabolite.41 Both the 
tmc and epn clusters have the same arrangement of homologous genes (figure 1.9A), 
and so TMC-86A 12 and eponemycin 8 are predicted to form through analogous 
biosynthetic routes. 
The proposed biosynthesis (figure 1.9B), covered in detail in the following sections, 
begins with condensation of an acetyl-CoA primer 37, catalysed by the FabH-like fatty 
acid synthase (FAS) enzyme TmcD, to a malonyl unit bound to the 
phosphopantetheine 43 (PPT) modified acyl carrier protein (ACP) encoded by tmcE.43 
The resulting β-keto thioester then undergoes reduction by normal Streptomyces FAS 
metabolism to form butanoyl-ACP 38. The two NRPS modules (groups of catalytic 
domains) encoded by tmcG ensure transpeptidation of the acyl chain by first L-serine 
followed by L-leucine.44 Desaturation of the leucine side chain is proposed to be 
catalysed by the cytochrome P450 encoded by tmcK, with initial hydroxylation 
followed by dehydration to provide the alkene bond, though the timing of this tailoring 
step is unclear. Activity assays of the second adenylation (A) domain in the NRPS 
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TmcG demonstrated greater preference for L-leucine than 4,5-dehydro-L-leucine, 
implying that desaturation takes place following action of TmcG.42  
 
 
Figure	1.9.	A:	Arrangement	of	genes	in	the	eponemycin	and	TMC-86A	biosynthetic	gene	
clusters.	 B:	 Proposed	 biosynthesis	 of	 TMC-86A.	 Exact	 timing	 of	 TmcK	 desaturation	
remains	unclear.	
 
The PKS module TmcH catalyses transacylation of the peptide intermediate by a 
malonate extender unit, followed by methylation of the α-position of the β-keto 
thioester mediated by the C-methyltransferase domain (cMT) with S-adenosyl 
methionine 60 (SAM) as the cofactor.45 Lastly, serine-residue mediated hydrolysis of  
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Table	1.2:	In	silico	BLAST	analysis	of	genes	from	the	TMC-86A	gene	cluster,	revealing	their	
amino	acid	length,	nearest	protein	homologue	and	its	accession	number	on	the	GenBank	
database,	as	well	sequence	identity/similarity	and	proposed	function.42	
Gene Amino 
Acids 
Protein 
homologue 
Accession 
Number 
Identity 
/similarity 
Proposed function 
tmcA 70 EpnA, S. 
hygroscopicus 
AHB38503 86/98 LuxR-like transcription 
factor 
tmcB 220 EpnB, S. 
hygroscopicus 
AHB38504 85/91 Type II 
Thioesterase 
tmcC 285 EpnC, S. 
hygroscopicus 
AHB38505 92/95 Proteosome β-subunit 
tmcD 340 EpnD, S. 
hygroscopicus 
AHB38506 89/94 Ketoacyl synthase III 
tmcE 76 EpnE, S. 
hygroscopicus 
AHB38507 84/90 Acyl carrier protein 
tmcF 557 EpnF, S. 
hygroscopicus 
AHB38508 89/92 Flavin-dependent 
dehydrogenase 
tmcG 2167 EpnG, S. 
hygroscopicus 
AHB38515 82/88 NRPS 
tmcH 2051 EpnH, S. 
hygroscopicus 
AHB38509 81/86 PKS 
tmcI 431 EpnI, S. 
hygroscopicus 
AHB38510 88/92 Cytochrome P450 
tmcJ 658 EpnJ, S. 
hygroscopicus 
AHB38511 90/93 Adenylation domain 
tmcK 408 EpnK, S. 
hygroscopicus 
AHB38512 93/96 Cytochrome P450 
tmcL 183 T261_3953, S. 
lydicus A02 
AJT65613 85/89 Response regulator 
receiver 
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the intermediate 41 by the thioesterase (TE) domain of TmcH is proposed to yield the 
substrate for epoxyketone formation. The initial hypothesis was that epoxidation could 
be facilitated by either flavin-dependent TmcF, cytochrome P450 TmcI, or a 
combination of both enzymes. 
Interestingly, recent unpublished research by Dr. C. Huang of the Challis group 
suggests that the epn cluster is also a TMC-86A 12 producer, and eponemycin 8 is a 
shunt metabolite obtained from using the fatty acid 6-methylhepatonoic acid from 
ordinary Streptomyces FAS metabolism. The epn cluster was heterologously 
expressed in S. albus, producing approximately equimolar amounts of eponemycin 
and TMC-86A 12. Complementation of this transformant with a plasmid that 
constitutively expressed both epnD and epnE lead to dramatically increased 
production of TMC-86A 12, and only minimal production of eponemycin 8. The 
current hypothesis is that the promoter region leading into epnD is has mutations 
which affect production compared to the corresponding region found in the tmc gene 
cluster, ensuring poor expression of epnD in S. hygroscopicus and therefore 
significant production of eponemycin 12 using an alternate fatty acid metabolite. 
 
1.3.1.1 Regulation and self-resistance 
The TMC-86A 8 biosynthetic gene cluster is regulated by LuxR-like transcription 
factor, tmcA. LuxR transcription factors are known to possess a helix-turn-helix 
domain in the C-terminal region, which binds to and represses DNA transcription, and 
an N-terminal region which binds an inducer molecule. In Gram-negative bacteria, 
this method of transcriptional regulation is moderated by diffusion of acyl-homoserine 
lactones, however in Gram-positive Streptomyces species inter-kingdom 
communication with many discreet compounds often prompts LuxR induction and 
subsequent expression of advantageous secondary metabolites.46 
Encoded by the cluster is an alternate proteasome subunit, TmcC. This subunit has 
homology to a similar subunit encoded in the biosynthetic gene cluster for proteasome 
inhibitor Salinosporamide A, produced by Salinispora tropica. Amino acid mutations 
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in the proteasome binding pocket ensure resistance to inhibition. By expression of 
TmcC, S. chromofuscus therefore has self-resistance to the epoxyketone inhibitor it 
produces.47 
 
1.3.1.2 Fatty acid biosynthesis by TmcD 
 
 
Figure	1.10.	A:	Structure	of	phosphopantetheine,	PPT.	B:	Proposed	biosynthesis	of	TMC-
86A	butyric	acid	moiety.	C:	Biosynthesis	of	6-methyl	heptanoic	acid	formation	proposed	
by	Moore	and	coworkers.	
 
In order to produce the butyric acid moiety incorporated into the structure of TMC-
86A 12, it is proposed a dedicated FabH-like FAS enzyme TmcD is required. FabH 
enzymes are responsible for the condensation of conserved cysteine-bound acyl units 
to a PPT 43 thiol-bound malonyl extender unit (figure 1.10A) of a standalone ACP 
like TmcE (figure 1.10B).48 ACP domains facilitate the transacylation of acyl-
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intermediates between enzymes. In the case of Streptomyces species, their FAS 
metabolism prefers different acyl-CoA units to the acetyl-CoA 37 required to make 
butyric acid, often producing branched fatty acids as a consequence.43 Therefore, a 
dedicated FAS enzyme with acetyl-CoA 37 specificity is required to produce β-keto 
thioester 46 on TmcE. This is then reduced down to butanoyl-ACP 38 by process of 
β-keto reduction, dehydration and enoyl reduction by FabG, FabA and FabI 
respectively of existing Streptomyces FAS metabolism.49–51 
In the proposed biosynthesis of eponemycin by Moore et al, it is suggested that the 
incorporated 6-methyl heptanoic alternative fatty acid is a result of deamination of 
leucine bound to NRPS enzyme EpnJ 47 by an unspecified mechanism, followed by 
EpnD mediated condensation of malonyl-CoA units to give the 6-methyl heptanoic 
fatty acid attached to EpnE 49 (figure 1.10C).41 However, as previously discussed, 
unpublished data from Dr. C. Huang demonstrate that constitutive promotion of EpnD 
and EpnE makes the epn cluster produce TMC-86A 12 as its major metabolite in S. 
albus. While low levels of eponemycin 8 in this expriment may result from EpnJ not 
also being constitutively promoted, or possibly from higher levels of butanoyl-CoA 
being present in S. albus compared to the original strain which out-competes 6-methyl 
heptanoic acid incorporation, it seems unusual for a biosynthetic gene cluster to 
produce two competing fatty acid precursors. Therefore, it seems more likely 6-methyl 
heptanoic acid is derived as a branched chain fatty acid from innate Streptomyces fatty 
acid metabolism. An alternate function for both TmcJ and EpnJ under this hypothesis 
remains unknown, with one possibility being they are non-functional. 
 
1.3.1.3 NRPS domains and peptide synthesis by TmcG 
Following butanoyl thioester synthesis, the next stage of TMC-86A assembly is 
peptidation by the NRPS TmcG. NRPS enzymes are composed of domains serving 
different catalytic functions organized into modules, making NRPS enzymes 
multifunctional.44 The key domains found in NRPS enzymes are: 
Adenylation (A) domain – typically around 500 amino acid residues in length, this 
domain possesses an active site pocket between a small C-terminal subunit and a large 
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N-terminal subunit.44 The role of the A domain is to activate an amino acid using ATP 
to form an aminoacyl adenylate (such as 51), allowing for reaction with the PPT 43 
thiol of a post-translationally modified PCP domain to furnish 52 (figure 1.11A). The 
A domain is also responsible for amino acid specificity of a module, with variations 
in eight amino acid residues found in the A domain binding pocket facilitating amino 
acid recognition.52 
Peptidyl carrier protein (PCP) domain – approximately 80-110 amino acids in 
length, the PCP domain is structured as four α-helices with the active site serine 
located just before the second α-helix. Posttranslational modification of this serine 
with PPT 43 in turn allows for the domain to facilitate transference of a peptide 
intermediate (figure 1.11B). 
 
 
 
Figure	1.11.	A:	Adenylation	domain	catalysed	ATP	activation	of	serine,	A	=	Adenylation,	
PCP	=	peptidyl	carrier	protein.	B:	Condensation	(C)	domain	mediated	transpeptidation,	
resulting	in	proposed	TmcG	module	2	intermediate	40.	
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Condensation (C) domain – usually near 450 amino acids in length, the condensation 
domain is responsible for catalysing peptide bond formation in an NRPS enzyme 
between an upstream module and a downstream PCP domain which has been charged 
with an amino acid (figure 1.11B).44 C have a nucleophilic docking site which 
interacts PPT 43 arm of the downstream PCP, and an electrophilic site for the 
upstream PPT tethered to a PCP, allowing for close association of amino acid and 
thioester substrates to facilitate formation of the peptidic bond, such as in 38. 
Thioesterase (TE) domain – about 250 amino acids in length the TE domain is 
responsible for release of a peptide chain from an NRPS module. The active site serine 
of the TE domain forms an ester linkage with the peptide thioester intermediate bound 
to the PPT 43 arm of a PCP domain by addition elimination, and then allows for chain 
release either by hydrolysis or cyclisation using a nucleophilic functionality in the 
peptide backbone.44 The catalytic mechanism of the TE domain is similar to that found 
in PKS enzymes (figure 1.12B). 
Tailoring domains – cyclisation (CY) domains are specialised forms of C domains 
which are responsible for both the condensation of a cysteine, serine or threonine 
residues and their subsequent cyclisation to form thiazoline or oxazoline, which often 
have a role in metal chelation when present in natural products.44 The epimerisation 
(E) domain of NRPS enzymes is responsible for epimierising the stereocenter of 
amino acids incorporated into a peptide compound, working in tandem with a C 
domain which is selective for incorporation of the D-stereochemistry due to E domains 
producing amino acids as an enatiomeric mixture. Lastly, C-methytransferase or N-
methytransferase (cMT or nMT) domains catalyse methylation of carbon and nitrogen 
respectively which discourages degradation of peptidic natural products by a protease. 
This reaction uses the cofactor SAM 60, and functions similarly to that seen for PKS 
enzymes (figure 1.12C).44 
The two modules in TmcG are composed of A, C and PCP domains, and condense L-
serine followed L-leucine to fatty acid chain providing 39 and 40 respectively (figure 
1.11B).44 
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1.3.1.4 PKS domains and extension by TmcH 
The final step of TMC-86A biosynthesis before release as the putative substrate for 
epoxyketone formation is elongation and dimethylation by the PKS TmcH. Similar to 
NRPS enzymes, type I PKS enzymes are made of modules formed from domains with 
differing catalytic activities: 
Acyl carrier protein (ACP) domain – similar in size and function to the PCP 
domains found in NRPS enzymes, with four helical bundles and around 80 amino 
acids in length, ACP domains carry a catalytic serine residue which is post-
translationally modified with PPT. The thiol of the PPT arm is responsible for the 
shuttling of polyketide intermediates by way of transacylation such as 58 (figure 
1.12B).53 
Acyl transferase (AT) domain – the AT domain is responsible for charging a ACP 
domain with an extender unit, most commonly malonyl-CoA 53 produced by acetyl-
CoA carboxylase. Approximately 300 amino acids in length, in cis-AT PKS enzymes 
the AT domain follows a ketosynthase (KS) domain, whereas in a trans-AT PKS there 
is a standalone AT enzyme. The catalytic serine residue of an AT domain is activated 
by histidine, which allows for addition-elimination at the malonyl-CoA thioester to 
give 54. Following this, nucleophilic addition-elimination of the PPT arm thiol on an 
ACP domain charges that ACP domain with the extender unit as in 55 (figure 
1.12A).53 
Ketosynthase (KS) domain – responsible catalysis of the carbon-carbon bond 
forming reaction in PKS enzymes, the KS domain is typically 430 amino acids 
residues in length and readily forms homodimers with the KS domains of identical 
PKS enzymes. The key catalytic sites in the domain are a TACSSS motif containing 
the catalytic cysteine as well as HGTGT and KSNIGHT containing vital histidine 
residues. The cysteine itself is close to an α-helix, the positive dipole of which assists 
in increasing the nucleophilicity of the catalytic residue. All this serves to facilitate 
acquisition of upstream substrate intermediate 56 from a carrier protein by addition-
elimination to form 57, followed by decarboxylative Claisen condensation with a 
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downstream extender-unit loaded ACP to form a β-keto thioester on that domain and 
thereby extend the length of the intermediate (figure. 1.11B).53 
 
 
 
Figure	 1.12.	 A:	 AT	 mediated	 ACP	 malonylation.	 B:	 Transacylation	 of	 KS	 domain,	 and	
subsequent	decarboxylative	Claisen	condensation	to	form	an	ACP-bound	β-keto	thioester.	
C:	Dimethylation	of	β-keto	thioester	using	SAM	60	by	cMT	domain.	D:	TE	domain	hydrolytic	
chain	release	of	polyketide	to	give	carboxylic	acid	40.	
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to an ACP domain using SAM cofactor 60 (figure 1.13). cMT domains are comprised 
of approximately 130 residue N-terminal region which recognises the substrate 
intermediate, and C-terminal region around 190 residues in length which binds SAM 
with a characteristic xGxGxG motif. The precise mechanism of deprotonation of 
intermediates such as 58 to allow for SN2 attack on SAM by way of enolate 59 is 
currently unknown (figures 1.11C and 1.12). O-methyltransferase (oMT) domains 
also exist which operate by a similar mechanism to methylate alcohol functionalities.53 
Thioesterase (TE) domains – similar to TE domains present in NRPS enzymes, this 
domain is responsible for release of the polyketide intermediate from the PKS enzyme, 
again either by cyclisation using a nucleophilic residue present in the intermediate or 
by hydrolysis. Usually ranging from 240-290 amino acids in length, the catalytic 
serine of a GxSxG motif is base activated and undergoes addition elimination at a 
thioester 62 attached to the PPT arm of an upstream ACP domain (figure 1.12D). 
Following this, attack by base activated water or an internal secondary alcohol 
facilitates release, in the case of TMC-86A resulting in carboxylic acid 64 (figure 
1.12D).45,53 
The PKS module in TmcH is comprised of KS, AT, cMT, ACP and TE domains, and 
putatively forms carboxylic acid 64 (figure 1.12). 
Other catalytic PKS domains – The ketoreductase (KR) domain is typically between 
420 and 460 residues in length and is responsible for stereoselective reduction of the 
β-keto group in a polyketide thioester intermediate using a reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) cofactor. The presence or absence of an 
important LDD motif dictates the resulting stereochemistry of the alcohol, with some 
KR domains also capable of furnishing specific stereochemistry of both the alcohol 
and α-methyl group in the case of methylation by a cMT domain.53 With a β-alcohol 
installed by the KR domain, the dehydratase (DH) domain is then responsible for 
dehydration to provide an α,β-unsaturated thioester. DH domains are ordinarily 
around 280 amino acids in length, use catalytic aspartic acid and histidine residues to 
protonate the alcohol and abstract the α-proton respectively. Lastly, enoylreducatse 
(ER) domains of around 310 amino acids in length use an NADPH cofactor to reduce 
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α,β-unsaturated thioester intermediates resulting from action of a DH domain to their 
saturated counterparts, with the capacity to produce a specific enantiomer in the case 
of α-substitution.53 
 
 
 
Figure	1.13:	Summary	of	[13C-methyl]-L-methionine	feeding	experiments	conducted	in	S.	
chromofuscus	by	D.	Zabala.	Red	circles	indicate	the	presence	of	a	[13C]-isotopic	label.	
 
To investigate whether the cMT domain was catalysing mono- or di-methylation, Dr. 
D. Zabala of the Challis group cultured S. chromofuscus in the presence of [13C-
methyl]-L-methionine. Subsequent 13C nuclear magnetic resonance (NMR) 
spectroscopy revealed incorporation on the isotopic label into both methylene carbons 
of the α-hydroxymethyl-α,β-epoxyketone moiety present in TMC-86A 12.42 This 
indicates that the thioester intermediate bound to the ACP in TmcH is dimethylated 
by the cMT domain, and that both of these methyl groups remain present while 
progressing from the putative substrate to TMC-86A 12 (figure 1.13). 
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1.3.2 Biosynthesis of the TMC-86A pharmacophore 
1.3.2.1 Putative substrates 
While hydrolytic release of the α-dimethyl-β-keto ester bound to the TE domain of 
TmcH (figure 1.12D) should theoretically yield α-dimethyl-β-keto carboxylic acid 66, 
α-dimethyl-β-keto carboxylic acid compounds are known to be unstable. This is 
primarily due to the β-keto group providing a natural electron sink and partner for 
hydrogen bonding with the carboxylic acid, encouraging a favourable conformation.54 
As rate of decomposition had been demonstrated to be independent of the dielectric 
constant of solvent for these compounds, indicating the presence of a neutral transition 
state, the most widely agreed upon mechanism of degradation is decarboxylation 
through a cyclic transition state to produce an enol.55 Enols 68 can then readily 
tautomerize to isopropyl ketones 69 (figure 1.14). 
 
 
Figure	 1.14:	 Decarboxylative	 degradation	 of	 an	 α-dimethyl-β-keto	 carboxylic	 acid	 67	
through	a	cyclic	transition	state	to	provide	enol	68,	and	subsequent	tautomerization	to	
produce	isopropyl	ketone	69.	
 
With this in mind, there are two possible products of hydrolysis of the TE domain 
bound α-dimethyl-β-keto ester 70: the α-dimethyl-β-keto carboxylic acid 66, and the 
isopropyl ketone 71 resulting from its decarboxylation. This decarboxylation could 
either occur spontaneously, or it may be catalysed by the TE domain itself (figure 
1.15). Both putative substrates would need to be synthesised in order to determine the 
true substrate required for epoxyketone formation. 
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Figure	1.15:	The	two	possible	substrates,	66	and	71,	resulting	from	hydrolysis	of	the	α-
dimethyl-β-keto	ester	bound	to	the	TE	domain	of	TmcH.	
 
1.3.2.2 Putative acyl-CoA dehydrogenase TmcF 
TmcF has homology to flavin-dependent acyl-CoA dehydrogenase (ACAD) enzymes, 
with 89% identity and 92% similarity to EpnF. The mechanism of action of ACAD 
enzymes is concerted fission of two C-H bonds adjacent to fatty acid CoA thioester 
73, with proton abstraction at the α-position facilitated by a conserved glutamate 
residue and concomitant hydride-equivalent donation from the β-position to a flavin 
cofactor.56 In the archetypal case of medium chain acyl-CoA dehydrogenase from 
FAS, ordinarily the pKa of the α-position would be too high to allow for deprotonation 
by glutamate (pKa > 20), however hydrogen-bonding to the thioester carbonyl by a 
ribityl-functionality of a cofactor decreases the pKa of this position to around 8.56 With 
a bound substrate, the pKa of the corresponding glutamic acid is around 9, facilitating 
the concerted mechanism and using the hydrogen atoms shown, previously 
demonstrated with deuterium labelling experiments (figure 1.16A). Other natural 
products which undergo catalysis by enzymes with ACAD homology are pyoluteorin 
76 and undecylprodigiosin 77 from Pseudomonas fluorescens Pf-5 and S. coelicolor 
A3(2) respectively, where PCP-bound proline is desaturated to a pyrrole moiety.57,58 
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Figure	 1.16.	 A:	 Mechanism	 of	 action	 of	 dehydrogenation	 in	 medium	 chain	 acyl-CoA	
dehydrogenase,	 with	 hydrogen	 bonding	 from	 a	 ribityl-functionality	 of	 a	 cofactor.	 B:	
Structures	of	pyoluteorin	and	undecylprodigiosin,	natural	products	dehydrogenated	by	
enzymes	with	ACAD	homology.	Moieties	highlighted	in	red	demonstrate	positions	of	the	
catalytic	desaturation.	
 
Though medium chain fatty acid-CoA molecules are the typical substrates for 
ACADs, due to the poor orbital overlap between the sulphur lone pair of electrons and 
the carbonyl group in a thioester bond, the chemical qualities of a thioester bond are 
not far removed from that of a ketone such as 71. One possible route to epoxyketone 
formation was therefore initial dehydrogenation of 71 by TmcF, using a mechanism 
directly analogous to the ACAD desaturation of thioesters. This reaction would form 
the reactive α,β-unsaturated ketone 79, facilitating epoxidation by the cytochrome 
P450 TmcI. Alternatively, TmcF was the most likely enzyme to react with the 
electron-rich carboxylic acid 66 in the instance of 71 not being a viable substrate, 
through a then unknown mechanism (figure 1.17).  
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Figure	1.17:	The	two	proposed	enzymatic	routes	to	epoxyketone	78.	
 
1.3.2.3 Cytochrome P450 TmcI 
With the α,β-unsaturated ketone 79 proposed to form by TmcF dehydrogenation, 
epoxidation is required to complete the epoxyketone pharmacophore of 78. 
Cytochrome P450s are known to catalyse epoxidation reactions with alkene 
substrates, and of the two P450 enzymes in the cluster it was determined that TmcI 
was most likely to be responsible for this catalysis, due to it being widely conserved 
across epoxyketone biosynthetic gene clusters.59 TmcK by contrast appeared to be 
only conserved in epoxyketone biosynthetic gene clusters where leucine desaturation 
occurred, making it putatively responsible for this tailoring reaction.41 
In order for P450 enzymes to be catalytically functional, the prosthetic heme group 
bound to a conserved cysteine residue needs to undergo reduction by an electron 
transport chain as it is incapable of being reduced directly by the necessary cofactors 
(figure 1.18A).60 In Streptomyces species, electron transport to a P450 is mediated by 
the proteins ferredoxin (Fdx) and ferredoxin reductase (FDR) from either reduced 
nicotinamide adenine dinucleotide (NADH) or NADPH (figure 1.18B).61 
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Figure	1.18.	A:	Structure	of	low	spin	ferric	resting	state	of	a	heme	prosthetic	group	in	a	
cytochrome	 P450.	 B:	 Electron	 transport	 chain	 of	 a	 P450,	 using	 ferredoxin,	 ferredoxin	
reductase	and	NAD(P)H.	
 
The catalytic cycle of cytochrome P450 enzymes (figure 1.19A) begins with 
conversion of the six coordinate low-spin ferric resting state of heme to high spin five 
coordinate ferric resting state upon substrate binding 81.59,60 Reduction by an electron 
transport chain converts iron to its ferrous state 82, which will reduce oxygen upon 
binding to form a ferric-superoxo species 83. Further electron transport chain 
mediated reduction and subsequent protonation converts this species to ferric peroxide 
84. Additional protonation of this hydroperoxy-species produces water and an oxy-
ferryl porphyrin cation radical species 85, believed to be the responsible for substrate 
catalysis.62 Monooxygenation of a substrate by this species, followed by substrate 
dissociation and the binding of a water molecule, restores the original six coordinate 
low-spin ferric resting state of heme 80.59,60 
Epoxidation by a P450 enzyme from the oxy-ferryl porphyrin cation radical species 
85 occurs by two electron oxidation to an alkene bond, though there is ongoing debate 
as to whether this is by a concerted or stepwise mechanism (figure 1.19B).59 Epoxide 
functionalities of several natural products, including epothilone A 89 and 
mycinamicin II 90 from Sorangium cellulosum and Micromonospora griseorubida 
respectively, are putatively produced by this mechanism (figure 1.19C).63,64 
As previously discussed, the second cytochrome P450 TmcK is putatively responsible 
for dehydrogenation of the leucine side chain occurring after release from TmcG 
(section 1.3.1). Following hydroxylation of the leucine side chain by species 85 (figure 
1.19D), dehydration would form the carbon-carbon double bond present in TMC-86A. 
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Figure	 1.19:	 A.	 The	 catalytic	 cycle	 of	 a	 cytochrome	 P450.	 B:	 Mechanism	 of	 alkene	
epoxidation	by	a	cytochrome	P450.	C:	Structures	of	epoxide	epothilone	A	and	mycinamicin	
II.	 D:	 Mechanism	 of	 hydroxylation	 by	 a	 cytochrome	 P450,	 allowing	 for	 resulting	
dehydration.	
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1.4 Project aims 
In the industrial production of epoxyketone proteasome inhibitors, the epoxidation 
step has proven to have poor stereoselectivity. Synthetic pharmaceuticals were 
originally designed based on the natural product epoxomicin, though the enzymes 
responsible for the stereoseletive biosynthesis of the α,β-epoxyketone pharmacophore 
in these compounds has remained poorly understood. The key aim of this research is 
therefore to determine which enzymes and substrates accomplish this biosynthetic 
reaction. 
To achieve this, firstly it is necessary to clone, express and subsequently overproduce 
the cytochrome P450 TmcI and flavin-dependent ACAD-like TmcF. Two putative 
substrates, the isopropyl ketone 71 and the α-dimethyl-β-keto carboxylic 66 will need 
to be produced through synthesis. Conducting in vitro assays with either 71 or 66 and 
TmcF or TmcI should reveal the responsible enzyme for α,β-epoxyketone, and 
therefore produce the TMC-86A analogue 78. 
In the event of successful determination of both substrate and enzyme required for 
α,β-epoxyketone biosynthesis, substrate tolerance of the corresponding enzyme as 
well as mechanistic interrogation will be conducted. 
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Chapter 2:     Overproduction of recombinant 
EpnF and TmcI
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2.1 Cloning of tmcF and tmcI into the pET151 vector 
To investigate the catalytic activity of the putative flavin-dependent dehydrogenase 
TmcF and the predicted cytochrome P450 TmcI, the genes encoding these proteins 
were cloned into an E. coli expression vector. Utilizing genomic DNA isolated from 
S. chromofuscus ATCC49982 and appropriate primers, polymerase chain reactions 
(PCRs) were conducted on the DNA to produce amplimers corresponding to each 
gene. The PCR products were visualised using agarose gel electrophoresis, and 
fragments of the correct size (1.3 kb and 1.7 kb for TmcI and TmcF respectively) were 
excised from the gel and purified (figure 2.1). 
 
 
Figure	 2.1:	 Agarose	 gel	 of	 tmcI	 (lanes	 1	 and	 2)	 and	 tmcF	 (lanes	 3	 and	 4)	 amplimers	
separated	by	electrophoresis.	PCR	was	conducted	at	55	°C	in	the	first	lane	and	60	°C	in	the	
second	lane	for	each	amplimer,	with	a	1	kb	marker	in	lane	5.	
 
Amplimers were cloned into pET151, which has several features that facilitate the 
overproduction and purification of a recombinant proteins encoded by the gene 
inserted into it (figure 2.2). The lacI gene of the vector encodes the lac repressor, 
which binds to the lac operon in the cloning site and controls transcription. This 
feature allows for induction by isopropyl β-D-1-thiogalactopyranoside (IPTG), a 
stable mimic of the natural inducer allolactose, which releases the lac repressor from 
the operon.65 The T7 promoter binds the highly specific T7 RNA polymerase encoded 
by DE3 Escherichia coli cell lines, enabling very efficient transcription of the gene of 
interest upon induction.66 The introduction of a start codon upstream of the cloning 
site allows for expression of recombinant proteins with a hexahistidine (His6) tag 
0.85 kb
2.0 kb
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1.3 kb
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fused to their N-termini facilitating purification by immobilized metal affinity 
chromatography (IMAC). The ribosome binding site upstream of the start codon 
ensures efficient translation of the resultant mRNA. Lastly the bla gene functions as 
a selectable marker for ampicillin, ensuring that only cells containing the vector (with 
or without an insert) will grow in culture media containing ampicillin. 
 
 
Figure	2.2:	Features	of	the	pET151	vector	(Invitrogen)	in	the	vicinity	of	the	cloning	site.	
RBS	denotes	the	ribosome	binding	site,	and	Met	signifies	the	methionine	start	codon.	
 
The resulting constructs were used to transform chemically competent E. coli TOP10 
cells, and positive colonies were selected for by plating on Luria-Bertani (LB) agar 
containing ampicillin. Single colonies were picked and grown in LB liquid medium 
containing ampicillin, and the resulting plasmids were isolated from pelleted cells (see 
experimental section for details). 
The integrity of the isolated plasmids was verified using restriction digests, with 
restriction enzymes selected that would cut once inside the gene of interest and once 
in the vector backbone (figure 2.3). This provided a distinctive pattern of DNA bands 
that confirmed the correct orientation of the gene in the vector, approximately 
corresponds to the kb markings in the kb marker. Plasmids yielding the anticipated 
digestion pattern were sent for DNA sequencing, and one correct clone was selected 
in each case for protein overproduction. 
Topoisomerase 
T7 promoter lac operon 
RBS Hexahistidine-tag V5 epitope 
V5 epitope TEV recognition site 
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Figure	 2.3:	 Agarose	 gel	 electrophoretic	 analysis	 of	 plasmids	 isolated	 from	 ampicillin-
resistant	clones	after	digestion	with	PvuI.	Clones	containing	tmcI	(lanes	marked	with	an	
asterisk)	are	expected	to	yield	bands	of	2.2	and	4.8	kb.	A	kb	marker	is	in	the	left	most	lane.	
 
2.2 Overproduction of recombinant proteins in E. coli and 
subsequent purification 
2.2.1 Overproduction of TmcF and TmcI 
To overproduce TmcF and TmcI, the plasmids containing the corresponding genes 
were used to transform E. coli BL21 (DE3). Transformants were selected by growth 
on ampicillin LB agar plates, and single colonies were picked and used to produce 
mini-cultures by overnight growth in liquid LB medium. The mini-cultures were used 
to inoculate large scale cultures, which were grown to an optical density at 600 nm 
(A600) of 0.5-0.7, during which period the cells are in the exponential growth phase. 
Expression was induced by addition of IPTG, allowing for efficient translation and 
transcription as discussed previously (section 2.1). To facilitate incorporation of the 
heme prosthetic group into TmcI, 5-aminolevulinic acid was added to the cultures at 
the same time as IPTG. 5-Aminolevulinic acid is a precursor of the porphyrin ligand 
incorporated into heme and has been reported to boost the levels of heme 
incorporation into cytochrome P450 enzymes.67 
Once induced, the cells were incubated overnight at 15 °C then pelleted by 
centrifugation. The cell pellet was re-suspended in buffer solution and the cells were 
lysed (see experimental procedures for details). The insoluble cell debris was 
separated from the soluble protein fraction by centrifugation. 
* 2.0 kbp –  * * * 
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The recombinant His6 fusion proteins were purified by IMAC on a nickel-nitrilo acetic 
acid column. The His6 tag binds specifically to the immobilised Ni2+, allowing other 
proteins in the lysate to flow through. Successive washing with buffer containing low 
and high concentrations of imidazole elutes non-specically bound proteins followed 
by the recombinant His6 fusion protein (section 7.2.6). 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) enables 
visualisation and screening of protein purity at different stages of the purification 
process. This allows problems such as poor solubility or a lack of protein binding to 
the nickel column due to burial of the His6 tag to be identified. SDS both denatures 
and binds to proteins giving them a uniform m/z ratio, allowing for separation on the 
basis of size. Coomassie Brilliant Blue dye was used to visualise proteins on the gel, 
which stabilises the blue anionic form of the dye. While the His6-TmcI fusion was 
found to be soluble, His6-TmcF was localised primarily in insoluble inclusion bodies 
(figure 2.4). 
 
 
Figure	2.4:	SDS-PAGE	analysis	of	insoluble	(left	lane)	and	soluble	(middle	lane)	fractions	
resulting	from	overproduction	of	His6-TmcF	(64.1	kDa)	in	E.	coli	(left),	and	two	different	
concentrations	of	purified	recombinant	His6-TmcI	 (51.3	kDa)	(right).	Molecular	weight	
markers	are	in	the	right	and	left	lanes,	respectively.	
 
To overcome the problem with the insolubility of His6-TmcF, expression in E. coli 
Rosetta (DE3) was attempted. This strain contains genes encoding tRNAs for rare 
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codons and is useful for expression of genes with high G + C content, such as those 
derived from Streptomyces species.68  The tmcF gene was also cloned into the pColdI 
vector, which facilitates induction of expression at 4 °C by action of the cspA 
promoter, though action of cspA is poorly understood.69 The use of low temperatures 
during induction of gene expression is known to increase both the solubility and 
production level of the corresponding protein. Neither approach resulted in the 
production of soluble His6-TmcF. Thus we sought to overproduce homologues 
encoded by other epoxyketone biosynthetic gene clusters.  
 
2.2.2 Overproduction of EpnF 
Both the structures and the biosynthetic gene clusters of TMC-86A 12 and 
eponemycin 8 (produced by S. hygroscopiscus ATCC53709) are very similar, and the 
eponemycin biosynthetic gene cluster encodes a homologue of TmcF (EpnF) with 
89% identity.41,42 Indeed, recent research by the Challis group has shown that 
heterologous expression of the eponemycin biosynthetic gene cluster in S. albus 
results in the production of approximately equimolar quantities of eponemycin 8 and 
TMC-86A 12 (sections 1.3.1 and 1.3.1.2). We thus attempted to overproduce EpnF in  
 
Figure	2.5:	SDS-PAGE	analysis	of	two	different	concentrations	of	purified	His6-EpnF	(68.9	
kDa)	(middle	and	right	lanes).	Molecular	weight	markers	are	in	the	left	lane.	
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E. coli and following the procedures used for TmcF and TmcI (sections 2.1 and 2.2.1) 
resulted in the production of soluble His6-EpnF, which was purified using IMAC to 
near-homogeneity (figure 2.5).42 
To optimise the overproduction of EpnF, different concentrations of IPTG were 
evaluated (25/50/100/250 µM). It was determined that 100 µM OF IPTG produced the 
greatest quantity of EpnF per litre of cell culture. Riboflavin was also added at the 
same time as IPTG, as this has been reported in the literature to promote the 
incorporation of the flavin cofactor into flavoproteins.70 
 
2.2.3 Characterisation of recombinant proteins 
To confirm the identity of the purified recombinant proteins they were analysed by 
electrospray ionisation-quadrupole-time of flight mass spectrometry (ESI-Q-TOF-
MS; by Dr. Matthew Jenner). The masses observed in the deconvoluted spectra 
obtained from these experiments were consistent with those calculated for His6-EpnF 
and His6-TmcI (figure 2.6), each in the absence of their cofactor. In addition, peptide 
mass fingerprinting was conducted on each of the purified proteins. Protein bands 
were excised from an SDS-PAGE gel and digested with trypsin. MALDI-TOF gave 
15 and 30 fragments for TmcI and EpnF respectively, corresponding to 33% and 37% 
sequence coverage (see appendix).42 
Gel filtration chromatography was conducted on each protein to determine their 
oligomerisation states. By comparison to the elution volume of protein standards of 
known molecular weight (section 7.2.9), which have a linear relationship, it was 
determined that the elution volume of TmcI corresponded to a monomer whereas that 
of EpnF corresponded to a dimer (figure 2.7).42 This is consistent with cytochromes 
P450 being widely observed as monomeric species.71 
 
 
	 	 	
	 38	
Figure	2.6.	Measured	(A,	C)	and	deconvoluted	(B,	D)	ESI-Q-TOF	mass	spectra	for	His6-EpnF	
(m/z+	 calculated:	 68921,	 observed:	 68924)	 and	 His6-TmcI	 (m/z+	 calculated:	 51269,	
observed	51270),	respectively.	
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Figure	2.7:	Chromatograms	from	gel	filtration	analysis	of	His6-EpnF	(top)	and	His6-TmcI	
(bottom),	 demonstrating	 elution	 volumes	 of	 purified	 proteins	 corresponding	 to	
absorbance	maxima.	
 
2.2.3.1 Characterisation of TmcI heme prosthetic group 
The observation of a species with m/z = 616.1765 (corresponding to the positively 
charged molecular ion for heme) in the ESI-Q-TOF mass spectrum of His6-TmcI 
(figure 2.8) indicated that it contains a heme prosthetic group, as expected for a 
cytochrome P450. The purity index of His6-TmcI was determined by first removing 
imidazole from the protein, and then measuring its UV-visible absorbance spectrum 
between 250 and 500 nm. The absorbance at 416 nm corresponds to the Soret band of 
the hexacoordinate low-spin iron(III) in the heme cofactor. A value between 1.0 and 
1.9 for the ratio of A280/A416 is expected for cytochrome P450 enzymes. The range of 
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values observed results from differences in the extinction coefficient at 280 nm for 
individual proteins. Impurities such as imidazole and other proteins will skew this 
ratio to higher values.42,72 In this instance, a value of approximately 1.0 was obtained 
(figure 2.8B).  
 
 
Figure	2.8.	A:	Mass	spectrum	of	heme	prosthetic	group	released	from	His6-TmcI	ESI-Q-TOF	
MS	 analysis	 (m/z	 calculated	 for	 C34H32FeN4O4+:	 616.1767,	 observed:	 616.1765).	 B:	 UV-
visible	absorbance	spectrum	of	His6-TmcI	(500	μM)	between	250	and	500	nm.	
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Formation of the characteristic high-spin carbon monoxide complex, absorbing at 450 
nm, was attempted using sodium dithionite as a reductant and 
tricarbonylchloro(glycinato)ruthenium II (carbon monoxide releasing molecule 3 – 
CORM3), which releases carbon monoxide in aqueous solution. However, this proved 
problematic, probably due to the presence of oxygen in the buffer solutions. The mass 
spectrometric and UV-vis spectroscopic analyses of TmcI were judged to have 
provided sufficient evidence for the presence of a heme prosthetic group in the protein 
for the purposes of proceeding with investigation into its catalytic function. 
 
2.2.3.2 Characterisation of EpnF flavin cofactor 
Figure	2.9:	UV-visible	absorbance	spectrum	of	His6-EpnF	(500	μM)	between	300	and	500	
nm.	
 
The observed mass of His6-EpnF in ESI-Q-TOF spectra showed that the protein did 
not contain any covalent modifications. The flavin cofactor was therefore judged to 
be non-covalently bound to the active site of the protein. To illuminate the nature of 
the flavin cofactor, the absorbance spectrum of His6-EpnF was measured between 300 
and 500 nm. An absorbance maximum at 447 nm was observed (figure 2.9).42 The 
absorbance maximum of flavin adenine dinucleotide (FAD) is at 450 nm, whereas that 
for flavin mononucleotide (FMN) is 446 nm. The spectroscopic analysis of EpnF thus 
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failed to provide conclusive insight into the nature of the flavin cofactor.73 Heat-
denaturation of EpnF, followed by liquid chromatography-mass spectrometry (LC-
MS) analysis of the supernatant was attempted. However no ions corresponding to 
either cofactor were observed, presumably because the quantities of cofactor released 
were below the limit of detection. 
In later research, FAD and FMN were added separately to in vitro assays with EpnF. 
An increase in the quantity of product formed relative to a control reaction without 
additional flavin cofactor was only observed in the case of FAD (section 4.2.7.3). 
These data strongly suggest that FAD is the flavin cofactor used by EpnF.  
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 Chapter 3:     Synthesis of potential substrates 
for EpnF and in vitro assays
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3.1 Synthesis of potential substrates 
3.1.1 Choice of substrate analogues 
While TMC-86A produced by S. chromofuscus has a peptidic N-butanoyl-L-seryl-L-
4,5-dehydroleucine motif appended to the epoxyketone moiety, the timing of 
desaturation of the leucine sidechain with respect to pharmacophore installation 
remains unclear. Therefore, α-dimethyl-β-keto carboxylic acid 66 and the isopropyl 
ketone 71 were first assessed as potential leucine-derived substrate analogues (figure 
3.1). Both substrates could be produced following TE domain mediated hydrolysis 
from the modular PKS multienzyme TmcH, providing 66 directly or 71 after 
decarboxylation (section 1.3.2.1). This decarboxylation could either occur 
spontaneously or through catalysis by the TmcH TE domain. 
 
	
Figure	3.1:	Structures	of	potential	substrates	isopropyl	ketone	66	and	α-dimethyl-β-keto	
carboxylic	 acid	 71,	 and	 the	 structurally-related	 natural	 products	 TMC-86A	 and	
eponemycin.	
 
The synthetic work detailed in this chapter was conducted concurrently with enzyme 
purification, and as detailed previously only EpnF was overproduced in soluble form, 
with TmcF residing in insoluble inclusion bodies (sections 2.2.1 and 2.2.2). At the 
time of conducting the research it was not known that the eponemycin biosynthetic 
gene cluster could also direct the production of TMC-86A when expressed in S. albus 
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(section 1.3.1). However, as eponemycin only differs from TMC-86A by 
incorporation of a methyl 6-heptanoyl group in place of the butanoyl group (figure 
3.1), 66 and 71 were expected to be viable substrates for EpnF. 
 
3.1.2 Synthesis of putative isopropyl ketone substrate 71 
3.1.2.1. Proposed synthetic route 
To develop a synthetic route to 71, the compound was retrosynthetically divided into 
amine 94 and carboxylic acid 93, and routes to these peptide coupling partners then 
devised on the basis of existing epoxyketone total syntheses reported in the literature 
(figure 3.2). 
 
Figure	3.2:	Disconnection	of	the	proposed	isopropyl	ketone	substrate	analogue	for	EpnF	
gives	carboxylic	acid	93	and	amine	94	coupling	partners	to	produced	71.	
 
The natural product carmaphycin A 15 has a leucine residue in an analogous position 
to 71, so as a starting point for synthesis of 94 the total synthesis of 15 was reviewed.22 
To synthesise the epoxyketone peptide coupling partner 99, Weinreb-Nahm ketone 
synthesis was used to produce α,β-unsaturated isopropenyl ketone 97 via Weinreb 
amide 96 (for further discussion, see section 3.1.2.3).74 The epoxyketone 98 was  
synthesised through base-catalysed epoxidation of 97, and finally tert-
butyloxycarbonyl (Boc) deprotection by TFA was used to liberate amine 99 (scheme 
3.1A). The total synthesis carmaphycin A 15 was completed by coupling 99 to the 
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corresponding carboxylic acid. To synthesise 94, an isopropyl Grignard reagent could 
be used during Weinreb-Nahm ketone synthesis to install isopropyl ketone 
functionality and give 100, forgoing epoxidation. Acidic Boc deprotection would then 
yield the desired peptide coupling partner 94 (scheme 3.1B). 
 
 
Scheme	3.1.	A:	Total	synthesis	of	carmaphycin	A,	with	a	single	diastereomer	purified	by	
HPLC.22	B:	Proposed	synthetic	route	to	amine	coupling	partner	94.	
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dicyclohexylcarbodiimide (DCC)-mediated coupling of L-serine methyl ester 101 to 
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and epoxidation, give eponemycin. Exchanging 6-methyl heptanoic acid for butyric 
acid should allow for synthesis of 93 by the same method (scheme 3.2B). 
 
 
Scheme	3.2.	A:	Key	synthetic	steps	in	eponemycin	total	synthesis.75	B:	Proposed	synthetic	
route	to	93.	
 
Peptide coupling reactions building on the C-terminus, as proposed between 94 and 
93 (figure 3.2), are typically avoided due to a degree of epimerisation from oxazolone 
106 formation (figure 3.3). However, epimerisation of the leucine stereocenter was 
already unavoidable, due to keto-enol tautomerization in the proposed acidic Boc 
deprotection as well as during the basic conditions required for peptide coupling 
(scheme 3.1).76 Taking this into account, a convergent synthesis was retained in the 
hopes of increasing overall yield relative to a linear synthesis by reducing total number 
of steps. 
 
 
Figure	3.3:	Mechanism	of	oxazolone	mediated	epimerization	during	peptide	coupling.	
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3.1.2.2. Synthesis of N-butanoyl-L-serine 93 
To couple butyric acid to L-serine methyl ester hydrochloride, a DCC-mediated 
coupling procedure was adapted from the total synthesis of eponemycin (scheme 
3.2).75 While the total synthesis of eponemycin used ammonia gas as a base to convert 
the amine salt and carboxylic acid to the amine and carboxylate necessary for peptide 
coupling, for the sake of practicality and safety, triethylamine was chosen for the 
synthesis of 104. The initial yield of 104 was low (12%). However, repeating the 
reaction under an atmosphere of argon and with freshly distilled triethylamine and 
butyric acid allowed for an improvement to 65%. The coupling was also repeated with 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) hydrochloride 110 with 
hydroxybenzotriazole (HOBt) 115 as an additive. However, a yield of only 62% was 
achieved. The synthesis of  93 was completed using lithium hydroxide, with the 
addition of a catalytic amount of hydrogen peroxide (scheme 3.3).75 
 
 
Scheme	3.3:	Synthesis	of	N-butanoyl-L-serine	93	 through	DCC	coupling	and	subsequent	
ester	hydrolysis.	
 
The role of coupling reagents such as the carbodiimides DCC 109 and EDC 110 in 
peptide synthesis is to activate the carboxylic acid towards addition-elimination by an 
amine (figure 3.4A).76 Without a coupling reagent, an unreactive ammonium 
carboxylate salt forms instead of the desired peptide bond. For carbodiimides, the 
thermodynamic driving force behind the coupling reaction is the formation of a stable 
urea. Additives such as HOBt 115 or 4-dimethylaminopyridine (DMAP) 116 can be 
added to ensure minimization of N-acylurea byproducts 114 (figure 3.4B). The rate at 
which these additives react is faster than rearrangement of the initially formed 
carbodiimide adduct of the carboxylic acid to form an N-acylurea 114, while still 
providing an adequate leaving group to ensure successful acyl transfer to an amine.76 
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Figure	 3.4.	 A:	 Proposed	 mechanism	 of	 carbodiimide-mediated	 peptide	 coupling.	 B:	
Structure	of	HOBt	115	and	DMAP	116,	 additives	used	 in	peptide	 coupling	 reactions	 to	
reduce	 the	 formation	 of	 N-acylureas	 114	 via	 rearrangement	 of	 the	 initially-formed	
carbodiimide-carboxylate	adduct	113.76	
 
3.1.2.3. Synthesis of 94 
Following the procedure used in the total synthesis of carmaphycin A 15, coupling of 
N,O-dimethylhydroxyamine to N-BOC-L-leucine 95 using (benzotriazol-1-
yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) 117 was 
attempted, producing a yield of 77% of the Weinreb amide 96 (scheme 3.4). BOP 117, 
similar to the carbodiimide reagents employed previously (section 3.1.2.2), assists 
peptide coupling by activation of the carboxyl group to addition-elimination by a 
nucleophile, with formation of a phosphorous-oxygen double bond providing a 
thermodynamic driving force.76 
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Scheme	3.4:	Synthesis	of	94	through	Weinreb-Nahm	ketone	synthesis	and	subsequent	Boc	
deprotection.	
 
Weinreb amides such as 96 are used to ensure only mono-addition of the Grignard 
reagent to the carbonyl functionality by formation of a stable metal chelate 
intermediate 119, which is converted to the corresponding ketone via a low 
temperature acidic workup (figure 3.5).74 Using this method with 
isopropylmagnesium chloride resulted in a yield of 51% of 100, which could likely be  
 
	
Figure	3.5:	Mechanism	of	mono-addition	of	a	Grignard	reagent	 to	a	Weinreb	amide	via	
stable	tetrahedral	intermediate	119	that	decomposes	upon	acidic	work	up.74	
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half of 71, an acid-catalysed Boc deprotection was performed, producing 94 in a 55% 
yield (scheme 3.4). 
 
3.1.2.4. Peptide coupling to produce isopropyl ketone substrate 71 
The final step in the synthesis of 71 was the coupling of 94 and 93. BOP was selected 
as the coupling reagent due to the high yield of 77% achieved previously for 96. 
Although monitoring of the reaction mixture was attempted using thin layer 
chromatography (TLC) and MS, the polar nature of the product and reagents as well 
as the presence of readily ionisable species such as triethylamine rendered this 
challenging. In the absence of effective monitoring, the reaction was left for four 
hours, consistent with the procedure for 96. However, this produced a much lower 
yield of 26% for 71. 
 
 
Scheme	3.5:	Synthesis	of	isopropyl	ketone	71	via	BOP-mediated	coupling.	
 
The yield of 71 could likely be improved by increasing the duration of the reaction, or 
by increasing the amount of base used, as reported for the final peptide coupling in 
the total synthesis of carmphycin A 15.22 
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Meldrum’s acid was proposed followed by thermolysis in the presence of benzyl 
alcohol to give 120. Subsequent α-dimethylation using potassium carbonate and 
iodomethane in an SN2 reaction would produce 121.77 As in the synthesis of 71, Boc 
deprotection to give 122 and coupling would afford the α-dimethyl-β-keto benzyl ester 
123, which could be converted readily to the carboxylic acid 66 by removing the 
benzyl ester protecting group via hydrogenolysis over palladium on activated carbon. 
 
 
Scheme	3.6:	Proposed	synthesis	of	putative	substrate	66.	
 
3.1.3.2. Synthesis of 122 
 
 
Scheme	3.7:	Synthesis	of	122	by	Meldrum’s	acid	adduct	 thermolysis	 in	 the	presence	of	
benzyl	alcohol,	dimethylation	with	iodomethane	in	the	presence	of	potassium	carbonate,	
and	Boc	deprotection.42	
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The synthesis of benzyl ester 122 was completed by Dr Douglas Roberts, a 
postdoctoral research fellow in the Challis group with extensive experience of similar 
procedures (scheme 3.7), in order to complete the research more rapidly for 
publication. 
The first steps in the synthesis of the α-dimethyl-β-keto benzyl ester 122 were to 
couple Meldrum’s acid to N-BOC-L-leucine 95 using EDC 110 and DMAP 116 
(scheme 3.7), and then heat the resulting adduct in the presence of benzyl alcohol to 
furnish the β-keto benzyl ester 120. A commonly reported mechanism of thermolysis, 
after addition of alcohol to one of the carbonyl functionalities to give 126, is concerted 
degradation driven by the evolution of carbon dioxide to provide a β-keto ester (figure 
3.6).77 
 
 
Figure	 3.6:	 Proposed	 mechanism	 of	 thermolysis	 of	 a	 Meldrum’s	 acid	 adduct	 in	 the	
presence	of	an	alcohol	to	form	β-keto	esters	128.77	
 
α-Dimethylation of 120 was accomplished by reaction with potassium carbonate and 
iodomethane, with the acidic α-position between the carbonyl functionalities readily 
deprotonated due to stabilization of the resultant anion by delocalization, yielding 121 
via two sequential methylation reactions. Lastly, BOC-deprotection was achieved 
using trifluoroacetic acid to produce 122 (scheme 3.7). 
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low (26%) and resulted in a mix of diastereomers, additional optimization was not 
attempted due to the instability of 66, which was formed via hydrogenolysis over 
palladium on activated carbon. Approximately 25% of 66 underwent decarboxylation 
during the course of this reaction to form ketone 71 (scheme 3.8). 
 
 
Scheme	 3.8:	 Synthesis	 of	 α-dimethyl-β-keto	 carboxylic	 acid	 66	 via	 EDC	 coupling	 and	
hydrogenolysis	of	the	benzyl	ester	protecting	group.	
 
As previously discussed (section 1.3.2.1), α-dimethyl-β-keto acids are prone to 
spontaneous decarboxylation to form an enol, which readily tautomerises to the 
corresponding isopropyl ketone (figure 3.7). This was observed on purification of 66, 
with isopropyl ketone 71 visible by MS and 1H NMR analysis and easily identifiable 
due to being previously synthesized (section 3.1.2.4). The amount of 71 increased over  
	
Figure	 3.7:	 Proposed	 mechanism	 of	 decarboxylative	 degradation	 to	 convert	 the	 α-
dimethyl-β-keto	acid	66	to	the	corresponding	isopropyl	ketone	71.	
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time, indicative of spontaneous degradation rather than a process that is promoted by 
the conditions of the hydrogenolysis reaction. 
To reduce the level of degradation observed in the hydrogenolysis reaction, an excess 
of Pd/C was used, facilitating rapid benzyl deprotection and minimizing the amount 
of time 66 spent in solution. This allowed 66 to be used for in vitro assays with EpnF. 
 
3.2 Activity assays with purified recombinant EpnF and TmcI  
3.2.1. EpnF assay with α-dimethyl-β-keto acid 66 
The ability of EpnF to catalyse epoxidation of either 71 or 66 was examined by 
incubating each with purified recombinant His6-EpnF for three hours. The enzyme 
was then precipitated with acetonitrile, and the supernatant was analysed by UHPLC-
ESI-Q-TOF MS. 
Despite screening a range of conditions, no formation of epoxyketone 78 was 
observed in assays containing 71. Similarly, no activity was observed when this 
substrate was incubated with TmcI, NADPH, spinach ferredoxin and ferredoxin 
reductase, consistent with the fact that the macyranone A 20 biosynthetic gene cluster 
contains an epnF homologue, but no tmcI homologue.25 This suggested that EpnF does 
not function as a conventional ACAD (figure. 1.14A), and may instead catalyse 
successive decarboxylation, desaturation and epoxidation of an α-dimethyl-β-keto 
acid (figures 3.8, 5.4).56 
 
 
Figure	3.8:	Products	observed	by	UHPLC-ESI-Q-TOF	MS	when	66	was	incubated	with	His6-
EpnF.	
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Consistent with this hypothesis, a compound with a molecular formula corresponding 
to epoxyketone 78 was observed when 66 was incubated with His6-EpnF (figures 3.8 
and 3.9). This compound was absent in a negative control containing heat denatured 
His6-EpnF. Interestingly, no cofactors were needed apart from the enzyme-bound 
flavin (section 2.2.3.2). The production of 78 was accompanied by consumption of 66 
and decarboxylation of 66 to form 71 was observed in both the enzymatic reaction 
and the negative control (figures 3.8 and 3.9). This strongly indicated that α-dimethyl-
β-keto acids are the substrate for this novel class of flavin-dependent enzymes. To the 
best of the author’s knowledge, the reaction proceeds via a previously uncharacterized 
decarboxylation, desaturation and epoxidation catalytic mechanism, which is 
discussed in detail in chapter 5. 
 
Figure	3.9.	EICs	at	m/z	=	381.20,	351.19,	337.21	corresponding	to	[M	+	Na]+	for	66,	78	and	
71	respectively	 from	UHPLC-ESI-Q-TOF	MS	analyses	of	assays	containing	66	and	native	
(top	trace)	or	heat-denatured	(bottom	trace)	His6-EpnF.	
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A remaining undetermined aspect of both TMC-86A and eponemycin biosynthesis 
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was thus hypothesized that TmcI/EpnI could be responsible for forming this group via 
a hydroxylation reaction.  
 
 
Figure	3.10:	Reactions	catalysed	by	EpnF	and	TmcI	with	66.	
 
To elucidate the role of TmcI, an in vitro assay containing recombinant His6-EpnF and 
His6-TmcI was conducted. In order for cytochromes P450 to catalyse monooxgenation  
reactions, they undergo reduction through an electron transport chain as previously 
discussed (section 1.3.2.3) In Streptomyces species, the electrons are usually supplied 
by NAD(P)H via the redox partners ferredoxin, ferredoxin reductase, but 
commercially available ferredoxin and ferredoxin reductase from Spinacia oleracea 
can be utilized as surrogates.61 
66 was therefore incubated with His6-EpnF, His6-TmcI, ferredoxin and ferredoxin 
reductase from spinach, and NADPH. Following acetonitrile precipitation of the 
proteins, UHPLC-ESI-Q-TOF MS analysis of the supernatant revealed the production 
of hydroxylated epoxyketone 42 (figure 3.10). No production of this compound was 
observed in negative control reactions containg boiled His6-EpnF or His6-TmcI (figure 
3.11). These data show that TmcI is able to hydroxylate 78, but not 66. 
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Figure	3.11:	EICs	at	m/z	=	367.18,	corresponding	to	[M	+	Na]+	for	42,	from	UHPLC-ESI-Q-
TOF	MS	analyses	of	assays	containing	66,	NADPH,	ferredoxin	and	ferredoxin	reductase,	
and	 either	 native	 His6-EpnF	 and	 His6-TmcI	 (top	 trace),	 heat	 denatured	 His6-EpnF	 and	
native	 His6-TmcI	 (middle	 trace),	 or	 native	 His6-EpnF	 and	 heat	 denatured	 His6-TmcI	
(bottom	trace).	
 
3.2.3 MS/MS analysis of products 
Due to the inherent instability of the substrate 66, a larger scale assay to isolate 
epoxyketone 78 in sufficient quantity for NMR spectroscopic analysis proved 
impossible. To further characterise the products of the EpnF and TmcI catalysed 
reactions they were subjected to MS/MS analyses by Dr. D. Zabala and the fragment 
ions produced were compared to those observed for TMC-86A. Signature sets of 
fragment ions were observed across the three species (figure 3.12), consistent with the 
proposed structures of 78 and 42.42 
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Figure	3.12	A:	MS/MS	spectrum	for	the	m/z	=	329.20	ion,	corresponding	to	[M	+	H]+	for	78.	
B:	MS/MS	spectrum	for	the	m/z	=	345.20	ion,	corresponding	to	[M	+	H]+	for	42.	C:	MS/MS	
spectrum	for	the	m/z	=	343.19	ion,	corresponding	to	[M	+	H]+	for	TMC-86A.	D:	Proposed	
structures	of	observed	fragment	ions	from	MS/MS	fragmentation,	from	dehydration	and	
cleavage	of	the	amide	bond	followed	by	intramolecular	cyclisation.	
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3.2.4 Reaction of EpnF assay product with N-acetylcysteamine 
Derivatization of the epoxyketone assay product 78 by nucleophilic ring-opening of 
the epoxide was investigated, to provide additional evidence for the presence of the 
pharmacophore. Thiols are slow to react with epoxide functionalities, with literature 
citing the necessity of 37 °C, a five-fold excess of  N-acetylcysteamine and a time 
scale of over 10 hours to drive an aqueous reaction to completion.78 In the instance of 
78, the presence of the electron withdrawing α-keto group was proposed to activate 
the epoxide towards nucleophilic attack (figure 3.13), as observed for the reaction of 
epoxyketones with the 20S proteasome (section 1.2.1). 
 
Figure	3.13:	Adducts	136	and	137	proposed	to	result	from	opening	of	the	epoxide	in	the	
product	of	the	EpnF-catalysed	oxidation	of	66	with	N-acetylcysteamine.		
 
The substrate 66 was incubated with His6-EpnF in the presence of an excess of N-
acetylcysteamine for three hours at room temperature. Upon acetonitrile precipitation 
of the protein, UHPLC-ESI-Q-TOF MS analysis of the supernatant revealed ion 
species with an m/z corresponding to the N-acetylcysteamine adduct of epoxyketone 
78 (figure 3.14). As there was a shoulder peak observed in the chromatogram trace, it 
is possible that both 136 and 137 were formed from reaction with the thiol. Neither of 
these species were present in the negative control using heat denatured EpnF. These 
data are consistent with the proposal that 78 contains an epoxide. 
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Figure	3.14:	EICs	at	m/z	=	470.23,	corresponding	to	[M	+	Na]+	for	136/137,	from	UHPLC-
ESI-Q-TOF	MS	analysis	of	reaction	mixture	containing	66,	an	excess	of	N-acetylcysteamine	
and	either	native	(top	trace),	or	heat	denatured	(bottom	trace)	His6-EpnF.	
 
3.3 Conclusions 
The synthesis of both the isopropyl ketone 71 and α-dimethyl-β-keto carboxylic acid 
66 was accomplished, and each was incubated with EpnF. The epoxyketone 78 was 
only produced in assays containing 66 and not 71, supporting the hypothesis that α-
dimethyl-β-keto carboxylic acids are the true substrates of this unusual class of flavin-
dependent decarboxylase-dehydrogenase-monooxygenases.42 Our results were 
independently corroborated by Zhang and coworkers, who showed that co-expression 
of EpnG, EpnH and EpnF in E. coli results in the production of epoxyketones upon 
feeding of appropriate N-acetylcysteamine thioesters.79 
TmcI was shown to function as a hydroxylase by incubating 66 with both EpnF and 
TmcI, as well as ferredoxin and ferredoxin reductase from spinach, and NADPH. This 
produced a compound with a molecular formula corresponding to the hydroxylated 
epoxyketone 42. Although Zhang and coworkers co-expressed the homologous 
enzyme EpnI from the eponemycin biosynthetic gene cluster with EpnG, EpnH and 
EpnF, they did not observe formation of an analogous hydroxylated product. 
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Presumably, this is due to poor compatibility of E. coli redox proteins with 
cytochrome P450 enzymes from Streptomyces species.61 
The pattern of fragment ions observed in MS/MS analyses of 78 and 42 were 
consistent with those observed for TMC-86A, providing support for the proposed 
structures of the products of the EpnF and TmcI-catalysed reactions. The addition of 
N-acetylcysteamine to 78 provided additional evidence that it contains an 
epoxyketone moiety. 
Decarboxylation of 66 to form the isopropyl ketone 71 presented a significant obstacle 
to further characterisation of the EpnF-catalysed reaction. In an attempt to circumvent 
this problem, methyl ester analogues of 66 were synthesised and various methods for 
their hydrolysis to the corresponding b-keto acids were investigated, as detailed in 
Chapter 4. 
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Chapter 4:    β-Keto methyl esters as stable 
precursors to EpnF substrates
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4.1 Synthesis of leucine derived α-dimethyl-β-keto methyl 
ester 
4.1.1 Rationale  
As previously discussed (sections 1.3.2.1 and 3.1.2.3), many α-dimethyl-β-keto 
carboxylic acids are metastable, and are prone to spontaneous decarboxylation and 
subsequent tautomerization to form ketones. To make the EpnF-catalysed reaction 
more efficient and to provide scalable improved methods for accessing its α-dimethyl-
β-keto acid substrate, an alternate substrate precursor was needed. Unlike α-dimethyl-
β-keto carboxylic acids, α-dimethyl-β-keto methyl esters 138 are not prone to 
spontaneous degradation to ketones under ambient conditions. Instead Krapcho 
decarboxylation (≥150 °C, LiCl) is required for the analogous reaction to occur (figure 
4.1A).80 Therefore the synthesis of 139, the methyl ester of 66, was targeted with the 
intention of investigating mild methods for converting it to the corresponding 
carboxylic acid (figure 4.1B). 
 
 
Figure	4.1.	A:	Conditions	required	to	transform	an	α-dimethyl-β-keto	carboxylic	acid	or	its	
methyl	ester	into	an	isopropyl	ketone	69.	B:	Structure	of	methyl	ester	precursor	139	of	the	
EpnF	substrate	66	targeted	for	synthesis.		
 
As the carboxylic acid 66 had been demonstrated to be a substrate for EpnF, the methyl 
ester 139 would be an appropriate precursor, provided a mild method for hydrolysing 
it could be identified. One possibility was to use a promiscuous hydrolase such as 
commercially available pig liver esterase (PLE) to generate the acid in situ. 
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PLE is a serine hydrolase which uses a catalytic triad of serine, histidine and aspartate 
residues. This triad enables nucleophilic attack of an ester substrate by the serine 
hydroxyl group, forming an acyl-ester intermediate, which undergoes hydrolytic 
cleavage.81 Preparations of PLE are mixtures of isoenzymes with different substrate 
specificities, with each isoenzyme composed of a trimer of different enzyme subunits. 
While this heterogeneity can be problematic when using PLE for enantioselective 
catalysis in organic synthesis, it helps to ensure substrate promiscuity in other 
applications.82 In lieu of an esterase with high specificity for 139, PLE seemed an 
appropriate enzyme with which to begin investigation into in situ substrate precursor 
hydrolysis (figure 4.2). 
 
 
Figure	4.2:	The	chemical	and	biological	strategies	for	preparation	of	EpnF	substrates.	
 
As discussed previously, α-dimethyl-β-keto carboxylic acids 141 lacking substituents 
that stabilize the enol tautomer are prone to decarboxylate through a cyclic transition 
state due to intramolecular hydrogen bonding (section 1.3.2.1). The lithium salt 142 
of such carboxylic acids lack the ability to form this intramolecular hydrogen bond, 
and as such may prove to be more stable (figure 4.2). Indeed, stable lithium α-alkyl-
β-keto carboxylates have been reported in the literature.83 
 
4.1.2 Synthetic plan 
The previous synthesis of 66 involved the use of a benzyl ester protecting group on 
the carboxylic acid, which was removed by hydrogenolysis in the final step.42 It was 
therefore reasoned that the existing synthesis could be adapted by thermolysis of a 
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leucine-derived Meldrum’s acid adduct in the presence of methanol instead of benzyl 
alcohol to produce methyl ester 143. Following this, completion of the same series of 
steps as used previously would provide the desired α-dimethyl-β-keto methyl ester 
139 (scheme 4.1).  
 
 
Scheme	4.1:	Proposed	synthesis	of	methyl	ester	substrate	precursor	139.	
 
4.1.3 Synthesis of 144 
N-BOC-L-Leucine 95 was first coupled to Meldrum’s acid 129 using EDC 110 and 
DMAP 116, followed by thermolysis in the presence of methanol to afford 143.42 In 
contrast to the previously employed procedure to produce 120 (section 3.1.3.2), 
monitoring by TLC revealed BOC-L-leucine 95 could still be observed after 27 hours. 
Therefore additional equivalents of DMAP 116 and EDC 110 (0.4 equivalents, 
increasing the total of each from 1.1 to 1.5) were added to drive the reaction to 
completion. This afforded a crude yield of 79% for the Meldrum’s acid adduct. 
In the second step of the reaction methanol was used as both solvent and reactant 
under refluxing conditions. Methanol reacted with the Meldrum’s acid adduct as 
previously described for 120 (figure 3.6). Following purification 143 was obtained in 
31% yield. 
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Since this was lower than the yield of the benzyl ester 120 (51%), and this reaction 
was the first step of the synthesis, optimization was desirable.42 Thermolysis of 
Meldrum’s adducts of Boc-protected amino acids are reported to form lactam 
byproducts (putatively resulting from nucleophilic attack and cyclisation by the amide 
nitrogen) under refluxing conditions.84 While only 143 was retained and characterized 
from silica gel chromatography, ions corresponding to a lactam byproduct were 
observed by MS analysis of the reaction mixture. The low yield in conjunction with 
this possibility of byproduct formation prompted a change of strategy. 
An alternative coupling partner, methyl potassium malonate, was investigated. This 
forms β-keto esters with carbonyl diimidazole (CDI) 146 activated carboxylic 
acids.85,86 Similarly to the BOP, DCC and EDC reagents mentioned previously 
(sections 3.1.2.2 and 3.1.2.3), CDI activates carboxylic acids towards nucleophilic 
addition-elimination by formation of adduct 150 with a good leaving group (figure 
4.3), and drives the reaction through evolution of carbon dioxide.76  
 
 
Figure	 4.3:	 Mechanism	 of	 CDI-mediated	 coupling	 of	 a	 carboxylic	 acid	 with	 a	 generic	
nucleophile.76	
 
This new approach offered several practical advantages over Meldrum’s acid. 
Although two steps are still required, the first step to form the reactive imidazole 
adduct takes two hours, rather than the 24 hours required for Meldrum’s acid adduct 
formation. Additionally, 143 could be isolated from the reaction using mild acidic and 
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basic washes, to remove imidazole and unreacted magnesium-malonate half ester salt, 
without the need for silica gel chromatography. This lead to an increase in yield from 
31% to 58% for 143 (scheme 4.2). 
 
 
Scheme	4.2:	Alternate	synthetic	routes	to	β-keto	methyl	ester	143,	and	dimethylation	to	
produce	α-dimethyl-β-keto	methyl	ester	144.	
 
To form the α-dimethyl-β-keto methyl ester 144, the carbon between the two carbonyl 
groups was methylated using iodomethane and potassium carbonate, as described 
previously (section 3.1.3.2), in a 40% yield (scheme 4.2). 
 
4.1.4 Synthesis of 145 
Initially the same conditions used for BOC removal of 121 (stirring in 10% TFA in 
DCM over 17 hours) were applied to remove the BOC group from 144.42 However 
these conditions did not yield the desired product, presumably because the methyl 
ester of 144 was more prone to acid hydrolysis than the benzyl ester of 121. By 
changing to completely anhydrous conditions and closely monitoring the reaction by 
TLC, the deprotection was found to go to completion in one hour, providing 145 in 
96% yield (scheme 4.3), an improvement on the 63% yield obtained for the benzyl 
ester 122. 
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Scheme	4.3:	Deprotection	of	α-dimethyl-β-keto	methyl	ester	144	using	trifluoroacetic	acid	
to	give	amine	salt	145.	
 
4.1.5 Coupling of 93 and 145 
The final stage of the proposed synthesis was the coupling of carboxylic acid 93 to 
TFA salt 145, using HOBT 115, EDC 110 and triethylamine, as previously described 
(section 3.1.2.3). Using 1.5 equivalents of Et3N, a yield of 22% was obtained (scheme 
4.4), giving an overall yield for the convergent synthesis of 4.9%. 
Other amide bond coupling reactions had been shown to produce higher yields using 
4.2 equivalents of triethylamine and THF instead of DMF as the solvent (section 
4.2.2). Ordinarily excess base can assist such coupling reactions by ensuring that 
carboxylic acids and ammonium salts are deprotonated. However, in this instance the 
amino group of 145 underwent intramolecular addition to the carbonyl group of the 
methyl ester, resulting in formation of lactam 151 as the major product (scheme 4.4). 
 
 
Scheme	4.4:	Attempted	coupling	of	145	and	93,	and	the	major	products	observed	in	each	
case.	
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This result is likely due to the Thorpe-Ingold (or gem-dimethyl) effect, whereby 
increasing the number of substituents on a tetrahedral carbon centre favours 
intramolecular reactions within that molecule due to a reduction in the bond angle 
between reacting groups.87,88 
Briefly, an alternate linear synthesis of 139 was attempted, however the coupling of 
N-butyryl-L-seryl-L-leucine 152 with methyl potassium malonate failed to produce 
any of the desired β-keto methyl ester 153 (figure 4.4). As this procedure had already 
produced 143 with N-BOC-L-leucine 95 (scheme 4.2), it was reasoned that the 
hydroxyl group of serine interferes with the coupling reaction. Protection of this 
hydroxyl group was consequently deemed to be required for further synthetic efforts 
(section 4.2). 
 
 
Figure	4.4:	Unsuccessful	CDI-mediated	coupling	of	152	and	methyl	potassium	malonate.	
 
4.1.6 Pig liver esterase and EpnF in vitro assays with 139 
As only a modest amount of 139 was obtained via the synthetic route outlined above, 
the stability of the carboxylate salt resulting from base-promoted hydrolysis of the 
methyl ester was not investigated at this stage (section 4.2.6). However, the in situ 
hydrolysis of the ester using PLE was explored (figure 4.5). 
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Figure	 4.5:	 Proposed	 method	 for	 production	 and	 decarboxylation-dehydrogenation-
epoxidation	of	66	using	PLE	and	EpnF	in	a	single	reaction	vessel.	
 
The ability of PLE to catalyse the hydrolysis of 139 was first investigated by 
incubating it with PLE at room temperature for three hours at pH 8 (section 7.4.4). 
After precipitation of the enzyme with acetonitrile, UHPLC-ESI-Q-TOF MS analysis 
of the supernatant confirmed production of 66, which was absent with heat denatured 
PLE (figure 4.6). While a low intensity peak was observed in both reactions 
 
 
Figure	4.6.	EICs	at	m/z	=	359.22,	corresponding	to	[M	+	H]+	for	66,	from	UHPLC-ESI-Q-TOF	
MS	analyses	of	assays	containing	139	and	native	(top	trace)	or	heat-denatured	(bottom	
trace)	PLE.		
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(approximately at 16.6 minutes), the corresponding ion did not have a molecular 
formula consistent with 66 by HR-MS analysis, and was therefore considered an 
unrelated impurity. 
A corresponding decrease in the amount of 139 was also observed in the PLE-
catalysed reaction relative to the negative control (figure 4.7). 
 
Figure	4.7:	EICs	at	m/z	=	395.22,	corresponding	to	[M	+	Na]+	for	139,	from	UHPLC-ESI-Q-
TOF	MS	analyses	of	assays	containing	139	and	native	(black	trace)	or	heat-denatured	
(red	trace)	PLE.	
 
Having confirmed that PLE can hydrolyze 139, the hydrolysis and subsequent 
decarboxylation-dehydorgenation-monooxygenation of 139 using PLE and purified 
recombinant His6-EpnF in a single vessel was investigated next. The epoxyketone 78 
was only produced in significant quantities when both PLE and EpnF were present 
(figure 4.7). A very small amount of 78 was also produced in the control reaction 
lacking PLE, presumbaly due to uncatalysed ester hydrolysis (figure 4.8). A negative 
control in which PLE and heat-denatured EpnF were present failed to produce any 78. 
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Figure	4.8:	EICs	at	m/z	=	351.19,	corresponding	to	[M	+	Na]+	for	78,	from	UHPLC-ESI-Q-TOF	
MS	analyses	of	 assays	 containing	139	and	either	native	His6-EpnF	and	PLE	 (top	 trace),	
native	His6-EpnF	 (middle	 trace),	 or	 native	 PLE	 and	 heat-denatured	His6-EpnF	 (bottom	
trace).	
 
This result provides an effective proof of concept for the use of α-dimethyl-β-keto 
methyl esters as stable precursors to the corresponding carboxylic acids and their one 
pot conversion to epoxyketones using EpnF in combination with an esterase. 
 
4.2 Preliminary investigation into EpnF substrate tolerance 
4.2.1 Synthesis of substrate analogue 154 
As 66 had previously been shown to be a substrate for EpnF, and in situ hydrolysis of 
the corresponding methyl ester 139 using PLE proved to be an effective strategy for 
producing epoxyketone 78, it was decided to investigate whether analogues of 139 
with different amino acid side chains can be converted to epoxyketones using PLE 
and EpnF. While most naturally occurring epoxyketones are derived from either L-
leucine or 4,5-dehydro-L-leucine, clarepoxcin A and tryptopeptin A incorporate L-
alanine and L-tryptophan respectively (figure 4.9A).23,24 An analogue of 139, 
containing an alanine-derived b-keto ester, was thus targeted for synthesis (figure 
4.9B). 
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Figure	4.9.	A:	Structures	of	clarepoxcin	A	and	tryptopeptin	A,	epoxyketones	obtained	from	
heterologous	expression	of	a	soil	metagenomic	 library	and	Streptomyces	 sp.	KUSC-G11,	
respectively.23,24	B:	Structure	of	alanine-derived	analogue	154	of	the	substrate	139	used	in	
the	PLE/EpnF	coupled	assays.	
 
4.2.1.1 Attempted adaptation of convergent synthetic route  
Concurrently with synthesis of 139 (sections 4.1.3-4.1.5), the same procedures were 
applied to N-BOC-L-alanine in an attempt to produce 154 (scheme 4.5). Yields for 
these procedures increased significantly compared to previously obtained yields for 
N-BOC-L-leucine. Meldrum’s acid coupling to methyl potassium malonate yielded 
84% of 156 compared to 58% for 143, and also an increase from 69% recorded in the 
literature for 156.86 Under milder reaction conditions, 157 was produced in a yield of 
58% using iodomethane and potassium carbonate, compared to the 40% yield of 144. 
Deprotection of the Boc group using TFA produced 158 in a yield of 97%, consistent 
with the 96% yield of 145. 
In the final coupling step to 93, the same issue of lactamization occurred, producing 
the byproduct 159 in a yield of 81% (scheme 4.5), with none of the desired methyl 
ester 154. This provided additional confirmation of the inherent problems of 
convergent synthesis for this application. 
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Scheme	4.5:	Attempted	convergent	synthesis	of	154.	
 
4.2.2 Proposed linear synthesis 
Convergent synthesis of α-dimethyl-β-keto methyl ester compounds had so far proved 
to be problematic, yielding both 151 and 159 as lactam byproducts (sections 4.1.5 and 
4.2.1.1). Additionally, a brief attempt at a linear synthesis of 139 had failed when 
trying to couple N-butyryl-L-seryl-L-leucine 152 to methyl potassium malonate using 
CDI (figure 4.4). As malonate coupling had been successful for Boc-protected leucine, 
it was reasoned that the hydroxyl side chain of serine must be interfering with the 
reaction. 
Therefore, a new linear synthesis of 154 was devised. Protection of the 104 serine 
hydroxyl group with tert-butyldimethylsilyl (TBS) chloride would give 161, which 
was anticipated to tolerate the basic conditions used in the peptide coupling and ester 
hydrolysis reactions used to produce 164 (scheme 4.6). Two carbon homologation of 
164 using CDI and methyl potassium malonate (sections 4.1.3 and 4.2.1.1), followed 
by dimethylation with iodomethane and potassium carbonate, and removal of the TBS 
protecting group, would give the desired methyl ester 154. 
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Scheme	 4.6:	 Linear	 route	 devised	 for	 the	 synthesis	 of	 alanine	 substrate	 precursor	
analogue	154.	
 
While N to C-terminal peptide synthesis suffers from the problem of oxazolone 
formation, as previously discussed (figure 3.3), the observed lactamization from 
intramolecular addition of the amino to α-dimethyl-β-keto methyl ester in attempted 
peptide coupling makes the reverse strategy impractical.76 In addition, two carbon 
homologation of dipeptides using CDI 146 and methyl potassium malonate has been 
reported to result in lower levels of α-carbon epimerization compared to other 
strategies, such as coupling with Meldrum’s acid 129 and subsequent thermolysis in 
the presence of methanol.89 
 
HO
O
H
N
O OH
OMe
O
Dimethylation
H
N
O OTBS
OMe
O
HN
O
OTBS
OH
O
HN
O
OTBS
NH
O
O
MeO
O
O
MeO
HN
O
OTBS
NH
O
O
HO
HN
O
OH
NH
O
Hydroxyl
deprotection
Two carbon
homologation
104 161
162163164
165 166 154
Peptide
coupling
O
O
MeO
HN
O
OTBS
NH
O
O
O
MeO
HN
O
OH
NH
O
TBS
protection
Peptide
coupling
Ester
hydrolysis
Ester
hydrolysis
160
	 	 	
	 77	
4.2.1 Synthesis of O-TBS-N-butanoyl-L-serine 162 
Protection of the side chain of previously synthesised 104 (section 3.1.2.2) was 
accomplished by nucleophilic substitution, using imidazole to activate the hydroxyl 
side chain and TBS-chloride. The method used was adapted from a literature 
procedure, in which all the reactants were added at the start of the reaction, giving 161 
in a 53% yield.90 By changing to dropwise addition of TBS-chloride over an hour, this 
yield was increased to 81%. Ester hydrolysis was completed using lithium hydroxide 
to produce 162 (scheme 4.7). 
 
 
Scheme	4.7:	Synthesis	of	TBS	protected	161,	with	yield	optimisation	 through	dropwise	
addition,	and	subsequent	methyl	ester	hydrolysis	to	provide	162.	
 
4.2.2 Coupling of O-TBS-N-butanoyl-L-serine 162 and L-
alanine methyl ester  
Coupling of 162 and L-alanine methyl ester was attempted using HOBt 115, EDC 110 
and triethylamine using equivalents that had previously given high yields (1.0 
equivalents of 162 and L-alanine methyl ester, 1.2 equivalents of HOBt 115, 2.0 
equivalents of EDC 110 and 4.2 equivalents of triethylamine). A workup for the 
reaction was avoided, as it had been observed that similarly hydrophilic compounds 
produced in the attempted L-leucine linear synthesis (figure 4.4) were extracted in the 
aqueous layer. Instead methyl ester 163 was purified by silica gel chromatography, 
providing a yield of 56%. In order to optimize the reaction further, the amount of 
HOBt 115 was increased to 2.4 equivalents, increasing the yield to 65% (scheme 4.8). 
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Scheme	4.8:	Synthesis	of	methyl	ester	163.	
 
4.2.3 Hydrolysis of methyl O-TBS-N-butyryl-L-seryl-L-alaninate 
163 and subsequent malonate coupling 
To hydrolyze methyl ester 163, lithium hydroxide was again employed. The reaction 
time was reduced, and strong acid was avoided during the workup to avoid TBS 
deprotection. Carboxylic acid 164 was produced in 80% yield. 
The β-keto methyl ester 165 was prepared via the CDI 146, methyl potassium 
malonate and magnesium chloride procedure previously established (sections 4.1.3 
and 4.2.1.1). However, in this instance initial yields were low (~7%). 164 was 
recovered from the reactions, and resubmitted to the coupling procedure. This resulted 
in improved yields, ranging from 24% to 40% of 165. 
This indicated an issue with the purification of 164 from the lithium hydroxide-
mediated ester hydrolysis reaction. It seemed likely that salts which are semi-soluble 
in organic solvents had carried through as impurities and were inhibiting the coupling 
reaction. Changing to an acidic workup, where after removal of THF from the reaction 
mixture the solution was acidified and 164 was extracted from the aqueous layer, 
increased the yield of the hydrolysis reaction to 82% and no TBS deprotection was 
observed (scheme 4.9). Subsequent formation of the β-keto methyl ester, using the 
conditions that had proved most successful in earlier work (1,4-dioxane as solvent, 
and 50 °C), afforded 165 in 79% yield (scheme 4.9). 
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Scheme	4.9:	Optimised	procedure	for	the	synthesis	of	164	and	165.	
 
4.2.4 Synthesis of 166 
Dimethylation to form the α-dimethyl β-keto methyl ester 166 was attempted using 
iodomethane and potassium carbonate, following the precedent set during the 
synthesis of 157 and 144. The highest yield was obtained when the reaction was 
conducted at room temperature for 43 hours. Elevating the reaction temperature to 40 
°C or increasing the reaction time further caused increased byproduct formation, 
according to TLC analysis. A mixture of diastereomeric mono- and dimethylated 
products was obtained, due to racemization of the alanine α-stereocentre. Separation 
of the mixture on a silica gel column yielded 28 and 15%, respectively, of the 
dimethylated diastereomers 166 and 167, and 20% of the monomethylated product 
168 as an inseparable mixture of diastereomers (scheme 4.10). The ability to separate 
166 and 167, likely due to the presence of the TBS protecting group, offers a distinct 
advantage over the previous convergent synthesis of 139 where separation of the 
diastereomers was not feasible using silica gel chromatography. While 167 and 168 
may have also proved to be suitable substrate precursor analogues, this was not 
investigated due to time constraints. 
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Scheme	 4.10:	 Products	 isolated	 from	 the	 methylation	 of	 165	 with	 iodomethane	 and	
potassium	carbonate.	
 
4.2.5 Synthesis of 154 
To selectively remove the TBS group without hydrolyzing the methyl ester of 166, 
very mild acidic conditions were used, dissolving 166 in a mixture of 3:3:1 acetic 
acid:water:THF. This yielded the desired α-dimethyl β-keto methyl ester 154 in 76% 
yield (scheme 4.11). 
 
 
Scheme	4.11:	TBS	deprotection	of	166	with	acetic	acid.	
 
The main problem encountered in the development of the linear synthetic route was 
the methylation reaction, which produced a mixture of diastereomeric mono- and 
dimethylated products. Doubtless this reaction could be optimized to produce 
predominantly the dimethylated products 166 and 167, albeit still as a mixture of 
diastereomers. However, this was not investigated due to time constraints. 
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4.2.6 Basic hydrolysis of 154  
Barbas and coworkers demonstrated that a stable lithium salt 169 of an α-alkyl-β-keto 
ester (figure 4.10A) could be formed using 0.95 equivalents of dilute aqueous lithium 
hydroxide solution (30 mM).83 These conditions were therefore investigated for the 
hydrolysis of 154. Only ions corresponding to the decarboxylation product 171, and 
not its progenitor 170, were observed when aliquots of the reaction mixture were 
analysed by MS, suggesting that 170 is highly susceptible to decarboxylation (scheme 
4.10B). 
 
Figure	 4.10.	 A:	 Structure	 of	 a	 lithium	 α-alkyl-β-keto	 carboxylate	 produced	 via	 ester	
hydrolysis	under	mild	conditions.83	B:	Attempted	formation	of	lithium	salt	170	from	154	
using	analogous	conditions.	171	was	the	only	observed	product.	
 
The reaction mixture was neutralized with acid, and the product was isolated by silica 
gel chromatography. 1H and 13C NMR spectroscopic analyses as well as HRMS, 
confirmed it was 171. It was thus concluded that base hydrolysis is not an effective 
strategy for producing EpnF substrates and in all further experiments PLE was used 
to produce carboxylic acid 172 in situ. 
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4.2.7 Conversion of 154 to an epoxyketone using pig liver 
esterase and EpnF  
UHPLC-ESI-Q-TOF MS analysis of the PLE-catalysed hydrolysis of 154 at pH 8 
indicated that the carboxylic acid 172 was produced (figure 4.11A). A small amount 
of 172 was observed in the negative control employing heat-denatured PLE, 
presumably resulting from either uncatalysed hydrolysis or residual PLE activity 
(figure 4.11B). 
 
 
Figure	4.11.	A:	PLE	catalyses	the	hydrolysis	of	154	to	produce	172,	which	is	converted	to	
epoxyketone	173	by	EpnF.	B:	EICs	at	m/z	=	317.17,	corresponding	to	[M	+	H]+	for	172,	from	
UHPLC-ESI-Q-TOF	MS	analyses	of	assays	containing	154	and	native	(top	 trace)	or	heat-
denatured	(bottom	trace)	PLE.	
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Figure	4.12	A:	EICs	at	m/z	=	309.14,	corresponding	to	[M	+	Na]+	for	173,	from	UHPLC-ESI-
Q-TOF	MS	analyses	of	 assays	 containing	154	and	either	His6-EpnF	and	PLE	 (top	 trace),	
native	His6-EpnF	and	no	PLE	(middle	trace),	or	native	PLE	and	heat-denatured	His6-EpnF	
(bottom	trace).	B:	MS/MS	spectrum	for	the	m/z	=	287.16,	corresponding	to	[M	+	H]+	for	
173.	C:	Proposed	structures	of	observed	fragment	ions.	
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UHPLC-ESI-Q-TOF MS analyses of reactions containing PLE, EpnF in pH 8 buffer 
and 154 showed that a species with a molecular formula corresponding to 
epoxyketone 173 was produced (figures 4.11A and 4.12A). This product was absent 
from a negative control containing heat-denatured EpnF, but a small quantity was 
detectable when PLE was omitted from the reaction, potentially due to residual 
hydrolysis. Analogous fragment ions to those observed for 66 were observed in 
MS/MS analyses of the product conducted by Dr. Lijiang Song (figure 4.12B), with 
similar predicted structures (figure 4.12C). These data strongly imply that 172 is a 
viable substrate for EpnF, which may possess a broad tolerance with respect to the 
amino acid-derived side chain adjacent to the α-dimethyl-β-keto carboxylic acid 
functionality of its substrate. 
 
4.2.7.1 Attempted trapping of alanine-derived epoxyketone with N-
acetylcysteamine 
To further characterise the epoxyketone moiety of 173, an excess of N-
acetylcysteamine was added to the reaction containing PLE, EpnF and 154. However, 
unlike with 78 (section 3.2.4), neither the epoxyketone 173 nor its N-acetylcysteamine 
adduct were observed by UHPLC-ESI-Q-TOF MS analysis. Levels of 154 when N-
acetylcysteamine had been added were consistent with a heat-denatured PLE negative 
control with no N-acetylcysteamine present, suggesting that N-acetylcysteamine 
inhibits the function or active site of PLE, with it also possessing an amide bond which 
cannot be cleaved by the enzyme. With signature MS/MS fragment ions obtained 
correlating 173 with previous epoxyketone compounds already obtained, nucleophilic 
derivatization as a means of additional epoxyketone characterisation was not 
investigated further. 
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4.2.7.2 Attempted overproduction of TmcH and EpnH thioesterase 
domains 
As an alternative to PLE for the in situ hydrolysis of α-dimethyl-β-keto methyl esters 
the TE domains of TmcH and EpnH were investigated. Although thioesters are the 
natural substrates of TE domains, it has been reported that they are also able to utilise 
oxoesters.91 The DNA corresponding to the TE domains in epnH and tmcH was 
therefore cloned into E. coli expression vectors, as described for EpnF and TmcI. 
(sections 2.1 and 2.2.1). Attempts to overproduce the corresponding proteins resulted 
in insoluble inclusion bodies (figure 4.13). As a consequence, this line of enquiry was 
not pursued further. 
 
Figure	4.13:	SDS-PAGE	analysis	of	the	overproduction	of	the	EpnH	(34.2	kDa,	left	hand	gel)	
and	TmcH	(34.4	kDa,	right	hand	gel)	TE	domains	in	E.	coli.	The	insoluble	protein	fractions	
are	 in	 the	outside	 lanes,	 the	 soluble	protein	 fractions	 are	 in	 the	middle	 lanes	 and	 the	
molecular	weight	marker	is	in	the	inside	lanes.	
 
4.2.7.3 Effect of adding of FAD or FMN to EpnF-catalysed reactions 
In the assays of EpnF activity towards 66, both FAD and FMN had been added to the 
reaction mixtures to see if there was any effect on the quantity of products formed. 
However, no difference in the production levels of epoxyketone 78 was observed. In 
comparison to the vibrant yellow colour of the His6-EpnF sample used in these assays, 
the batch of purified enzyme used for the experiments described in section 4.2.7 was 
pale yellow (figure 4.14), indicating less endogenous flavin cofactor. As efforts to 
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determine whether the cofactor bound to EpnF was FAD or FMN had proved 
unsuccessful (section 2.2.3.2), FAD and FMN were added separately to assays 
containing PLE, EpnF and 154. 
 
 
Figure	4.14:	A	comparison	of	yellow	colour	between	batches	of	EpnF,	indicating	a	greater	
amount	of	endogenous	flavin	present	in	the	older	purified	batch.	
 
 
Figure	4.15	A:	EICs	at	m/z	=	309.14,	corresponding	to	[M	+	Na]+	for	173,	from	UHPLC-ESI-
Q-TOF	MS	analyses	of	assays	containing	154,	EpnF,	PLE	and	either	FAD	as	an	additive	(top	
trace),	no	additive	(middle	trace)	or	FMN	as	an	additive	(bottom	trace).	
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reaction mixture reduced the production of 173 relative to the positive control. This 
indicates that the flavin cofactor utilized by EpnF is FAD. 
 
4.3 Conclusions 
Synthetic routes to two α-dimethyl-β-keto methyl esters, 139 and 154, were 
developed. These compounds were converted to β-keto acid substrates (66 and 172) 
for EpnF via in situ PLE-mediated ester hydrolysis, overcoming the problem of 
decarboxylation of the substrate discussed in chapter 3. Although the PLE and EpnF-
catalysed reaction cascade is far from optimized, the results obtained indicate that it 
has the potential to be developed into an efficient catalytic system for production of 
epoxyketones. 
The final peptide coupling step in the convergent synthesis of 139 was found to 
produce a lactam byproduct. By adopting a linear synthetic route to 154, this problem 
was avoided. In addition, the synthesis also allowed disatereomeric separation to give 
TBS-protected a-dimethyl-b-keto methyl ester 166. While this may be a result of 
changing from L-leucine to L-alanine amino acid side chains, it is more likely a result 
of the TBS-protection itself, which may prove a valuable strategy for similar 
purification of disastereomers in future analogue syntheses – though leucine methyl 
ester substrate precursors would have to be prepared through this method to confirm 
this is the case. a-Dimethyl-b-keto acid 171 produced by in situ PLE-catalysed 
hydrolysis of 154, was converted to the corresponding epoxyketone by EpnF, showing 
that the enzyme tolerates alterations to the leucine-derived side chain of 66. The 
synthetic procedure developed for 154 could be used in future to produce further 
substrate analogues, allowing the substrate tolerance of EpnF to be more extensively 
evaluated. 
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Chapter 5:    Mechanistic investigations of 
EpnF
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5.1 Proposed mechanism of EpnF 
In proposing a mechanism for EpnF, several factors need to be taken into 
consideration. Firstly, the α-dimethyl-β-keto carboxylic acid substrate needs to be 
converted into an intermediate which could conceivably undergo epoxidation. Since 
there are no additional cofactors, this process must result in FAD being reduced and 
converted to a species that could epoxidize a reactive substrate intermediate. The 
ketone functionality of an α-dimethyl-β-keto carboxylic acid has been described as 
electron sink, facilitating decarboxylation by subsequent formation of an enolate 
anion.54 Dr Zabala’s labelled precursor incorporation experiments (figure 1.13) 
showed that while both of the α-methyl carbon atoms incorporated by the cMT domain 
of TmcH into TMC-86A, the carbon atom of the terminal carboxyl group is lost.42 
When these facts are combined with the knowledge that 66 is prone to spontaneous 
decarboxylation to produce 71, a plausible starting point for the EpnF-catalysed 
reaction is decarboxylation of an α-dimethyl-β-keto carboxylate to form the 
corresponding enolate 177 (figure 5.1). 
 
 
Figure	5.1:	Decarboxylation	of	the	b-keto	carboxylate	substrate	of	EpnF	resulting	in	
formation	of	enolate	177.		
 
With enolate 177 as a potential intermediate in the EpnF-catalysed reaction, the next 
question is how can it serve as reductant? It was proposed that the enolate can transfer 
a hydride ion from one of its β-carbon atoms to enzyme bound FAD. This produces 
the reduced flavin anion 179 and converts the enolate into the α,β-unsaturated ketone 
178 (figure 5.2). Similar chemistry is well-established for flavin-dependent 
dehydrogenases (section 1.3.2.2).56 
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Figure	5.2:	Reduction	of	FAD	cofactor	by	enolate	intermediate	to	give	α,β-unsaturated	
ketone	and	anionic	reduced	flavin.	
 
179 must be converted to a species capable of epoxidation, such as 4a-
hydroperoxyflavin 182 which is widely implicated in a variety of monooxygenation 
reactions.92 This reactive moiety forms through initial single electron transfer from 
the resonance form 180 of anionic reduced flavin to dioxygen to generate flavin-
semiquinone 181 and superoxide. Coupling of the radicals in these two species gives 
anionic 4a-peroxyflavin, which undergoes protonation to give 4a-hydroperoxyflavin 
182 (figure 5.3). 
  
Figure	5.3:	 Single	 electron	 transfer	 and	 radical	 coupling	 to	 form	4a-hydroperoxyflavin	
182.	
 
Epoxidation of electron-rich alkenes by 4a-hydroperoxyflavin is known, and is 
proposed to proceed by a peracid-like mechanism.59,93 With electron-poor alkenes, 
such as those present in α,β-unsaturated carbonyl compounds, epoxidation is believed 
to proceed via nucleophilic attack of anionic 4a-peroxyflavin or base-activated 4a-
hydroperoxyflavin.94,95 In the case of 178, Michael-addition to the α,β-unsaturated 
ketone would result in the enolate 183. This could undergo 1,3-elimination to form 
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the epoxyketone 184 and 4a-hydroxyflavin 185, which can eliminate water to 
regenerate the flavin cofactor 72 in its oxidized form.59 Putting these various processes 
together, a catalytic cycle for EpnF involving a decarboxylation-dehydrogenation-
monooxygenation cascade can be proposed (figure 5.4).42 
 
  
Figure	 5.4:	 Proposed	 mechanism	 for	 conversion	 of	 α-dimethyl-β-keto	 acids	 67	 to	
epoxyketones	184	by	FAD-dependent	enzyme	EpnF.42	
 
5.1.1 Detection of α,β-unsaturated ketone intermediates in 
the EpnF catalytic cycle 
To obtain evidence for the above mechanistic proposal, it was investigated whether α, 
β-unsaturated ketone intermediates can be detected in the reactions of 66 with EpnF 
and 154 with EpnF plus PLE. UHPLC-ESI-Q-TOF MS analyses revealed the presence 
of compounds with molecular formulae corresponding to 79 and 186 in the 
transformations involving 66 and 154, respectively. These α,β-unsaturated ketones 
were absent from control reactions containing heat-denatured EpnF. 
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Figure	5.5.	A:	EICs	at	m/z	=	335.18,	corresponding	to	[M	+	Na]+	for	79,	from	UHPLC-ESI-Q-
TOF	MS	analyses	of	assays	containing	66	native	(top	 trace)	or	heat	denatured	(bottom	
trace)	His6-EpnF.	B:	EICs	at	m/z	=	293.15,	corresponding	to	[M	+	Na]+	for	186,	from	UHPLC-
ESI-Q-TOF	MS	analyses	of	assays	containing	154,	PLE	and	either	native	(top	trace)	or	heat	
denatured	(bottom	trace)	His6-EpnF.	
 
To confirm the structure of 186 an authentic standard was synthesized by building on 
the synthetic methods developed previously (section 4.2.1.1). 
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5.2 Synthesis of an authentic standard of the α,β-unsaturated 
ketone intermediate  
Several of the procedures developed in earlier work, such as the Weinreb-Nahm 
ketone synthesis and the BOC-deprotection (section 3.1.2.3), were directly applicable 
to the synthesis of 186.42,74 The synthesis of 186 was accomplished in 4 steps from N-
BOC-L-alanine 155 and N-butyryl-L-serine 93 in an overall yield of 14% (scheme 5.1). 
 
 
Scheme	5.1:	Synthetic	scheme	to	produce	α,β-unsaturated	ketone	mechanistic	probe	186.	
 
5.2.1 Comparison of 186 with the proposed intermediate 
The authentic standard of 186 had the same retention time as the putative α,β-
unsaturated ketone intermediate detected in reactions containing 154, PLE and EpnF 
(figure 5.6), providing strong support for the proposed catalytic mechanism of EpnF. 
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Figure	5.6:	EICs	at	m/z	=	293.15,	corresponding	to	[M	+	Na]+	for	186,	from	UHPLC-ESI-Q-
TOF	MS	analyses	of	a	mixture	of	 the	authentic	 standard	and	 the	 supernatant	 from	 the	
enzymatic	reaction	(top	trace),	the	authentic	standard	(middle	trace)	and	the	supernatant	
from	the	enzymatic	reaction		(bottom	trace).	
 
5.3 Further attempts to probe the EpnF catalytic mechanism 
The proposed mechanism for EpnF involves an α,β-unsaturated ketone intermediate 
that reacts with 4a-hydroperoxyflavin 182 to form an epoxide (figure 5.3). It was 
reasoned that reduction of the EpnF-bound FAD may lead to the formation of 182, 
which could be incubated with 186 to produce epoxyketone 173. As a consequence, 
the reduction of EpnF-bound FAD with nicotinamide adenine dinucleotide (NADH) 
and nicotinamide adenine dinucleotide phosphate (NADPH) was investigated. 
 
5.3.1 Reduction of EpnF-bound FAD with NAD(P)H 
NADH and NADPH both have UV absorbance maxima at 340 nm. A decrease in 
absorbance at 340 nm can therefore be used to monitor the oxidation of NADH or 
NADPH to NAD+ or NADP+, respectively, by an electron acceptor such as the flavin 
cofactor of EpnF (figure 5.7).96,97 
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Figure	5.7:	Reduction	of	the	EpnF-bound	flavin	cofactor	with	NAD(P)H	can	be	monitored	
by	measuring	the	decrease	in	absorbance	at	340	nm	
 
A steady decrease in absorbance at 340 nm was observed when His6-EpnF was 
incubated with NADH, whereas no change in absorbance occurred when the enzyme 
was incubated with NADPH (figure 5.8). This suggests that EpnF may have evolved 
from a flavin-dependent monooxygenase, as it appears to have retained the ability to 
specifically bind NADH and transfer hydride from it to the bound flavin cofactor, 
even though such as reaction is not required for epoxyketone formation by the 
enzyme. 
Figure	5.8:	Plot	of	absorbance	at	340	nm	versus	time	for	incubations	of	EpnF	(40	μM)	
with	NADH	(200	μM)	and	NADPH	(200	μM).	
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5.4 Incubation of EpnF with NADH and 186 
In an attempt to obtain further evidence for an α,β-unsaturated ketone intermediate in 
the EpnF catalytic cycle, the conversion of 186 to 173 by EpnF in the presence of 
NADH was investigated. 
 
 
Figure	5.9:	Attempted	 conversion	of	α,β-unsaturated	ketone	186	 to	 epoxykketone	173	
using	EpnF	and	NADH.	
 
Despite using several different NADH concentrations (0.5/2.0/50.0 mM) no 
conversion of 186 (1 mM) to 173 was observed (figure 5.9). One possible explanation 
for this is that once the α,β-unsaturated ketone intermediate is released from the active 
site of EpnF, the enzyme undergoes a conformational change that prevents the 
intermediate from re-associating with the active site. Another possible explanation is 
that NADH/NAD+ bind to the same site of EpnF as the α,β-unsaturated ketone 
intermediate and act as competitive inhibitors. Kinetic studies of the effect of 
NADH/NAD+ on the PLE and EpnF-catalysed conversion of 154 to 173 could be 
employed to investigate the latter possibility, whereas structural studies of EpnF may 
shed light on the former.  
 
5.5 Conclusions 
Evidence for an α,β-unsaturated ketone intermediate in the EpnF catalytic cycle was 
obtained by UHPLC-ESI-Q-TOF MS analyses of previous reactions involving 
conversion of 66 and 154 to their corresponding epoxyketones. The structure of the 
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intermediate 186 in the reaction utilising 154 as a substrate was confirmed by 
chromatograhic comparisons with a chemically synthesised authentic standard. 
The flavin cofactor of EpnF could be reduced with NADH but not NADPH, 
suggesting that it may have evolved from an NADH-dependent monooxygenase. 
Attempts to convert the α,β-unsaturated ketone intermediate 186 to the corresponding 
epoxyketone using EpnF in the presence of NADH were unsuccessful. The reason for 
this is unclear and merits further investigation. 
The data obtained are consistent with a catalytic mechanism for EpnF involving 
decarboxylation of the β-keto acid substrate to form an enolate that transfers hydride 
from its β-carbon to the flavin cofactor. Reaction of the resulting FADH2 with 
dioxygen forms a flavin hydroperoxide that epoxidises the carbon-carbon double bond 
of the α,β-unsaturated ketone resulting from oxidation of the enolate. This likely 
proceeds via Michael addition of the deprotonated hydroperoxide to the α,β-
unsaturated ketone followed by 1,3-elimination.  
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Chapter 6:     Conclusions and future work
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6.1 Completion of aims 
6.1.1 Enzyme cloning and purification 
At the onset of this project, one of the first aims was to clone and purify both the 
flavin-dependent TmcF and the cytochrome P450 TmcI. While TmcF was 
overproduced entirely in insoluble exclusion bodies, TmcI by was overproduced in a 
soluble form as a His6-fusion. In light of this a homologue from the eponemycin 
biosynthetic gene cluster EpnF, with 89% amino acid sequence identity to TmcF, was 
selected for cloning. Later, unpublished research by Dr. C. Huang demonstrated that 
the eponemycin biosynthetic gene cluster can also produce TMC-86A, validating 
EpnF’s suitability as a homologue (section 1.3.1). EpnF was soluble, and purified in 
near homogeneity as a His6-fusion. 
The identity of both proteins was confirmed by peptide mass fingerprinting, MS 
analysis and their elution profile in gel filtration chromatography, the latter to 
determine their oligomerisation state. UV-vis absorbance revealed the presence of a 
flavin cofactor in EpnF, with later assays demonstrating this to be FAD rather than 
FMN. Both MS analysis and UV-vis absorbance revealed the mass and Soret band 
absorbance of a heme cofactor in the cytochrome P450 TmcI. 
Through the methods proposed, EpnF and TmcI can be purified for additional 
biochemical investigation, with a good degree of characterisation data available to 
confirm the identity of the purified enzymes. 
 
6.1.2 Synthesis of putative substrates, and in vitro assays 
Through a peptide coupling approach, both the potential substrates 71 and 66 were 
successfully synthesised. An issue arising from 66 was its anticipated spontaneous 
degradation to isopropyl ketone 71 through decarboxylation, facilitated by 
intramolecular hydrogen bonding in a cyclic transition state in the α-dimethyl-β-keto 
carboxylic acid (section 1.3.2.1). A new aim arising from this issue was to purify either 
a stable analogue of the substrate, or a stable substrate precursor. 
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Investigation of in vitro activity of 66 and 71, with appropriate negative controls, 
revealed 66 and not 71 to be a putative substrate for EpnF. From this assay, 
epoxyketone 78 was produced, confirmed by UHPLC-ESI-Q-TOF MS analysis. 
While a suitable quantity for NMR analysis could not be purified in a scale-up assay 
using EpnF and 66 due to the aforementioned substrate instability, MS/MS 
fragmentation and derivatization using N-acetylcysteamine provided a measure of 
characterisation data for epoxyketone 78. This result corroborated the findings of 
Wenjun and coworkers, who had determined through heterologous expression in E. 
coli that EpnF was vital for epoxyketone formation.79  
As TMC-86A and eponemycin natural products are produced as a single diastereomer, 
this is likely the case for the epoxyketone 78, supported by the elution of species with 
the correct molecular formula in a single peak in UHPLC-ESI-Q-TOF MS analysis of 
the assay supernatant. From an industrial perspective, chemoenzymatic synthesis 
using this class of flavin dependent enzymes could ensure a high degree of 
stereoselectivity in the epoxyketone forming reaction. By comparison only 65% of the 
desired enantiomer is produced via industrial synthesis (scheme 1.1). 
As the role of TmcI had yet to be determined, it was used in an assay with 66, EpnF 
and an appropriate ferredoxin/ferredoxin reductase redox system from spinach. 
UHPLC-ESI-Q-TOF MS analysis revealed that TmcI was responsible for 
hydroxylation of the α-methyl group of the TMC-86A epoxyketone pharmacophore, 
producing 42. This result was confirmed by MS/MS analysis, which when compared 
to the MS/MS fragmentation of TMC-86A and 78 produced a signature pattern of 
fragment ions.42  
It is worth noting that while the epoxomicin biosynthetic gene cluster from 
Goodfellowiella coeruleoviolacea contains a homologue to both TmcI and EpnI in the 
form of EpxC, no similar hydroxylation of the α-methyl group of the epoxomicin 
epoxyketone is observed (table 1.1).41 This indicates that EpxC is likely a mutated or 
inactive variation of TmcI/EpnI. 
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6.1.3 Synthesis of a stable substrate precursor analogue 
With the issue of decarboxylative degradation presenting itself in the synthesis of 66, 
a new aim arising for the project was to synthesise a stable substrate precursor, which 
was attempted for methyl ester 139. Initially a Meldrum’s acid derived procedure was 
chosen for the two carbon homologation step to produce β-keto methyl ester 143, 
however yield for this compound was significantly improved with a CDI mediated 
methyl potassium coupling. 139 was obtained in a total yield of 4.9%, with attempts 
at optimization of the last coupling step yielding the lactam byproduct 151, likely due 
to the Thorpe-Ingold effect leading to an increase in the intramolecular reaction 
between the amino group and β-keto methyl ester of 145. This would need to be 
addressed in future syntheses of these methyl ester substrate precursors. 
In order to convert 139 into the substrate 66, PLE was investigated as a mild esterase. 
Turnover to 66 was observed with PLE, and as purification of a more specific esterase 
in the form of the TE domains of TmcH and EpnH was unsuccessful, it was selected 
as the esterase of choice for an attempted one pot epoxyketone synthesis with PLE. 
In a paired assay of PLE and EpnF, 139 was successfully converted into a compound 
with the mass of epoxyketone 78, which was absent in controls with heat-denatured 
EpnF by UHPLC-ESI-Q-TOF MS. As PLE is routinely used in the chiral resolution 
of esters adjacent to a racemic stereocenter, there is however the possibility that PLE 
was selectively hydrolysing the SR-disatereomer of 139 rather than the putatively 
favoured SS-diastereomer.82 This merits further investigation into the possibility of 
whether EpnF accepts the SR-disastereomer, either by purification of the separate 
diastereomers or by identification of an esterase lacking a bias towards a specific 
stereochemistry. 
While this process was not efficient, it demonstrated a proof of concept of a one pot 
synthesis of epoxyketone compounds from α-dimethyl-β-keto methyl esters. 
Optimization of this one pot reaction is also a natural focus for future investigation, 
and could lead to a scalable method of epoxyketone production for industrial, due to 
the inherent improved stability of the methyl ester precursors as opposed to the 
putative natural α-dimethyl-β-keto carboxylic acid substrates. 
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6.1.4 Investigation into substrate specificity of EpnF 
To investigate the substrate specificity of EpnF, an analogue based on alanine 154 was 
selected as the synthetic target, due to a natural epoxyketone clarepoxcin A also 
having alanine in this position (table 1.1). 
While initially a convergent synthesis was attempted at the same time as 139, coupling 
by peptide synthesis two halves of the desired compound, lactam byproduct formation 
was also observed for the alanine synthetic route producing 159. In a briefly attempted 
linear synthesis of 139, presence of the hydroxyl group of an attached serine residue 
appeared to inhibit the reaction of the leucine carboxylic acid with CDI and methyl 
potassium malonate, suggesting protection of this hydroxyl group was necessary in 
other attempts at analogue synthesis. Therefore a linear synthetic route was proposed 
to 154, using TBS protection of the serine side chain. Diastereomeric separation in the 
subsequent α-dimethylation reaction of the β-keto methyl ester 165 was accomplished 
through, likely arising from the presence of the sterically large non-polar TBS group. 
This offered a significant advantage of the previously proposed route to 139, where 
separation of diastereomers could not be accomplished through silica gel 
chromatography. This linear synthesis proved successful, providing an attractive 
synthetic route to future analogues. 
154 was in the presence of PLE demonstrated turnover to carboxylic acid 171. In a 
one pot reaction with both PLE and EpnF, the mass of a new epoxyketone compound 
172 was observed by UHPLC-ESI-Q-TOF MS analysis of the assay supernatant. This 
demonstrates that EpnF has a broader substrate tolerance than the leucine amino acid 
residue incorporated in 139 and 66, and invites more investigation into substrate 
tolerance of the enzyme. 
 
6.1.5 Authentic standard and mechanistic intermediate 
A decarboxylation-dehydrogenation-monooxygenation mechanism for EpnF was 
proposed (figure 5.4) that resolved the question of how the innate FAD cofactor of 
EpnF could be reduced in the absence of an additional external cofactor. A substrate 
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intermediate on this proposed mechanistic pathway, before the reaction with 
hydroperoxyflavin to produce an epoxyketone, was a reactive α,β-unsaturated ketone 
species. Analysis of assay supernatant for the EpnF-catalysed reactions with 66, 139 
or 154 revealed the presence of compounds with masses consistent to these reactive 
intermediates in each instance. 
In light of this it was desirable to produce an authentic standard of one of these 
intermediates, and as syntheses of alanine containing analogues had provided higher 
yields than their leucine counterparts, synthesis of the α,β-unsaturated ketone 186 was 
devised. This synthesis was readily completed in total yield of 14%, using procedures 
established during the course of this project. 
Co-injection of 186 with the supernatant of an assay containing PLE, EpnF and 154 
and subsequent UHPLC-ESI-Q-TOF MS analysis revealed 186 to be an authentic 
standard for the corresponding proposed α,β-unsaturated ketone intermediate. This 
provides significant evidence that the putative decarboxylation-dehydrogenation-
monooxygenation mechanism for this class of flavin-dependent proceeds through 
such intermediates to produce epoxyketone compounds. Briefly, use of 186 as a 
substrate with EpnF was attempted, which had its flavin cofactor reduced by NADH. 
However, no turnover was observed in this instance, indicating either that these 
intermediates cannot re-associate with the active site, or that NADH may inhibit the 
active site. The latter of these two possibilities may be a result of EpnF evolving from 
flavin dependent enzymes which require NADH reduction, with NADH still 
successfully being able to reduce EpnF. 
 
6.2 Future work 
6.2.1 Further investigation into substrate tolerance 
With a consistent route to substrate synthesis now identified for the methyl ester 
substrate precursor 154, and a reproducible one pot reaction using PLE and EpnF 
established, it would be desirable to further evaluate the substrate tolerance of EpnF 
to produce novel analogues of epoxyketones. These epoxyketone compounds may 
have improved efficacies over existing clinically used pharmaceuticals such as 
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carfilzomib (figure 1.7). Possible areas for functional group variation of substrates for 
EpnF are the amino acid side chain adjacent to the α-dimethyl-β-keto methyl ester 
functionality, different α-alkyl substitution between the carbonyl functionalities, and 
use of a different peptide backbone, as demonstrated in structure 192 (figure 6.1). Two 
particularly interesting substrates to produce may be analogues with either an L-
tryptophan or an L-phenylalanine residue adjacent to the α-dimethyl-β-keto methyl 
ester, compounds 193 and 194. A tryptophan side chain is observed in the natural 
product tryptopeptin A (table 1.1), while an L-phenylalanine side chain can be 
observed in the second generation epoxyketone pharmaceutical oprozomib.23,98 
Additionally, chemoenzymatic total synthesis of Carfilzomib would further evidence 
the industrial relevance of this class of enzymes. 
Lastly, as previously mentioned the Histone Deacetylase HDAC8 inhibitor trapoxin 
A also has an epoxyketone pharmacophore at the end of a long alkyl chain (figure 
1.4B). It would be interesting to see if a similar α-methyl-β-keto methyl ester 
functionality at the end of a long alkyl chain such as 195 could be used in the one pot 
PLE and EpnF reaction to produce an epoxyketone, as this would make EpnF capable 
of yielding another anticancer epoxyketone compound with a different biological 
target (figure 6.1).29 
 
Figure	6.1:	Potential	substrate	candidates	to	explore	EpnF	substrate	tolerance.	
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6.2.2 Identification of an esterase with increased activity 
Acquiring a range of esterases and screening them for hydrolytic activity against an 
α-dimethyl-β-keto ester substrate analogue would help to identify an ideal esterase for 
pairing in a one pot reaction with EpnF. One means of high-throughput screening of 
esterase activity is achieved by use an ester which fluoresces upon hydrolysis. An 
example of fluorescent tag is an umbelliferone based cyanohydrin ester, which 
degrades to umbelliferone 200 upon hydrolysis and can be monitored by measuring 
absorbance at 440 nm (figure 6.2).99 Synthesis of an appropriate analogue, such as 
196, would allow for screening of esterases using this procedure. 
 
 
Figure	6.2:	An	example	of	high-throughput	esterase	screening	by	use	of	a	fluorescent	tag.	
 
6.2.3 Crystal structure of EpnF 
With the seemingly novel mechanism of EpnF, it would be very interesting to evaluate 
the nature of the binding pocket within the active site which facilitates this process. 
With the synthesis of a variety of ligands which may aid crystal formation already 
completed (139, 154, 186), and NADH potentially having serving as an active site 
inhibitor (section 5.4), formation of crystals for X-ray crystallographic study would 
be highly desirable. With a crystal structure produced, techniques like a directed 
evolution approach could be employed to increase the tolerance of EpnF for unnatural 
substrates.100 
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Chapter 7: Experimental procedures 
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7.1 General 
7.1.1 Chemical reagents 
Chemical reagents were bought from Sigma Aldrich, Fisher Scientific, Acros 
Organics, Alfa Aesar or Chem-Impex international. Solvents were sourced from 
Sigma Aldrich or VWR Chemicals. (S)-1-(Benzyloxy)-2,2,6-trimethyl-1,3-
dioxoheptan-4-ammonium trifluoroacetate 122 was synthesized by Dr. D. Roberts.42 
HR-MS, 500 MHz 1H-NMR and 125 MHz 13C-NMR data were obtained by the 
departmental MS and NMR services, run by Dr. Lijiang Song and Dr. Ivan Prokes 
respectively. 
 
7.1.2 Instrumentation 
UHPLC-MS and UHPLC-MS/MS analyses were carried out using a Bruker MaXis 
Impact ESI-TOF-MS connected to a Dionex 3000 RS UHPLC instrument fitted with 
an Agilent Zorbax Eclipse Plus C18 column (100 × 2.1 mm, 1.8 µm, 25 °C) for 
chemical compounds and Chromatography Technologies ACE 3 C4-300 reverse 
phase column ( 100 × 2.1 mm, 1.8 µm, 25 °C) for purified proteins.42 
NMR spectra of synthetic compounds were measured on Bruker AV 300, 400 or 500 
MHz spectrometers. Low resolution mass spectra of synthetic compounds were 
recorded using an Agilent 6130B single Quad spectrometer. High resolution mass 
spectra of synthetic compounds were measured on a Bruker MaXis ESI-Q-TOF-MS 
spectrometer.42 Infrared spectra were recorded using a PerkinElmer Universal ATR 
Sampling Accessory. Optical rotations were recorded using a Optical Activity AA-
1000 Polarimeter. 
Centrifugation was conducted using eppendorf 5804 R and 5415 R centrifuges and a 
Sorvall RC 6 Plus centrifuge fitted with either a SLA-3000 or SS-34 rotor. PCR 
reactions were conducted using an eppendorf Mastercycler gradient machine. The pH 
of buffer solutions was measured using a Fisher Hydrus 300 pH meter. The shaker-
incubator used during cell growth was a New Brunswick Scientific innova44 
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incubator. Optical density measurements to determine cell growth were measured with 
Thermo BioMate3 spectrophotometer. 
PCR reactions were conducted using an eppendorf Mastercycler gradient machine. 
Agarose gel electrophoresis was carried out using a BioRad Wide Mini-Sub Cell GT 
tank connected to a BioRad Power Pac 300 power supply. Agarose gels resulting from 
electrophoresis were visualized using under UV light using a UVP imaging system 
UV transilluminator. Both protein and DNA concentrations were measured using a 
Thermo Scientific NanoDrop Lite spectrophotometer. Cells were lysed under pressure 
using a Constant Systems cell disruptor. SDS-PAGE analysis was conducted with a 
BioRad Mini PROTEAN Tetra Cell tank connected to a BioRad Power Pac 300 power 
supply.  
A Varian Cary 50 Bio UV-Visible spectrophotometer was used for protein UV-visible 
measurements. Gel filtration chromatography was carried out using an Amersham 
Biosciences ÄKTA purifier connected to a GE Healthcare HiLoad 16/600 Superdex 
200 pg column.42 
 
7.1.3 Plasmids, strains and commercial enzymes 
Genomic DNA was prepared from S. hygroscopicus ATCC 53709 and S. 
chromofuscus ATCC 49982. Competent cells used were either Invitrogen E. coli One 
Shot TOP10 or E. coli One Shot BL21 Star (DE3) Chemically Competent Cells. The 
plasmid vector used was pET151 from an Invitrogen Champion pET151 Directional 
TOPO Expression Kit. Unless otherwise stated commercial enzymes were purchased 
from Sigma Aldrich. 
 
7.1.4 Biological reagents and media 
Fisher Luria-Bertani (LB) miller media was made to a concentration of 25 g/L in 
deionized water. Solid LB-agar media was made using 25 g/L LB media and 15 g/L 
of Becton, Dickinson and Company bacto agar in deionized water. Stock solutions of 
ampicillin were made to a concentration of 100 mg/mL and sterilized by syringe 
filtration, and when used to supplement media it was added such that the final 
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concentration of antibiotic would be 100 µg/mL. Fluka tryptic soy broth (TSB) media 
for growth of Streptomyces species was prepared to the supplier’s specifications in 
deionized water. Biological reagents were purchased from Sigma Aldrich unless 
otherwise stated. 
 
7.2 Biological procedures 
7.2.1 Isolation of genomic DNA  
TSB media (50 mL) was inoculated with a Streptomyces 106 spore stock solution (50 
µL) and grown at 30 °C and 180 rpm for 2 days. The culture was centrifuged at 4000 
rpm for 10 min and the supernatant discarded. 
The cell pellet was washed twice with STE buffer (5 mL - 100 mM sodium chloride, 
100 mM Tris pH 8.0, 1 mM ethylenediaminetetraacetic acid – EDTA). Cells were 
resuspended in both STE buffer (5 mL) and lysozyme (5 mL, 10 mg/mL in STE 
buffer). Solution was incubated at room temperature for 30 min with gentle shaking. 
Sodium dodecyl sulfate solution (0.5 mL, 10% w/v) was added and the solution was 
incubated for 5 min with gentle shaking at room temperature. The solution was heated 
to 70 °C for 5 min and then cooled on ice for 5 min. Potassium acetate (1.25 mL, 5 M) 
was added and the solution was incubated for 5 min on ice. 
Phenol-chloroform-isoamyl alcohol (25:24:1, 5 mL) was added and the solution 
mixed gently by inversion for 5 min. The solution was centrifuged at 7000 rpm for 10 
min at 20 °C. Sodium acetate (1 mL, 3 M) and ice-cold isopropanol (6 mL) were added 
to the supernatant and mixed by inversion to precipitate the genomic DNA. The 
solution was centrifuged at 7000 rpm for 10 min at 4 °C, then the supernatant 
discarded. The pellet was washed with 70% ethanol (100 µL) in deionized water, and 
centrifuged at 7000 rpm for 10 min at 4 °C discarding the supernatant and leaving the 
pellet to dry. Once dry the DNA was resuspended with Geneaid RNase in water (500 
µL, 10 mg/mL). The concentration was measured using a NanoDrop 
spectrophotometer and the genomic DNA was stored at -20 °C.  
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7.2.2 Polymerase chain reactions and agarose gel 
electrophoresis 
Complementary primers (Sigma Aldrich) were ordered for the amplification of epnF, 
tmcF and tmcI from the genomic DNA of S. hygroscopicus and S. chromofuscus 
respectively (table 7.1), with forward primers utilizing a CACC tag for cloning into a 
pET151 vector. 
 
Table	7.1:	Primers	used	for	amplification	(-f	or	-r)	or	sequencing	(-seq)	of	epnF	or	tmcF	
and	tmcI	from	S.	hygroscopicus	and	S.	chromofuscus	respectively.	
Primers Nucleotide sequence (5’  3’) 
epnF-f CACCGTGAGTGACAGCAAATCGG 
epnF-r TCATGCTTCCCCGGGTGAG 
epnF-seq ATCCAGACAGCCGTCGGCTC 
tmcF-f CACCGTGGTGGAACGCCTGGCGGATA 
tmcF-r TCATCGCTCCCCCGGGTGGGTG 
tmcI-f CACCATGGTGACGATCGACCCGAACA 
tmcI-r CTGTCAGACATGGGCGTTCTCT 
 
PCR reactions were prepared using a Roche Diagnostics Expand High Fidelity PCR 
System kit, using forward and reverse primers for gene of interest (table 7.1) and 
genomic DNA (Section. 7.2.1.), in the volumes specified in the kit’s protocol (table. 
7.2). 
 
Table	7.2:	Quantities	of	reagents	used	for	PCR	reactions.	
Reagent Volume (µL) 
Genomic DNA (100 ng/µL) 2 
Buffer 2 (MgCl2) 5 
dNTPs (10 mM) 1 
Forward primer (10 µM) 1.5 
Reverse primer (10 µM) 1.5 
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High Fidelity polymerase 0.5 
DMSO 5 
Deionized water 33.5 
Total volume 50 
 
Annealing temperatures between 55 °C and 65 °C were screened for all PCR reactions, 
with tmcI and epnF favoring 55 °C and tmcF favoring 60 °C. The following 
temperature scheme was used for the PCR reactions, with 35 cycles of steps 2-4, using 
an eppendorf Mastercycler gradient machine: 
 1) Denaturation:	94	°C	for	5	min	2) Denaturation:	94	°C	for	1	min	3) Annealing:	55	°C	(tmcI/epnF)	or	60	°C	(tmcF)	for	1	min	4) Extension:	72	°C	for	2	min	5) Final	extension:	72	°C	for	10	min	6) Stop	reaction:	4	°C	until	ready	for	use	
 
PCR products were visualized and purified using agarose gel electrophoresis. Agarose 
gels were prepared by dissolving Appleton D-1 LE agarose (1.0 g) in TBE buffer (100 
mL - 4.46 M Tris, 4.45 M boric acid, 200 M EDTA) by microwave heating. The 
solution was allowed to cool to ca. 50 °C and Biotium GelRed Nucleic Acid Gel Stain 
(5 µL, ×10000 concentrated) was added. The gel was allowed to set in a gel tray with 
a comb to ensure well formation. 
PCR products were mixed with Thermo Scientific ×6 loading dye (2 µL) and added 
to separate wells of the agarose gel. The gel was submerged in TBE buffer in a BioRad 
Wide Mini-Sub Cell GT tank, and ran at 90 V at room temperature for ca. 1 hour. The 
resulting gel was visualized under UV light, the PCR products excised and purified as 
per the manufacturer’s protocol using a Thermo Scientific GeneJET Gel Extraction 
Kit. Concentration of the PCR product was measure using a Thermo Scientific 
NanoDrop Lite spectrophotometer. 
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7.2.3 Gene cloning, competent cell transformation and 
plasmidic DNA extraction 
PCR product (ca. 2 ng) was added to salt solution (1 µL, 1.2 M NaCl, 0.06 M MgCl2) 
and pET151 vector (1 µL, 15-20 ng/µL) from an Invitrogen Champion pET151 
Directional TOPO Expression kit, making up to a final volume (6 µL) with deionized 
water. The reaction was left for 30 min at room temperature, and added to an 
Eppendorf tube of Invitrogen E. coli One Shot TOP10 chemically competent cells, 
stirring with a pipette tip. Cells were left for 5 min on ice before transforming the cells 
with the plasmid using heat shock (42 °C for 30 sec). The vial was transferred back to 
ice and LB media (500 µL) was added to the Eppendorf tube. The mini-culture was 
shaken at 180 rpm and 37 °C for 1 hr. The solution was spread on ampicillin 
supplemented LB-agar plates and which were then incubated overnight at 37 °C. 
From the LB-agar plate five single colonies were picked and added to separate tubes 
LB media (10 mL) supplemented with ampicillin stock solution (10 µL). The cultures 
were allowed to grow at 180 rpm and 37 °C overnight. 
Glycerol stocks were made by centrifuging this cell culture (1.5 mL) at 13200 rpm for 
1 min, discarding the supernatant then re-suspending the cell pellet in LB (500 µL) 
and glycerol (500 µL, 50% v/v in deionized water). Glycerol stocks were stored at -80 
°C. Plasmids were extracted from the remaining culture liquid using a 
ThermoScientific GeneJET Plasmid Miniprep Kit as per the manufacturer’s protocol. 
Concentration was measured using a Thermo Scientific NanoDrop Lite 
spectrophotometer. 
 
7.2.4 Construct restriction digests and gene sequencing 
The restriction enzymes PvuI or SacI were selected to screen potential epnF and tmcI 
or tmcF pET151 constructs respectively, cleaving both the gene of interest and the 
plasmid vector once in order to confirm orientation of the gene. Digests were prepared 
by combing PvuI or SacI (1 µL, 10 units/µL, New England Biolabs), NE 3.1 or 1.1 
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buffer (1 µL, ×10 concentrated), deionized water (3 µL) and the plasmid construct (5 
µL, concentrations between 10 ng/µL and 30 ng/µL) and incubated at 37 °C. Agarose 
gel electrophoresis (section 7.2.2) was conducted on the digests and they were 
visualized under UV light. Constructs which appeared to correspond to successful 
digestion were sequenced by GATC Biotech, using the primers T7 and pET-RP which 
flank the cloned gene in the construct. The epnF-pET151 construct required an 
additional sequencing primer to sequence the middle section of the gene (epnF-seq, 
table 7.1). The genetic sequence of the constructs was checked for mutations using the 
ClustalW2 alignment program software, comparing to the original sequence of each 
gene. 
 
7.2.5 Protein overexpression 
Both epnF-pET151 and tmcI-pET151 plasmid constructs were used to transform 
Invitrogen E. coli One Shot BL21 Star (DE3) chemically competent cells (section 
7.2.3). Single colonies from ampicillin supplemented LB-agar plates were selected 
and transferred to ampicillin supplemented LB media (10 mL), growing overnight at 
37 °C and 180 rpm. 
The overnight culture was used to inoculate LB media (1.0 L) supplemented with 
ampicillin stock solution, and cells were grown at 37 °C and 180 rpm until they 
reached an A600 optical density of between 0.5-0.7. Syringe filter sterilized IPTG was 
added to the culture (final concentration of 500 mM for TmcI, 100 mM for EpnF), in 
addition to riboflavin (500 mM final concentration) in the EpnF culture and 5- 
aminolevulinic acid (250 mM final concentration) for the TmcI culture in order to 
assist formation of the flavin and heme cofactors respectively. The culture was shaken 
overnight at 180 rpm and 15 °C. 
Cultures were centrifuged at 4000 rpm and 4 °C for 30 minutes and the supernatant 
discarded. The cell pellet was re-suspended in washing buffer (20 mM Tris-HCl, 100 
mM NaCl, 10 % glycerol, 20 mM imidazole, pH 8), and then either stored at -80 °C or 
used in protein purification. 
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7.2.6 Protein purification by nickel ion affinity 
chromatography and SDS-PAGE analysis 
Ice cold phenylmethylsulfonyl fluoride (PMSF – 1 mM final concentration) was added 
to the suspended cell pellet (section 7.2.5), and the cells lysed by pressure using a 
Constant Systems cell disruptor. Cellular debris was pelleted by centrifugation (2 × 
20 min, 15000 rpm, 4 °C) and the supernatant passed through a 0.45 µm syringe filter. 
Filtrate was loaded onto a GE Healthcare HisTrap HP 1 mL nickel affinity column, 
and washed with washing buffer (10 mL, section 7.2.5). Protein was eluted with 
buffers of increasing imidazole concentration (3 mL each - 20 mM Tris-HCl, 100 mM 
NaCl, 10 % glycerol, and 100/200/300 mM imidazole). 
An 10% acrylamide/bis-acrylamide SDS-PAGE gel was prepared (table 7.3), adding 
the stacking gel with comb to the loading gel once it had set. When the entire gel was 
set the comb was removed and the gel placed in a BioRad Mini PROTEAN Tetra Cell 
tank, submerging in running buffer (2 M glycine, 1% SDS, 250 mM Tris-HCl, pH 8). 
Protein fractions (15 µL) were mixed with SDS-PAGE loading dye (5 µL, 1.5 mL 1 
M Tris-HCl pH 6.8, 3 mL 1 M dithiothreitol – DTT, 0.6 g SDS, 0.03 g bromophenol 
blue, 2.4 mL glycerol and deionized water to a total volume of 7.5 mL), and loaded 
onto to the SDS-PAGE gel along with Thermo Scientific Page Ruler Plus Prestained 
Protein Ladder (6 µL). Electrophoresis was run at 180 V for ca. 45 minutes using a 
BioRad Power Pac 300 power supply, and the protein bands visualized using an 
Expedeon Instant Blue stain. 
 
Table	7.3:	Reagents	and	quantities	required	for	a	10%	acrylamide/bis-acrylamide	SDS-
PAGE	gel.	APS	=	Ammonium	persulfate.	
Reagents 
10% Loading gel 
(µL) Stacking gel (µL) 
Deionized water 2000 1050 
30% acrylamide/bis-acrylamide 1650 250 
1.5 m Tris-HCl pH 8.8 1250 - 
1.0 m Tris-HCl pH 6.8 - 190 
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10% SDS 50 15 
10% APS 50 15 
TEMED 2.0 1.5 
 
Bands corresponding to an appropriate mass for the proteins were excised and trypsin 
digested using a Sigma Aldrich Trypsin Profile IGD kit as per the manufacturer’s 
specifications, and the peptide mass fingerprint analysed using MALDI-TOF mass 
spectrometry using a Sigma Aldrich α-cyano-4-hydroxycinnamic acid matrix and a 
Bruker Autoflex Spectrometer. 
TmcI was loaded onto a GE Healthcare PD-10 column, eluting with concentration 
buffer (20 mM Tris-HCl, pH 8, 100 mM NaCl, 10% glycerol), in order to remove 
excess imidazole. Proteins were concentrated by centrifugation using a GE Healthcare 
30 kDa MWCO Vivaspin 20 spin filter, washing with concentration buffer (2 × 5 mL). 
Concentrations of the proteins was determined using a Thermo Scientific NanoDrop 
Lite spectrophotometer, and the proteins divided into aliquots (20 µL each) and stored 
at -80 °C. ESI-MS analyses were conducted using a Bruker MaXis Impact 
spectrometer connected to a Dionex 3000 RS UHPLC instrument fitted with a 
Chromatography Technologies ACE 3 C4-300 reverse phase column (100 × 2.1 mm, 
1.8 µm, 25 °C).  
TmcI yield = 1.8 mg/L  
EpnF yield = 11.1 mg/L 
 
7.2.7 Characterization of heme cofactor for TmcI 
TmcI was analysed by UHPLC-ESI-Q-TOF MS using the following elution profile: 0 
min: 5% acetonitrile + 0.1 % formic acid, 95% water + 0.1 % formic acid; 30 min: 
5% acetonitrile + 0.1 % formic acid ; 40 min: 5% acetonitrile + 0.1 % formic acid, 
using a Bruker MaXis Impact spectrometer connected to a Dionex 3000 RS UHPLC 
instrument fitted with a Chromatography Technologies ACE 3 C4-300 reverse phase 
column (100 × 2.1 mm, 1.8 µm, 25 °C). An absorbance for the heme prosthetic group 
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was observed in the 280 nm UV chromatogram, as well as in the corresponding EIC 
(m/z calcd for C34H32FeN4O4+: 616.1767, observed: 616.1765). 
The purity index heme content of desalted TmcI (8 M) in Tris-HCl, pH 8 (25 mM) was 
evaluated by measuring absorbance between 500-250 nm using a Varian Cary 50 Bio 
UV-Visible spectrophotometer. A purity index of 1.0 was calculated from the ratio 
A418/A280.72  
 
7.2.8 Characterization of a flavin cofactor for EpnF 
The UV-Vis absorbance of EpnF (20 µM) in concentration buffer (section 7.2.6) was 
measured between 500-300 nm using a Varian Cary 50 Bio UV-Visible 
spectrophotometer. An absorbance maximum at 447 nm was observed, consistent with 
a bound flavin cofactor. 
 
7.2.9 Oligomerization state of EpnF and TmcI 
A calibration solution of thyroglobulin (bovine thyroid, Sigma), apoferritin (equine 
spleen, Sigma), β-amylase (sweet potato, Sigma), bovine serum albumin (bovine, 
Sigma) and lysozyme (hen egg white, Fluka) in concentration buffer (200 µL, section 
7.2.6) was analysed by gel filtration chromatography on a GE Healthcare Superdex 
200 column using concentration buffer as the eluent and monitoring absorbance at 280 
nm (table 7.4). Comparison of the elution volumes for TmcI and EpnF with those of 
the molecular weight lead to the conclusion that they are monomeric and dimeric 
proteins respectively.42 
 
Table	7.4:	Molecular	weights	and	elution	volumes	for	proteins	used	to	calibrate	the	gel	
filtration	column.	
Protein MWt (kDa) Elution volume (mL) 
Thyroglobulin 669 46.6 
Apoferritin 443 50.4 
β-Amylase 200 65.5 
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Bovine serum albumin 66 76.1 
Lysozyme 13 108.6 
 
7.3. Chemical synthesis 
All compounds synthesised have been characterised by 1H and 13C NMR analyses. 
Novel compounds were additionally characterised by HR-MS analysis, while known 
compounds were characterised by MS analysis. 
 
7.3.1 Synthesis of isopropyl ketone putative substrate 
96 tert-Butyl (S)-(1-(methoxy(methyl)amino)-4-methyl-1-oxopentan-2-
yl)carbamate 
 
To a stirred solution of BOC-L-leucine (2.5 g, 11.0 mmol) in DCM (50 mL) was added 
O,N-dimethylhydroxylamine hydrochloride (1.2 g, 12.1 mmol), triethylamine (3.2 
mL, 23.0 mmol) and BOP reagent (4.9 g, 11.0 mmol). After 3.5 hours the solution 
was diluted with DCM (200 mL) and washed with HCl (3 M, 3 × 30 mL), saturated 
NaHCO3 (3 × 30 mL) and brine (3 × 30 mL). The organic layer was dried (MgSO4), 
solvent removed in vacuo and the resulting residue purified by silica gel 
chromatography (1:3 ethyl acetate:n-hexane) to give the desired product as a yellow 
oil (2.3 g, 8.5 mmol, 77%).22 
δH (CDCl3, 400 MHz): 5.04 (1H, br d, J 9.0 Hz, H-4), 4.77-4.62 (1H, m, H-5), 3.77 
(3H, s, H-11), 3.18 (3H, s, H-10), 1.70 (1H, septet, J 7.0 Hz, H-7), 1.48-1.36 (11H, m, 
H-1, H-6), 0.95 (3H, d, J 6.5 Hz, H-8), 0.91 (3H, d, J 6.5 Hz, H-8). 
δC (CDCl3, 100 MHz): 177.2 (C-9), 155.8 (C-3), 79.6 (C-2), 61.7 (C-11), 49.1 (C-5), 
42.2 (C-6), 32.2 (C-10), 28.5 (C-1), 24.8 (C-7), 23.5 (C-8), 21.7 (C-8). 
m/z ES+ (%): 275 (9, [M+H]+), 297 (100, [M+Na]+). 
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100 tert-Butyl (S)-(2,6-dimethyl-3-oxoheptan-4-yl)carbamate 
 
Under an argon atmosphere, a stirred solution of 96 (2.3 g, 8.5 mmol) in THF (13 mL) 
was cooled to 0 °C and isopropylmagnesium chloride (2 M in diethyl ether, 21.5 mL, 
43.0 mmol) was added dropwise. The reaction was allowed to reach 25 °C and, after 
4 hours stirring, was quenched with HCl (1 M, 2.5 mL), forming a precipitate. The 
precipitate was removed by filtration and washed with ethyl acetate (3 × 50 mL). The 
organic extractions were combined and washed with brine (3 × 30 mL). The organic 
layer was dried (MgSO4), solvent removed in vacuo and the resulting residue purified 
by silica gel chromatography (1:4 ethyl acetate:n-hexane) to give the desired product 
as a colorless oil (1.1 g, 4.3 mmol, 51%).101 
δH (CDCl3, 400 MHz): 5.00 (1H, br d, J 8.0 Hz, H-4), 4.49 (1H, dt, J 9.5, 3.5 Hz, H-
5), 2.80 (1H, septet, J 7.0 Hz, H-10), 1.77-1.65 (1H, m, H-7), 1.53-1.39 (10H, m, H-
1, H-6), 1.34-1.25 (1H, m, H-6), 1.14 (3H, d, J 7.0 Hz, H-11), 1.11 (3H, d, J 7.0 Hz, 
H-11), 0.98 (3H, d, J 6.5 Hz, H-8), 0.93 (3H, d, J 6.5 Hz, H-8). 
δC (CDCl3, 100 MHz): 213.9 (C-9), 155.5 (C-3), 79.3 (C-2), 56.0 (C-5), 40.7 (C-6), 
37.6 (C-10), 28.2 (C-1), 24.8 (C-7), 23.3 (C-8), 21.6 (C-8), 18.8 (C-11), 17.7 (C-11). 
m/z ES+ (%): 256 (5, [M+H]+), 280 (100, [M+Na]+). 
 
94 (S)-2,6-Dimethyl-3-oxoheptan-4-ammonium chloride42 
 
To 100 (1.1 g, 4.3 mmol) at 0 °C was added HCl in 1,4-dioxane (4 M, 86 mL). The 
resulting mixture was stirred while warming to 25 °C. After a further 45 minutes 
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stirring, the solvent was removed in vacuo, and the resulting residue washed with 
diethyl ether (3 × 10 mL) to yield the desired product as a brown oil (459 mg, 2.4 
mmol, 55%).  
δH (CDCl3, 400 MHz): 8.52 (3H, br s, H-1), 4.42 (1H, s, H-2), 2.82 (1H, septet, J 6.5 
Hz, H-7), 2.13-2.01 (1H, m, H-4), 1.93-1.83 (1H, m, H-3), 1.67-1.57 (1H, m, H-3), 
1.20 (3H, d, J 7.5 Hz, H-8), 1.11 (3H, d, J 7.5 Hz, H-8), 1.04 (3H, d, J 6.0 Hz, H-5), 
0.99 (3H, d, J 6.5 Hz, H-5). 
δC (CDCl3, 100 MHz): 209.7 (C-6), 56.4 (C-2), 39.1 (C-3), 37.5 (C-7), 24.8 (C-4), 
23.4 (C-5), 21.6 (C-5), 19.3 (C-8), 17.6 (C-8). 
HRMS (ESI+): calcd for C9H20NO+: 158.1539, found: 158.1535. 
IR (cm-1): 2936 (N-H stretch), 1719 (C=O stretch). 
 
104 Methyl butyryl-L-serinate42 
 
Under an argon atmosphere to a stirred solution of L-serine methyl ester hydrochloride 
(2.0 g, 13.0 mmol) in DCM (10 mL) was added triethylamine (1.8 mL, 12.9 mmol) at 
-20 °C. After stirring for 10 minutes to this was added freshly distilled butyric acid 
(1.0 mL, 10.9 mmol) and DCC (2.2 g, 10.9 mmol). The solution was allowed to reach 
25 °C and left to stir for 16 hours. Urea precipitate was removed by filtration and 
solvent removed in vacuo. The resulting residue was purified by silica gel 
chromatography (ethyl acetate) to give the desired product as a white powder (1.3 g, 
7.1 mmol, 65%). 
δH (CDCl3, 400 MHz): 6.51 (1H, br d, J 6.0 Hz, H-5), 4.67 (1H, quintet, J 4.0 Hz, H-
6), 3.93 (1H, dd, J 11.0, 3.5 Hz, H-7), 3.89 (1H, dd, J 11.0, 3.5 Hz, H-7), 3.78 (3H, s, 
H-10), 2.99 (1H, br s, H-8), 2.24 (2H, t, J 7.0, H-3), 1.68 (2H, sextet, J 7.5 Hz, H-2), 
0.96 (3H, t, J 7.5 Hz, H-1). 
δC (CDCl3, 100 MHz): 173.8 (C-4), 171.2 (C-9), 63.6 (C-7), 54.7 (C-6), 52.9 (C-10), 
38.5 (C-3), 19.1 (C-2), 13.8 (C-1). 
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HRMS (ESI+): calcd for C8H15NNaO4+: 212.0893, found: 212.0891. 
IR (cm-1): 3294 (O-H stretch), 1740 (C=O stretch). 
[α]D20 = +13.5 (c 0.375, CHCl3). 
 
93 N-Butanoyl-L-serine42 
 
To a stirred solution of 104 (1.3 g, 7.1 mmol) in THF (17 mL) was added 30% (w/w) 
hydrogen peroxide (0.17 mL) and aqueous lithium hydroxide (0.76 M, 14.2 mL, 10.7 
mmol) dropwise. After 2 hours the solvent was removed in vacuo and the residue 
dissolved in deionized water (10 mL). The aqueous layer was washed with diethyl 
ether (2 × 10 mL), acidified to pH 1 with hydrochloric acid (1 M), and sodium chloride 
added (ca. 5 g). The aqueous layer was extracted with ethyl acetate (20 × 10 mL), and 
the organics combined and dried (MgSO4). Solvent was removed in vacuo to give the 
desired product as a clear oil (969 mg, 5.5 mmol, 78%). 
δH (MeOD, 300 MHz): 4.50 (1H, br t, J 4.5 Hz, H-6), 3.90 (1H, dd, J 11.0, 5.0 Hz, H-
7), 3.82 (1H, dd, J 11.0, 4.0 Hz, H-7), 2.26 (2H, t, J 7.5 Hz, H-3), 1.66 (2H, sextet, J 
7.5 Hz, H-2), 0.97 (3H, t, 7.5 Hz, H-1). 
δC (CDCl3, 75 MHz): 176.2 (C-4), 173.5 (C-9), 63.0 (C-7), 56.1 (C-6), 38.7 (C-3), 
20.2 (C-2), 14.0 (C-1). 
HRMS (ESI-): calcd for C7H12NO4-: 174.0772, found: 174.0772. 
IR (cm-1): 3308 (O-H stretch), 1720 (C=O stretch).  
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71 N-((S)-1-(((S)-2,6-Dimethyl-3-oxoheptan-4-yl)amino)-3-hydroxy-1-
oxopropan-2-yl)butyramide42 
 
To a stirred solution of 104 (31.7 mg, 181 µmol) in dioxane (1.3 mL) was added 
triethylamine (25 µL, 179 µmol), BOP reagent (81.1 mg, 183 µmol) and a solution of 
94 (38.5 mg, 199 µmol) in dioxane (1.7 mL) and triethylamine (28 µL, 200 µmol). 
After 4 hours, precipitate formed was removed by filtration and solvent removed in 
vacuo. Resultant residue was dissolved in ethyl acetate (10 mL), then washed with 
HCl (3 M, 3 × 10 mL), saturated NaHCO3 (3 × 10 mL) and brine (3 × 10 mL). The 
organic layer was dried (MgSO4), solvent removed in vacuo and resulting residue 
purified by silica gel chromatography (ethyl acetate) to yield a mixture of 
diastereomers (demonstrated to have distinct retention times by LCMS) as a light 
brown solid (14.9 mg, 47 µmol, 26%, major:minor 8:5). 
HRMS (ESI+): calcd for C16H30N2NaO4+: 337.2098: found 337.2100. 
IR (cm-1): 3313 (O-H stretch), 1715 (C=O stretch).  
 
Predicted major diastereomer (SS): 
δH (CDCl3, 500 MHz): 7.24-7.19 (1H, m, H-10), 6.68 (1H, br d, J 7.0 Hz, H-5), 4.74-
4.69 (1H, m, H-11), 4.57-4.41 (1H, m, H-6), 4.10-4.04 (1H, m, H-7), 3.70-3.53 (1H, 
m, H-7), 2.86-2.74 (1H, septet, J 6.5 Hz, H-16), 2.25 (2H, t, J 7.0 Hz, H-3), 1.72-1.62 
(3H, m, H-2, H-13), 1.57-1.50 (1H, m, H-12), 1.45-1.37 (1H, m, H-12), 1.13 (3H, d, 
J 7.0 Hz, H-17), 1.10-1.06 (3H, m, H-17), 0.98-0.91 (9H, m, H-1, H-14). 
δC (CDCl3, 125 MHz): 212.6 (C-15), 173.3 (C-4), 170.1 (C-9), 62.1 (C-7), 54.5 (C-
11), 53.1 (C-6), 39.1 (C-3), 37.4 (C-12), 36.8 (C-16), 24.3 (C-13), 22.5 (C-14), 20.6 
(C-14), 18.2 (C-17), 18.1 (C-2), 16.9 (C-17), 12.8 (C-1). 
 
Predicted minor diastereomer (SR): 
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δH (CDCl3, 500 MHz): 7.15-7.10 (1H, m, H-10), 6.59 (1H, br d, J 7.0 Hz, H-5), 4.57-
4.51 (1H, m, H-6), 4.74-4.69 (1H, m, H-11), 4.01 (1H, dd, J 12.0, 3.5 Hz, H-7), 3.88-
3.79 (1H, m, H-7), 2.86-2.74 (1H, septet, J 6.5 Hz, H-16), 2.21 (2H, dt, J 7.5, 2.0 Hz, 
H-3), 1.72-1.62 (3H, m, H-2, H-13), 1.57-1.50 (1H, m, H-12), 1.45-1.37 (1H, m, H-
12), 1.13 (3H, d, J 7.0 Hz, H-17), 1.10-0.96 (3H, m, H-17), 0.98-0.91 (9H, m, H-1, H-
14). 
δC (CDCl3, 125 MHz): 212.1 (C-15), 172.8 (C-4), 170.2 (C-9), 62.1 (C-7), 55.0 (C-
11), 52.9 (C-6), 38.8 (C-3), 37.4 (C-12), 36.7 (C-16), 24.3 (C-13), 22.5 (C-14), 20.5 
(C-14), 18.3 (C-17), 18.1 (C-2), 16.9 (C-17), 12.8 (C-1). 
 
7.3.2 Synthesis of α-dimethyl-β-keto carboxylic acid putative 
substrate 
123 Benzyl (S)-4-((S)-2-butyramido-3-hydroxypropanamido)-2,2,6-
trimethyl-3-oxoheptanoate42 
 
To a solution of 93 (42.1 mg, 240 µmol) in dichloromethane (DCM, 3 mL) and 
triethylamine (36.5 µL, 262 µmol) was added (S)-1-(Benzyloxy)-2,2,6-trimethyl-1,3-
dioxoheptan-4-ammonium trifluoroacetate (96.6 mg, 238 µmol), HOBT (68.2 mg, 
505 µmol) and EDC (91.4 mg, 477 µmol). After 24 hours stirring at 25 °C the solution 
was washed with saturated NaHCO3 (3 × 5 mL), deionized water (5 mL) and brine (5 
mL), and the organic layer was dried (MgSO4). The solvent was removed in vacuo 
and the resulting residue purified by silica gel chromatography (1:1 ethyl acetate:n-
hexane) to yield the desired product as a yellow crystalline solid (27.6 mg, 62 µmol, 
26%). 1H NMR spectroscopic analysis indicated that it contained approximately 10% 
of the C-11 epimer. The data reported are for predicted major diastereomer (SS).  
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δH (CDCl3, 400 MHz): 7.59-7.24 (5H, m, H-21, H-22, H-23), 7.06 (1H, d, J 8.5 Hz, 
H-10), 6.61 (1H, d, J 6.5 Hz, H-5), 5.24-5.09 (2H, m, H-19), 4.96-4.88 (1H, m, H-11), 
4.40-4.34 (1H, m, H-6), 3.97 (1H, dd, J 11.5, 2.5 Hz, H-7), 3.53 (1H, dd, J 11.5, 5.0 
Hz, H-7), 2.21 (2H, dt, J 7.5, 3.0 Hz, H-3), 1.71-1.60 (2H, m, H-2), 1.58-1.29 (3H, m, 
H-12, H-13), 1.45 (3H, s, H-17), 1.41 (3H, s, H-17), 0.97-0.82 (9H, m, H-1, H-14). 
δC (CDCl3, 100 MHz): 207.5 (C-15), 174.1 (C-4), 173.1 (C-18), 171.0 (C-9), 135.4 
(C-20), 128.8 (C-21), 128.6 (C-23) 128.3 (C-22), 67.5 (C-19), 62.7 (C-7), 55.0 (C-
16), 53.6 (C-6) 53.3 (C-11), 41.1 (C-12), 38.3 (C-3), 24.9 (C-13), 23.5 (C-14), 22.6 
(C-17), 22.4 (C-17), 21.2 (C-14), 19.1 (C-2), 13.8 (C-1). 
HRMS (ESI+): calculated for C24H36N2NaO6+: 471.2466, found: 471.2465.  
 
66 (S)-4-((S)-2-Butyramido-3-hydroxypropanamido)-2,2,6-trimethyl-3-
oxoheptanoic acid42  
 
123 (27.6 mg, 62 µmol) was stirred in methanol (2 mL) containing 10% Pd/C (ca. 25 
mg) under a hydrogen atmosphere (1 atm). After 2 hours the mixture was filtered 
through celite and the solvent was removed in vacuo to give the product as a clear oil 
(16.3 mg, 47 µmol, 75%). 1H NMR spectroscopic analysis showed that this contained 
approximately 20% of 71 resulting from decarboxylation of the product. Further 
decarboxylation was observed to occur during subsequent spectroscopic analysis. 
After 48 hours the ratio of α-dimethyl-β-keto acid to isopropyl ketone was estimated 
to be 4:5 by 1H NMR spectroscopic analysis. Spectroscopic data for the α-dimethyl-
β-keto acid are given below. Spectroscopic data for 71 are reported in the experimental 
section for that compound.42 
δH (CDCl3, 500 MHz): 7.15-7.10 (1H, br s, H-10), 6.67 (1H, br s, H-5), 5.01-4.94 (1H, 
m, H-11), 4.75-4.69 (1H, m, H-6), 4.03-3.92 (1H, m, H-7), 3.64-3.59 (1H, m, H-7), 
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2.26 (2H, t, J 6.5 Hz, H-3), 1.72-1.61 (1H, m, H-13), 1.60-1.50 (2H, m, H-12), 1.41 
(3H, s, H-17), 1.39 (3H, s, H-17), 0.98- 0.89 (H11, m, H-14, H-1, H-2). 
δC (CDCl3, 125 MHz): 207.6 (C-15), 175.9 (C-18), 170.8 (C-9), 168.1 (C-4), 63.9 (C-
7), 54.8 (C-16), 53.9 (C-11), 53.5 (C-6), 38.3 (C-3), 24.8 (C-13), 22.5 (C-14), 21.8 
(C-14), 19.2 (C-2), 13.8 (C-1). 
HRMS (ESI-): calculated for C17H29N2O6-: 357.2031, found: 357.2028. 
 
7.3.3 Synthesis of α-dimethyl-β-keto methyl ester substrate 
analogues 
143 Methyl (S)-4-((BOC)amino)-6-methyl-3-oxoheptanoate 
 
Method A: To a solution of N-BOC-L-leucine (1.5 g, 6.5 mmol) in DCM (20 mL) was 
added EDC (1.4 g, 7.1 mmol), DMAP (873 mg, 7.1 mmol) and Meldrum’s acid 
(recrystallized from acetone prior to use, 937 mg, 6.5 mmol). Reaction was stirred and 
monitored by MS, revealing the reaction had not gone to completion after 27 hours, 
additional EDC (496 mg, 2.6 mmol) and DMAP (320 mg, 2.6 mmol) were added, and 
the reaction stirred for an additional 69 hours. The reaction was mixture was poured 
in HCl (1 M, 20 mL) and the organic layer collected. The aqueous layer was extracted 
with DCM (3 × 20 mL), the organic extractions combined and dried (MgSO4). Solvent 
was removed in vacuo to provide the Meldrum’s adduct as a yellow solid (1.8 g, 5.1 
mmol, ca. 79%), which was used without further purification. 
Meldrum’s adduct (1.8 g, 5.1 mmol) was dissolved in methanol (20 mL) and refluxed 
at 70 °C	for	24	hours.	Solvent	was	removed	in	vacuo,	and the resulting residue was 
purified by silica gel chromatography (2:3 ethyl acetate:n-hexane) to give the desired 
product as a yellow oil (573 mg, 2.0 mmol, 31%). 
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Method B: Under an atmosphere of argon to a stirred solution N-BOC-L-leucine (1.0 
g, 4.3 mmol) in THF (9.9 mL) was added CDI (841 mg, 5.2 mmol). The solution was 
stirred at room temperature for two hours. Methyl potassium malonate (1.0 g, 6.5 
mmol) and MgCl2 (624 mg, 5.2 mmol) were added and the reaction allowed to stir 
overnight. Solvent was removed in vacuo, and the crude residue was partitioned 
between ethyl acetate (40 mL) and HCl (1 M, 40 mL). The organic layer was collected, 
and the aqueous phase was extracted with ethyl acetate (3 × 40 mL). Organic 
extractions were combined, washed with 5% NaHCO3 (w/w, 2 × 40 mL) and brine (40 
mL), and dried (MgSO4). Solvent was removed in vacuo to provide the desired 
product as a yellow oil (718 mg, 2.5 mmol, 58%).86 
δH (CDCl3, 300 MHz): 4.91 (1H, br d, J 8.0 Hz, H-4), 4.40-4.26 (1H, m, H-5), 3.73 
(3H, s, H-12), 3.56 (2H, d, J 6.5 Hz, H-10), 1.78-1.54 (2H, m, H-6, H-7), 1.43 (9H, s, 
H-1), 1.41-1.33 (1H, m, H-6), 0.97-0.91 (6H, m, H-8). 
δC (CDCl3, 75 MHz): 202.9 (C-9), 167.6 (C-11), 162.5 (C-3), 80.3 (C-2), 58.3 (C-5), 
52.5 (C-12), 46.1 (C-10), 39.9 (C-6), 28.4 (C-1), 24.9 (C-7), 23.3 (C-8), 21.7 (C-8). 
m/z ES+ (%): 310 (100, [M+Na]+). 
IR (cm-1): 1751 (C=O stretch), 1704 (C=O stretch). 
[α]D20 = -16.1 (c 0.375, CHCl3). 
 
144 Methyl (S)-4-((BOC)amino)-2,2,6-methyl-3-oxoheptanoate 
 
To a stirred solution of 143 (189 mg, 658 μmol)	and	potassium	carbonate	(909	mg,	6.6	 mmol)	 under	 reflux	 (70	 °C)	 and	 an	 atmosphere	 of	 argon	 was	 added	iodomethane	(400	μL,	6.4	mmol).	The	reaction	was	allowed	to	stir	for	23	hours.	Solvent	was	removed	in	vacuo	and	the	crude	residue	partitioned	between	water	(20	mL)	and	ethyl	acetate	(20	mL).	Sodium	chloride	(ca.	1	g)	was	added	to	the	mixture,	and	the	organic	layer	collected.	The	aqueous	layer	was	extracted	with	
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ethyl	acetate	(3	× 20 mL), the organic layers combined and washed with brine (2 × 
40 mL), and dried (MgSO4). Solvent was removed in vacuo, and the resulting residue 
was purified with was purified by silica gel chromatography (1:4 ethyl acetate:n-
hexane) to give the desired product as a clear oil (82.4 mg, 261 μmol 40%).102 
δH (CDCl3, 300 MHz): 4.78 (1H, br d, J 10.0 Hz, H-4), 4.65, (1H, dt, J 10.0, 4.0 Hz, 
H-5), 3.73 (3H, s, H-13), 1.75-1.62 (H-7), 1.45-1.40 (15H, m, H-1, H-12), 1.39-1.30 
(2H, m, H-6), 0.95 (3H, d, J 6.5 Hz), 0.92 (3H, d, J 6.5 Hz). 
δC (CDCl3, 75 MHz): 209.0 (C-9), 173.0 (C-11), 162.5 (C-3), 79.8 (C-2), 54.3 (C-10), 
54.0 (C-5), 52.7 (C-13), 41.9 (C-6), 28.4 (C-1), 24.8 (C-7), 23.7 (C-8), 22.5 (C-12), 
22.2 (C-12), 21.5 (C-8). 
m/z ES+ (%): 338 (100, [M+Na]+). 
IR (cm-1): 1743 (C=O stretch), 1706 (C=O stretch). 
[α]D20 = -42.9 (c 0.275, CHCl3). 
 
145 (S)-1-Methoxy-2,2,6-trimethyl-1,3-dioxoheptan-4-ammonium 
trifluoroacetate 
 Under	an	atmosphere	of	argon to a 10% TFA in DCM solution (5 mL) while stirring 
was added 144 (74.7 mg, 236 μmol).	After	half	an	hour	the	solution	was	diluted	with	DCM	(3 × 15 mL), removing solvent in vacuo successively. The resulting crude 
oil was washed with petroleum ether (3 × 5 mL), and residual solvent removed in 
vacuo from the immiscible oil to give the desired product as a brown oil (74.6 mg, 
227	μmol,	96%).	
δH (MeOD, 500 MHz): 4.52-4.48 (1H, m, H-2), 3.76 (3H, s, H-10), 1.84-1.69 (1H, m, 
H-4), 1.61-1.55 (2H, m, H-3), 1.48 (3H, s, H-8), 1.47 (H-8), 1.04-0.98 (6H, m, H-5). 
δC (MeOD, 125 MHz): 206.1 (C-6), 174.5 (C-9), 55.7 (C-7), 55.6 (C-2), 53.4 (C-10), 
40.5 (C-3), 25.6 (C-4), 23.7 (C-5), 23.1 (C-8), 22.9 (C-8), 20.8 (C-5). 
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HRMS (ESI+): calcd for C11H22NO3+: 216.1594, found: 216.1597. 
IR (cm-1): 2935 (N-H stretch), 1763 (C=O stretch). 
[α]D20 = -5.7 (c 0.290, CHCl3). 
 
139 Methyl 4-((S)-2-butyramido-3-hydroxypropanamido)-2,2,6-trimethyl-
3-oxoheptanoate 
 
To a stirred solution of 93 (39.7 mg, 219 μmol) in	DMF	(1	mL)	was added HOBt (62.0 
mg, 459 μmol), EDC (84.4 mg, 440 μmol) and triethylamine (23.0 μL,	165 μmol),	and	the	solution	was	stirred	for	1	hour.	145	(72.4	mg,	231	μmol)	in	DMF	(1	mL)	with	triethylamine (23.0 μL,	165 μmol)	was	added,	and	the	reaction	stirred	for	a	further	90	hours.	Reaction	mixture	was	diluted	with	ethyl	acetate	(5	mL),	and	washed	with	HCl (1 M, 5 mL), NaHCO3 (1 M, 5 mL) and brine (3 × 5 mL). Organic 
layer was dried (MgSO4) and solvent removed in vacuo to provide crude residue (36.3 
mg). To obtain more material, aqueous washings were further extracted with ethyl 
acetate (3 × 10 mL), organic extractions combined and washed with brine (10 mL), 
and dried (MgSO4). Organic extractions were combined with original crude residue 
and solvent was removed in vacuo. The resulting residue was purified with was 
purified by silica gel chromatography (a gradient of 1% methanol in DCM to 10% 
methanol in DCM) to yield the product as a brown oil (17.7 mg, 47.5 µmol, 22%). 1H 
NMR spectroscopic analysis indicated the compound was approximately a 1:1 
mixture of diastereomers, which were assigned without evaluating their 
stereochemistry. 
HRMS (ESI+): calcd for C18H32N2NaO6+: 395.2153, found: 395.2152. 
IR (cm-1): 3271 (O-H stretch), 1761 (C=O stretch), 1744 (C=O stretch), 1693 (C=O 
stretch). 
 
H
N N
H
O
O OOH
O
OMe1 2 3 4
5
6
7
9
10
11
12
13
14
15 16
17
18 19
8
	 	 	
	128	
  
Diastereomer 1: 
δH (MeOD, 500 MHz): 4.99-4.91 (1H, m, H-11), 4.44-4.38 (1H, m, H-6), 3.79-3.67 
(2H, m, H-7), 3.71 (3H, s, H-19), 2.24 (2H, br t, J 7.5 Hz, H-3), 1.69-1.60 (3H, m, H-
2, H-13), 1.56-1.41 (2H, m, H-12), 1.40 (3H, s, H-17), 1.36 (3H, s, H-17), 0.98-0.89 
(9H, m, H-1, H-14). 
δC (MeOD, 125 MHz): 208.5 (C-11), 176.3 (C-4), 175.0 (C-18), 172.0 (C-9), 62.9 (C-
7), 56.6 (C-6), 56.2 (C-16), 53.6 (C-19), 53.2 (C-11), 42.0 (C-12), 38.7 (C-3), 25.7 
(C-13), 23.8 (C-14), 22.6 (C-17), 21.7 (C-14), 20.2 (C-2), 14.0 (C-1). 
 
Diastereomer 2: 
δH (MeOD, 500 MHz): 4.99-4.91 (1H, m, H-11), 4.44-4.38 (1H, m, H-6), 3.79-3.67 
(2H, m, H-7), 3.70 (3H, s, H-19), 2.24 (2H, br t, J 7.5 Hz, H-3), 1.69-1.60 (3H, m, H-
2, H-13), 1.56-1.41 (2H, m, H-12), 1.40 (3H, s, H-17), 1.36 (3H, s, H-17), 0.98-0.89 
(9H, m, H-1, H-14). 
δC (MeOD, 125 MHz): 208.3 (C-11), 176.1 (C-4), 174.9 (C-18), 171.9 (C-9), 63.0 (C-
7), 56.5 (C-6), 56.2 (C-16), 53.6 (C-19), 53.1 (C-11), 42.0 (C-12), 38.7 (C-3), 25.7 
(C-13), 23.8 (C-14), 22.6 (C-17), 21.7 (C-14), 20.2 (C-2), 14.0 (C-1). 
 
151 (S)-5-isobutyl-3,3-dimethylpyrrolidine-2,4-dione 
 
Under an atmosphere of argon to a stirred solution of 93 (79.5 mg, 439 μmol), 145 
(139 mg, 443 μmol) and HOBt (143 mg, 1.1 mmol) in THF (8.9 mL) at 0 °C was 
added triethylamine (260 μL, 1.9 mmol) and EDC (173 mg, 902 μmol). The reaction 
was warmed to room temperature and stirred for 24 hours. Reaction mixture was 
filtered, and solvent removed in vacuo. The resulting residue was purified by silica 
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gel chromatography (ethyl acetate) to provide the lactam byproduct 151 as a white 
solid (29.4 mg, 161 μmol, 36%) and none of the desired 139. 
δH (MeOD, 500 MHz): 4.09 (1H, dd, J 9.0, 5.0 Hz, H-2), 1.88-1.76 (1H, m, H-4), 
1.63-1.55 (1H, m, H-3), 1.50-1.42 (1H, m, H-3), 1.20 (3H, s, H-8), 1.17 (3H, s, H-8), 
0.97 (3H, d, J 4.0 Hz, H-5), 0.95 (3H, d, J 4.0 Hz, H-5). 
δC (MeOD, 125 MHz): 216.3 (C-6), 180.3 (C-9), 61.1 (C-2), 43.1 (C-3), 25.9 (C-4), 
23.6 (C-5), 21.8 (C-5), 21.3 (C-8), 21.2 (C-8). The signal due to C-7 was not observed 
due to low relative intensity. 
HRMS (ESI+): calcd for C10H17NNaO2+: 206.1151, found: 206.1152. 
IR (cm-1): 1765 (C=O stretch), 1692 (C=O stretch). 
[α]D20 = -73.0 (c 0.265, CHCl3). 
 
156 Methyl (S)-4-((BOC)amino)-3-oxopentanoate 
 
Under an atmosphere of argon to a stirred solution N-BOC-L-alanine (2.0 g, 10.6 
mmol) in THF (24.4 mL) was added CDI (2.1 g, 12.7 mmol). The solution was stirred 
at room temperature for two hours. Methyl potassium malonate (2.5 g, 16.0 mmol) 
and MgCl2 (1.5 g, 12.7 mmol) were added and the reaction allowed to stir overnight. 
Solvent was removed in vacuo, and the crude residue was partitioned between ethyl 
acetate (40 mL) and HCl (1 M, 40 mL). The organic layer was collected, and the 
aqueous phase was extracted with ethyl acetate (3 × 40 mL). Organic extractions were 
combined, washed with 5% NaHCO3 (w/w, 2 × 40 mL) and brine (40 mL), and dried 
(MgSO4). Solvent was removed in vacuo to yield the desired product as a pale yellow 
solid (2.2 g, 8.9 mmol, 84%).103 
δH (CDCl3, 300 MHz): 5.09 (1H, br s), 4.38 (1H, br t, J 7.5 Hz), 3.74 (3H, s), 3.57 
(1H, d, J 16.0 Hz), 3.54 (1H, d, J 16.0 Hz), 1.45 (9H, s), 1.36 (3H, d, J 7.0 Hz). 
δC (CDCl3, 75 MHz): 202.3 (C-7), 167.7 (C-9), 162.5 (C-3), 80.1 (C-2), 55.5 (C-5), 
52.7 (C-10), 45.7 (C-8), 28.5 (C-1), 17.1 (C-6). 
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m/z ES+ (%) 268 (100, [M+Na]+). 
IR (cm-1): 1749 (C=O stretch), 1718 (C=O stretch), 1683 (C=O stretch). 
[α]D20 = -18.6 (c 0.350, CHCl3). 
 
157 Methyl (S)-4-((BOC)amino)-2,2-dimethyl-3-oxopentanoate 
 
Under an atmosphere of argon to a stirred solution 157 (300 mg, 1.2 mmol) and 
potassium carbonate (1.7	g,	12.3	mmol) in THF (10.2 mL) was added iodomethane 
(760 μL,	 12.2	 mmol),	 and	 the	 solution	 stirred	 for	 17.5	 hours.	 Solvent	 was	removed	in	vacuo	and	the	crude	residue	partitioned	between	water	(20	mL)	and	ethyl	acetate	(20	mL).	Sodium	chloride	(ca.	1	g)	was	added	to	the	mixture,	and	the	organic	layer	collected.	The	aqueous	layer	was	extracted	with	ethyl	acetate	(3	× 20 mL), the organic extractions combined and washed with brine (2 × 40 mL), 
and dried (MgSO4). Solvent was removed in vacuo, and the resulting residue was 
purified with was purified by silica gel chromatography (3:17 ethyl acetate:n-hexane) 
to give the desired product as pale yellow solid (244	mg,	893 μmol,	73%).	
δH (MeOD, 500 MHz): 4.54 (1H, q, J 7.0 Hz, H-5), 3.71 (3H, s, H-11), 1.44 (9H, s, 
H-1), 1.39 (3H, s, H-9), 1.37 (3H, s, H-9), 1.22 (3H, d, J 7.0 Hz, H-6). 
δC (MeOD, 125 MHz): 209.5 (C-7), 175.1 (C-10), 157.3 (C-3), 80.6 (C-2), 55.4 (C-
8), 53.0 (C-11), 52.8 (C-5), 28.1 (C-1), 22.8 (C-9), 18.1 (C-6). 
HRMS (ESI+): calcd for C13H23NNaO5+: 296.1468, found: 296.1471. 
IR (cm-1): 1748 (C=O stretch), 1713 (C=O stretch), 1677 (C=O stretch). 
[α]D20 = -24.7 (c 0.255, CHCl3). 
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158 (S)-5-Methoxy-4,4-dimethyl-3,5-dioxopentan-2-ammonium 
trifluoroacetate 
 Under	an	atmosphere	of	argon to a 10% TFA in DCM solution (5 mL) while stirring 
was added 144 (105 mg, 386 μmol).	After	half	an	hour	the	solution	was	diluted	with	DCM	(3 × 15 mL), removing solvent in vacuo successively. The resulting crude 
oil was washed with petroleum ether (3 × 5 mL), and residual solvent removed in 
vacuo from the immiscible oil to give the desired product as a brown oil (107 mg, 373	μmol,	97%).	
δH (MeOD, 500 MHz): 4.51 (1H, q, J 6.5 Hz, H-2), 3.76 (3H, s, H-8), 1.48 (3H, s, H-
6), 1.47 (3H, s, H-6), 1.45 (3H, d, J 7.0 Hz, H-3). 
δC (MeOD, 125 MHz): 206.1 (C-4), 174.4 (C-7), 55.4 (C-5), 53.4 (C-8), 53.2 (C-2), 
23.0 (C-6), 22.5 (C-6), 16.9 (C-3). 
HRMS (ESI+): calcd for C8H16NO3+: 174.1125, found: 174.1126. 
 
159 (S)-3,3,5-Trimethylpyrrolidine-2,4-dione 
 
Under an atmosphere of argon to a stirred solution of 93 (50.6 mg, 279 μmol), 158 
(79.1 mg, 275 μmol) and HOBt (47.2 mg, 349 μmol) in THF (5.5 mL) at 0 °C was 
added triethylamine (160 μL, 1.1 mmol) and EDC (105 mg, 549 μmol). The reaction 
was warmed to room temperature and stirred for 24 hours. Reaction mixture was 
filtered, and solvent removed in vacuo. The resulting residue was purified by silica 
gel chromatography (ethyl acetate) to provide the lactam byproduct 159 as a white 
solid (31.4 mg, 222 μmol, 80%) and none of the desired 154.104 
δH (MeOD, 500 MHz): 4.11 (1H, q, J 7.0 Hz, H-2), 1.32 (3H, d, J 7.0 Hz, H-3), 1.20 
(3H, s, H-6), 1.18 (3H, s, H-6). 
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δC (MeOD, 125 MHz): 216.3 (C-4), 180.1 (C-7), 64.4 (C-5), 58.1 (C-2), 21.4 (C-6), 
21.0 (C-6), 18.0 (C-3). 
m/z ES+ (%): 163.7 (100, [M+Na]+). 
 
7.3.4 Synthesis of alanine based α-dimethyl-β-keto methyl 
ester substrate analogue 
161 Methyl O-TBS-N-butyryl-L-serinate 
 
Under an argon atmosphere to a stirred solution of 104 (4.4 g, 23.5 mmol) and 
imidazole (3.9 g, 56.7 mmol) in DMF (75 mL) was added TBS-chloride (4.3 g, 28 
mmol) in DMF (50 mL) dropwise over 1 hour. Upon full addition of the TBS-chloride 
solution, the reaction was stirred for 24 hours. The reaction was diluted with diethyl 
ether (250 mL), washed with HCl (1 × 250 mL, 1 M), saturated NaHCO3 (1 × 250 mL) 
and brine (3 × 250 mL). The organic layer was dried, solvent removed in vacuo, and 
the resulting residue purified by silica gel chromatography (3:1 n-hexane:ethyl 
acetate) to give the desired product as a yellow oil (5.8 g, 19.0 mmol, 81%). 
δH (CDCl3, 500 MHz): 6.27 (1H, br d, J 8.0 Hz, H-5), 4.66 (1H, dt, J 8.0, 3.0 Hz, H-
6), 4.03 (1H, dd, J 10.0, 2.5 Hz, H-7), 3.80 (1H, dd, J 10.0, 3.0 Hz, H-7), 3.72 (3H, s, 
H-12), 2.22 (2H, br t, J 7.5 Hz, H-3) 1.66 (2H, sextet, J 7.5 Hz, H-2), 0.95 (3H, t, J 
7.5 Hz, H-1), 0.84 (9H, s, H-10), 0.01 (3H, s, H-8), -0.00 (3H, s, H-8). 
δC (CDCl3, 125 MHz): 172.8 (C-4), 171.1 (C-11), 63.7 (C-7), 54.2 (C-6), 52.4 (C-12), 
38.6 (C-3), 25.8 (C-10), 19.1 (C-2), 18.2 (C-9), 13.8 (C-1), -5.5 (C-8), -5.6 (C-8). 
HRMS (ESI+): calcd for C14H29NNaO4Si+: 326.1758, found: 326.1767. 
IR (cm-1): 1747 (C=O stretch), 1650 (C=O stretch). 
[α]D20 = +36.1 (c 0.478, CHCl3). 
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162 O-TBS-N-butanoyl-L-serine 
 
161 (4.5 g, 14.8 mmol) was dissolved in a mixture of THF (35 mL) and aqueous 
lithium hydroxide (30 mL, 0.75 M, 22.4 mmol). The reaction was stirred for half an 
hour, then THF removed in vacuo. The solution was washed with diethyl ether (5 × 
50 mL), pH adjusted to 7 with HCl (1 M), water removed in vacuo and the resulting 
residue dissolved in ethyl acetate (40 mL). The solution was dried (MgSO4), filtered 
and solvent removed in vacuo to yield the desired product as a pale pink solid (3.0 g, 
10.3 mmol, 69%). 
δH (MeOD, 500 MHz): 4.33 (1H, t, J 4.5 Hz, H-6), 3.97 (2H, d, J 4.5 Hz, H-7), 2.24 
(2H, t, J 7.5 Hz, H-3), 1.66 (2H, sextet, 7.5 Hz, H-2), 0.97 (3H, t, J 7.5 Hz, H-1), 0.89 
(9H, s, H-10), 0.06 (3H, s, H-8), 0.05 (3H, s, H-8). 
δC (MeOD, 125 MHz): 177.2 (C-11), 175.4 (C-4), 65.0 (C-7), 58.1 (C-6), 39.2 (C-3), 
26.4 (C-10), 20.3 (C-2), 19.2 (C-9), 14.1 (C-1), -5.2 (C-8). 
HRMS (ESI+): calcd for C13H27NNaO4Si+: 312.1602, found: 312.1604. 
IR (cm-1): 1702 (C=O stretch), 1656 (C=O stretch). 
 
163 Methyl O-TBS-N-butyryl-L-seryl-L-alaninate 
 
Under an atmosphere of argon to a stirred solution of 162 (1.2 g, 4.3 mmol), L-alanine 
methyl ester hydrochloride salt (597 mg, 4.3 mmol) and HOBt (1.4 g, 10.3 mmol) in 
THF (50 mL) at 0 °C was added triethylamine (2.5 mL, 17.9 mmol) and EDC (1.6 g, 
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8.5 mmol). The reaction was warmed to room temperature and stirred for 24 hours. 
Reaction mixture was filtered, and solvent removed in vacuo. The resulting residue 
was purified by silica gel chromatography (gradient of 1:1 n-hexane:ethyl acetate to 
ethyl acetate) to yield the desired product as yellow solid (1.0 g, 2.8 mmol, 65%). 1H 
NMR spectroscopic analysis indicated that it contained approximately 20% of the C-
6 epimer. The data reported are for the predicted major diastereomer (SS). 
δH (MeOD, 500 MHz): 4.54-4.35 (2H, m, H-6, H-13), 3.91-3.81 (2H, m, H-7), 3.71 
(3H, s, H-16), 2.25 (2H, t, J 7.5 Hz, H-3), 1.65 (2H, sextet, J 7.5 Hz, H-2), 1.38 (3H, 
d, J 7.5 Hz, H-14), 0.96 (3H, t, J 7.5 Hz, H-1), 0.90 (9H, s, H-10), 0.09 (6H, s, H-8). 
δC (MeOD, 125 MHz): 176.1 (C-4), 174.4 (C-16), 171.7 (C-11), 64.3 (C-7), 56.4 (C-
6), 52.8 (C-16), 49.9 (C-13), 38.8 (C-3), 26.3 (C-10), 18.8 (C-2), 17.7 (C-14), 16.5 
(C-9), 14.0 (C-1),  
-5.4 (C-8). 
HRMS (ESI+): calcd for C17H34N2NaO5Si+: 397.2129, found: 397.2137. 
IR (cm-1): 1745 (C=O stretch). 
 
164 O-TBS-N-butanoyl-L-seryl-L-alanine 
 
163 (467 mg, 1.2 mmol) was dissolved in a mixture of THF (3 mL) and aqueous 
lithium hydroxide (2.5 mL, 0.82 M, 1.9 mmol). The reaction was stirred for half an 
hour, pH adjusted to 1 using HCl (1 M), and THF removed in vacuo. Solution was 
diluted with water (5 mL), sodium chloride added (ca. 0.5 g) and extracted with ethyl 
acetate (5 × 50 mL). Organic extractions were dried (MgSO4) and solvent removed in 
vacuo to yield the desired product as a clear oil (369 mg, 1.0 mmol, 82%). 1H NMR 
spectroscopic analysis indicated that it contained approximately 20% of the C-6 
epimer. The data reported are for the predicted major diastereomer (SS). 
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δH (MeOD, 500 MHz): 4.46 (1H, t, J 5.5 Hz, H-6), 4.16 (1H, q, J 7.0 Hz, H-13), 3.93-
3.85 (1H, m, H-7), 2.35-2.22 (2H, m, H-3), 1.67 (2H, sextet, J 7.5 Hz, H-2), 1.35 (3H, 
d, J 7.0 Hz, H-14), 0.97 (3H, t, J 7.5 Hz, H-1), 0.90 (9H, s, H-10), 0.09 (3H, s, H-8), 
0.08 (3H, s, H-8). 
δC (MeOD, 125 MHz): 179.0 (C-15), 176.2 (C-4), 170.9 (C-11), 64.3 (C-7), 56.8 (C-
6), 52.1 (C-13), 38.9 (C-3), 26.4 (C-10), 20.3 (C-2), 19.7 (C-14), 19.2 (C-9), 14.1 (C-
1), -5.3 (C-8). 
HRMS (ESI-): calcd for C16H31N2O5Si-: 359.2008, found: 359.2008. 
 
165 Methyl (S)-4-((S)-3-((TBS)oxy)-2-butyramidopropanamido)-3-
oxopentanoate 
 
Under an atmosphere of argon to a stirred solution of 164 (215 mg, 6.0 mmol) in 1,4-
dioxane (8.3 mL) at 50 °C was added CDI (118 mg, 7.3 mmol). The solution was 
stirred at 50 °C for two hours. Methyl potassium malonate (141 mg, 9.0 mmol) and 
MgCl2 (86.4 mg, 7.2 mmol) were added and the reaction allowed to stir for 24 hours 
maintaining 50 °C. Solvent was removed in vacuo, and the crude residue was 
partitioned between ethyl acetate (50 mL) and HCl (1 M, 50 mL). The organic layer 
was collected, and the aqueous phase was extracted with ethyl acetate (5 × 50 mL). 
Organic extractions were combined, washed with 5% NaHCO3 (w/w, 2 × 50 mL) and 
brine (50 mL), and dried (MgSO4). Solvent was removed in vacuo to yield the desired 
product as a clear oil 3:2 mixture of diastereomers resulting from epimerization at C-
13 (196 mg, 4.7 mmol, 79%). 
HRMS (ESI+): calcd for C19H36N2NaO6Si+: 439.2235, found: 439.2238. 
IR (cm-1): 1739 (C=O stretch), 1723 (C=O stretch). 
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Predicted major diastereomer (SS): 
δH (CDCl3, 500 MHz): 7.11 (1H, br d, J 7.0 Hz, H-12), 6.38-6.28 (1H, m, H-5), 4.64 
(1H, br t, J 7.0 Hz, H-13), 4.46-4.39 (1H, m, H-6), 4.05 (1H, br dd, J 9.5, 4.0 Hz, H-
7), 3.74 (3H, br s, H-18), 3.64-3.41 (3H, m, H-7, H-16), 2.23 (2H, br t, J 8.0 Hz, H-
3), 1.68 (2H, sextet, J 7.5 Hz, H-2), 1.38 (3H, d, J 7.0 Hz, H-14), 0.96 (3H, t, J 7.3 
Hz, H-1), 0.90 (9H, s, H-10), 0.12 (3H, s, H-8), 0.11 (3H, s, H-8). 
δC (CDCl3, 125 MHz): 201.1 (C-15), 173.3 (C-4), 170.4 (C-11), 167.3 (C-17), 62.8 
(C-7), 54.6 (C-13), 54.2 (C-6), 52.7 (C-18), 45.8 (C-16), 38.6 (C-3), 25.9 (C-10), 19.1 
(C-2), 18.3 (C-9), 16.9 (C-14), 13.9 (C-1), -5.4 (C-8). 
 
Predicted minor diastereomer (SR): 
δH (CDCl3, 500 MHz): 7.28 (1H, br d, J 6.6 Hz, H-12), 6.38-6.28 (1H, m, H-5), 4.66 
(1H, br t, J 7.0 Hz, H-13), 4.46-4.39 (1H, m, H-6), 4.05 (1H, br dd, J 9.5, 4.0 Hz, H-
7), 3.74 (3H, br s, H-18), 3.64-3.41 (3H, m, H-7, H-16), 2.23 (2H, br t, J 8.0 Hz, H-
3), 1.68 (2H, sextet, J 7.5 Hz, H-2), 1.39 (3H, d, J 7.0 Hz, H-14), 0.96 (3H, t, J 7.5 
Hz, H-1), 0.90 (9H, s, H-10), 0.11 (3H, s, H-8), 0.09 (3H, s, H-8). 
δC (CDCl3, 125 MHz): 201.1 (C-15), 173.3 (C-4), 170.3 (C-11), 167.2 (C-17), 62.8 
(C-7), 54.5 (C-13), 54.2 (C-6), 52.7 (C-18), 45.8 (C-16), 38.6 (C-3), 25.9 (C-10), 19.1 
(C-2), 18.3 (C-9), 16.9 (C-14), 13.9 (C-1), -5.3 (C-8), -5.4 (C-8). 
 
166 Methyl (S)-4-((S)-3-((TBS)oxy)-2-butyramidopropanamido)-2,2-
dimethyl-3-oxopentanoate 
 
Under an atmosphere of argon to a stirred solution of 165 (499 mg, 1.2 mmol) was 
added potassium carbonate (1.7 g, 12.0 mmol) and iodomethane (750 µL, 12.1 mmol). 
The reaction was stirred at room temperature for 43 hours, filtered and the solvent 
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removed in vacuo. The resulting residue was purified by silica gel chromatography 
(gradient of 7:3 n-hexane:ethyl acetate to 2:3 n-hexane:ethyl acetate). The α-dimethyl-
β-keto methyl ester C-13 epimers were separated (SS and SR), providing the desired 
predicted major C-13 epimer 166 (SS) as a clear oil (147 mg, 331 µmol, 28%) and the 
predicted minor C-13 epimer 167 (SR) as a white powder (79.2 mg, 178 µmol, 15%), 
as well as a mixture of mono-methylated diastereomers 168 (101 mg, 235 µmol, 20%). 
The data reported are for the desired major C-13 epimer (SS). 
δH (CDCl3, 500 MHz): 7.14 (1H, br d, J 7.5 Hz, H-12), 6.30 (1H, br d, J 6.0 Hz, H-5), 
4.97-4.90 (1H, m, H-13), 4.39-4.34 (1H, m, H-6), 4.02 (1H, dd, J 9.5, 4.0 Hz, H-7), 
3.72 (3H, s, H-19), 3.55 (1H, dd, J 9.5, 8.0 Hz, H-7), 2.22 (2H, t, J 7.5 Hz, H-3), 1.67 
(2H, sextet, J 7.5 Hz, H-2), 1.44 (3H, s, H-17), 1.41 (3H, s, H-17), 1.28 (3H, d, J 6.9 
Hz, H-14), 0.95 (3H, t, J 7.5 Hz, H-1), 0.90 (9H, s, H-10), 0.11 (3H, s, H-8), 0.10 (3H, 
s, H-8). 
δC (CDCl3, 125 MHz): 207.3 (C-15), 173.5 (C-11), 173.2 (C-4), 169.6 (C-18), 62.8 
(C-7), 54.8 (C-16), 54.2 (C-6), 52.8 (C-19), 50.4 (C-13), 38.6 (C-3), 25.9 (C-10), 22.5 
(C-17), 22.3 (C-17), 19.1 (C-2), 18.9 (C-14), 18.3 (C-9), 13.9 (C-1), -5.4 (C-8). 
HRMS (ESI+): calcd for C21H40N2NaO6Si+: 467.2548, found: 467.2553. 
IR (cm-1): 1750 (C=O stretch), 1719 (C=O stretch). 
 
154 Methyl (S)-4-((S)-2-butyramido-3-hydroxypropanamido)-2,2-
dimethyl-3-oxopentanoate 
 
166 (40.1 mg, 90 µmol) was dissolved in an acetic acid, water and THF mixture (3:3:1, 
940 µL) and stirred for 17 hours. Toluene was added sequentially (3 × 30 mL) and 
solvent removed in vacuo. Residue was washed with petroleum ether (5 mL) and 
residual solvent removed in vacuo to give the desired product as a cloudy oil (22.7 
mg, 69 µmol, 76%). 
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δH (MeOD, 500 MHz): 4.91 (1H, q, J 7.0 Hz, H-11), 4.40 (1H, t, J 5.5 Hz, H-6), 3.77-
3.68 (2H, m, H-7), 3.72 (3H, s, H-18), 2.25 (2H, t, J 7.0 Hz, H-3), 1.65 (2H, sextet, 
7.0 Hz, H-2), 1.41 (3H, s, H-15), 1.38 (3H, s, H-15), 1.27 (3H, d, J 7.0 Hz, H-12), 
0.96 (3H, t, J 7.5 Hz, H-1). 
δC (MeOD, 125 MHz): 208.6 (C-13), 176.3 (C-4), 175.0 (C-17), 171.7 (C-9), 63.0 (C-
7), 56.7 (C-6), 55.9 (C-14), 53.1 (C-18), 51.3 (C-11), 38.7 (C-3), 22.7 (C-15), 22.6 
(C-15), 20.2 (C-2), 18.2 (C-12), 14.0 (C-1). 
HRMS (ESI+): calcd for C15H26N2NaO6+: 353.1683, found: 353.1680. 
 
171 N-((S)-3-Hydroxy-1-(((S)-4-methyl-3-oxopentan-2-yl)amino)-1-
oxopropan-2-yl)butyramide 
 
154 (11.7 mg, 35 µmol) was dissolved in aqueous lithium hydroxide solution (1.1 mL, 
30 mM, 33 µmol) and left to stir. After two hours, 171 byproduct was observed by 
ESI-MS, and water removed in vacuo. The resulting residue was purified by silica gel 
chromatography (1% methanol in ethyl acetate) to yield the byproduct 171 as a clear 
oil (2.3 mg, 8.4 µmol, 24%) and allowing for reclamation of 154 (5.3 mg, 16 µmol, 
45%). 1H NMR spectroscopic analysis of 171 indicated that it contained 
approximately 25% of the C-11 epimer. The data reported are for the predicted major 
diastereomer (SS). 
δH (CDCl3, 500 MHz): 7.07 (1H, br d, J 6.5 Hz, H-10), 6.46 (1H, br d, J 7.0 Hz, H-5), 
4.70 (1H, t, J 7.0 Hz, H-11), 4.51-4.46 (1H, m, H-6), 4.08 (1H, dd, J 11.5, 3.0 Hz, H-
7), 3.77-3.66 (1H, m, H-7), 3.61 (1H, br s, H-8), 2.83 (1H, septet, J 7.0 Hz, H-14), 
2.23 (2H, t, J 7.5 Hz, H-3), 1.68 (2H, sextet, J 7.5 Hz, H-2), 1.36 (3H, d, J 7.0 Hz, H-
12), 1.16 (3H, d, J 7.0 Hz, H-15), 1.12 (3H, d, J 6.5 Hz, H-15), 0.95 (3H, t, J 7.5 Hz, 
H-1). 
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δC (CDCl3, 125 MHz): 212.9 (C-13), 173.8 (C-4), 170.8 (C-9), 63.1 (C-7), 53.7 (C-
11), 53.00 (C-6), 38.5 (C-3), 37.4 (C-14), 19.2 (C-15), 19.2 (C-2), 17.8 (C-15), 17.2 
(C-12), 13.8 (C-1). 
HRMS (ESI+): calcd for C13H24N2NaO4+: 295.1628, found: 295.1632. 
IR (cm-1): 3253 (O-H stretch), 1715 (C=O stretch). 
 
7.3.4 Synthesis of α,β-unsatured ketone authentic standard 
187 tert-Butyl (S)-(1-(methoxy(methyl)amino)-1-oxopropan-2-
yl)carbamate 
 
To a stirred solution of N-BOC-L-alanine (402 mg, 2.1 mmol) in DCM (9.6 mL) was 
added O,N-dimethylhydroxylamine hydrochloride (227 mg, 2.3 mmol), triethylamine 
(620 µL, 4.4 mmol) and BOP reagent (937 mg, 2.1 mmol). Solvent was removed in 
vacuo, and the resulting residue purified by silica gel chromatography (3:2 ethyl 
acetate:n-hexane) to give the desired product as a white solid (266 mg, 1.1 mmol, 
54%).105 
δH (CDCl3, 500 MHz): 5.25 (1H, br d, J 7.0 Hz, H-4), 4.68 (1H, m, H-5), 3.77 (3H, s, 
H-9), 3.21 (3H, s, H-8), 1.44 (9H, s, H-1), 1.31 (3H, d, J 7.0 Hz, H-6). 
δC (CDCl3, 125 MHz): 173.9 (C-7), 155.4 (C-3), 78.0 (C-2), 61.8 (C-9), 46.7 (C-5), 
32.3 (C-8), 28.5 (C-1), 18.9 (C-6). 
m/z ES+ (%) 255 (100, [M+Na]+). 
IR (cm-1): 1702 (C=O stretch). 
[α]D20 = -1.3 (c 0.260, CHCl3). 
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188 tert-Butyl (S)-(4-methyl-3-oxopent-4-en-2-yl)carbamate 
 
Under an atmosphere of argon to a stirred solution of 187 (200 mg, 863 µmol) in THF 
(3.5 mL) at 0 °C was added isopropenylmagnesium bromide in THF (500 mM, 3.6 
mL, 1.8 mmol) dropwise. The reaction was stirred at 0 °C for 6 hours, then poured 
into saturated ammonium chloride solution (5 mL) and ice (ca. 5 mL). When ice had 
melted, pH was adjusted to 7 with HCl (6 M). Solution was extracted with ethyl acetate 
(3 × 30 mL). Organic extracts were combined and washed with saturated NaHCO3 (2 
× 10 mL), brine (2 × 10 mL) and dried (MgSO4). Solvent was removed in vacuo to 
yield the desired product as a pale yellow oil (113 mg, 530 µmol, 61%).106 
δH (CDCl3, 500 MHz): 6.04 (1H, s, H-9), 5.89 (1H, s, H-9), 5.38 (1H, br d, J 5.5 Hz, 
H-4), 5.07-4.99 (1H, m, H-5), 1.91 (3H, s, H-10), 1.44 (9H, s, H-1), 1.31 (3H, d, J 7.0 
Hz). 
δC (CDCl3, 125 MHz): 201.2 (C-7), 155.2 (C-3), 141.9 (C-8), 126.4 (C-9), 79.8 (C-2), 
50.3 (C-5), 28.5 (C-1), 20.4 (C-6), 18.0 (C-10). 
m/z ES+ (%) 236 (100, [M+Na]+). 
IR (cm-1): 1703 (C=O stretch), 1678 (C=O stretch). 
[α]D20 = +38.4 (c 0.250, CHCl3). 
 
189 (S)-4-methyl-3-oxopent-4-en-2-ammonium trifluoroacetate 
 
To a stirred solution of 188 (97.3 mg, 456 µmol) in DCM (8 mL) was added TFA (2 
mL) dropwise. After	half	an	hour	the	solution	was	diluted	with	DCM	(3 × 20 mL), 
removing solvent in vacuo successively. The resulting crude oil was washed 
successively with petroleum ether (3 × 5 mL), and residual solvent removed in vacuo 
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from the immiscible oil to give the desired product as an orange oil (92.7 mg, 408 
µmol, 89%). 
δH (MeOD, 500 MHz): 6.17 (1H, s, H-6), 6.13 (1H, br d, J 1.0 Hz, H-6), 4.83 (1H, q, 
J 7.5 Hz, H-2), 1.93 (3H, s, H-7), 1.49, (3H, d, J 7.0 Hz, H-3). 
δC (MeOD, 125 MHz): 198.5 (C-4), 142.3 (C-5), 129.2 (C-6), 52.0 (C-2), 18.0 (C-3), 
17.6 (C-7). 
HRMS (ESI+): calcd for C6H12NO+:114.0913, found: 114.0913. 
IR (cm-1): 2992 (N-H stretch), 1728 (C=O stretch). 
[α]D20 = +17.2 (c 0.250, CHCl3). 
 
186 N-((S)-3-hydroxy-1-(((S)-4-methyl-3-oxopent-4-en-2-yl)amino)-1-
oxopropan-2-yl)butyramide 
 
Under an atmosphere of argon to a stirred solution of HOBt (72.6 mg, 537 µmol) in 
THF (4.8 mL) at 0 °C was added 93 (39.0 mg, 223 µmol) in THF (390 µL), 189 (50.4 
mg, 222 µmol) in THF (500 µL), triethylamine (130 µL, 933 µmol) and EDC (85.2 
mg, 444 µmol). The reaction was warmed to room temperature and stirred for 24 
hours. Reaction mixture was filtered, and solvent removed in vacuo. The resulting 
residue was purified by silica gel chromatography (gradient of 5% methanol in ethyl 
acetate to 10% methanol in ethyl acetate) to yield the desired product as a pale yellow 
solid (28.4 mg, 105 µmol, 47%). 
δH (MeOD, 500 MHz): 6.12 (1H, s, H-15), 5.94 (1H, br d, J 1.5 Hz, H-15), 5.21 (1H, 
q, J 7.0 Hz, H-11), 4.45 (1H, t, J 5.5 Hz, H-6), 3.76 (2H, d, J 5.5 Hz, H-7), 2.26 (2H, 
dt, J 7.4, 1.5 Hz, H-3), 1.88 (3H, s, H-16), 1.66 (2H, sextet, J 7.5 Hz, H-2), 1.32 (3H, 
d, J 7.0 Hz, H-12), 0.96 (3H, t, J 7.5 Hz, H-1). 1.41 
δC (MeOD, 125 MHz): 201.9 (C-13), 176.3 (C-4), 171.9 (C-9), 143.3 (C-14), 126.9 
(C-15), 63.1 (C-7), 56.7 (C-6), 50.7 (C-11), 38.7 (C-3), 20.2 (C-2), 18.7 (C-12), 18.0 
(C-16), 14.0 (C-1). 
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HRMS (ESI+): calcd for C13H22N2NaO4+: 293.1472, found: 293.1467. 
IR (cm-1): 3273 (O-H stretch), 1703 (C=O stretch), 1678 (C=O stretch). 
 
7.4. In vitro assays 
7.4.1 LC elution profile 
UHPLC-ESI-Q-TOF MS analyses of supernatant from assays containing 66 or 154 as 
a substrate, or 186 as an authentic standard, used the following elution profile: 
 
Table	7.5:	Elution	profile	for	assays	containing	either	66	or	154	as	a	substrate.	
Time / minutes Acetontrile + 0.1% 
formic acid percentage 
Water + 0.1% formic 
acid percentage 
0 5 95 
5 5 95 
17 100 0 
22 100 0 
25 5 95 
33 5 95 
 
UHPLC-ESI-Q-TOF MS analyses of supernatant from assays containing 139 as a 
substrate used the following elution profile: 
 
Table	7.6:	Elution	profile	for	assays	containing	139	as	a	substrate.	
Time / minutes Acetontrile + 0.1% 
formic acid percentage 
Water + 0.1% formic 
acid percentage 
0 5 95 
5 5 95 
19 100 0 
24 100 0 
27 5 95 
35 5 95 
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7.4.2. EpnF activity assay using 66 substrate 
EpnF (20 µM) was incubated with 66 (2 mM) in concentration buffer (200 µL final 
volume, section 7.2.6) at 25 °C for 3 hours. The reaction was stopped and protein 
precipitated by addition of 200 µL acetonitrile containing 0.1% formic acid. The 
precipitate was pelleted by centrifugation and the supernatant was analysed by 
UHPLC-ESI-Q-TOF MS.42 
 
7.4.2.1 Trapping of α,β-unsaturated ketone intermediate in EpnF-
catalysed reaction 
N-Acetylcysteamine (total concentration 4 mM) was added to the EpnF catalysed 
reaction. UHPLC-ESI-Q-TOF MS analysis showed that the both products 136 and 
137 formed.42 
 
7.4.3 TmcI activity assay with EpnF using 66 substrate 
EpnF (10 µM) and TmcI (10 µM) were incubated with 66 (2 mM), ferredoxin (1 µM) 
and ferredoxin-NADP+ reductase (1 µM) from Spinacia oleracea, and NADPH (4 mM) 
in concentration buffer (200 µL final volume, section 7.2.6) at 25 °C for 3 hours. The 
reaction was stopped by addition of 200 µL acetonitrile containing 0.1% formic acid. 
The precipitated protein was pelleted by centrifugation and the supernatant was 
analysed by high resolution LC-MS/MS.42 
 
7.4.4 Pig liver esterase activity assay 
Pig liver esterase (10 µM) was incubated with either 139 or 154 (1 mM) in 
concentration buffer (200 µL final volume, pH 8, section 7.2.6) at 25 °C for 3 hours. 
The reaction was stopped and protein precipitated by addition of 200 µL acetonitrile 
containing 0.1% formic acid. The precipitate was pelleted by centrifugation and the 
supernatant was analysed by UHPLC-ESI-Q-TOF MS. 
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7.4.5 EpnF and pig liver esterase tandem assay 
EpnF (10 µM) and pig liver esterase (10 µM) were incubated with either 139 or 154 (1 
mM) in concentration buffer (200 µL final volume, pH 8, section 7.2.6) at 25 °C for 3 
hours. The reaction was stopped and protein was precipitated by by addition of 200 
µL acetonitrile containing 0.1% formic acid. The precipitate was pelleted by 
centrifugation and the supernatant was analysed by UHPLC-ESI-Q-TOF MS in the 
case of 139 and LC-MS/MS in the case of 154. 186 was co-injected with the 
supernatant of a 154 assay as an authentic standard for a substrate intermediate. 
 
7.4.6 EpnF, PLE and FAD or FMN assay 
To 154 assays set up as per section 7.4.5 was added either FAD or FMN (2 mM). The 
precipitated protein was pelleted by centrifugation and the supernatant was analysed 
by UHPLC-ESI-Q-TOF MS. 
 
7.4.7 EpnF nicotinamide adenine dinucleotide reduction 
EpnF (20 µM) in Tris-HCl pH 8 buffer (25 mM) was mixed with varying 
concentrations of NADH (20 – 500 µM final concentration) and absorbance measured 
at 340 nm over 10 minutes. A decrease in absorbance was observed in each case, 
corresponding to the conversion of NADH to NAD+. 
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Appendix I: Plasmid maps 
 
pET151 (https://www.thermofisher.com/order/catalog/product/K15101) 
 
 
 
pCold-I (https://www.addgene.org/vector-database/2261/) 
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Appendix II: Peptide mass fingerprinting 
 
TmcI: 
 
 
Intensity Coverage: 49.3 % (20029 counts) 
Sequence Coverage MS: 33.2% 
 
EpnF: 
 
 
 
Intensity Coverage: 69.6 % (121262 counts) 
Sequence Coverage MS: 37.2% 
 
 
